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ABSTRACT
Chronic respiratory colonisation by the adaptable opportunistic pathogen
Pseudomonas aeruginosa is a major debilitating feature of the inherited disease
cystic fibrosis (CF). This thesis considers various aspects of the pathogenesis of
P. aeruginosa in CF, including the serological response to bacterial colonisation,
and possible factors involved in early colonisation.
Anti-P. aeruginosa lipopolysaccharide (LPS) antibodies in sera, saliva and sputa
from patients with CF were measured by enzyme-linked immunosorbent assay
(ELISA) incorporating either a polyvalent Pseudomonas smooth LPS extract
vaccine, or P. aeruginosa core, rough LPS. Elevated levels of anti-LPS IgG
antibodies in serum, and IgA antibodies in saliva and sputum were demonstrat¬
ed in patients chronically colonised by P. aeruginosa. Low levels of serum anti-
LPS IgG antibodies were detected in some patients intermittently colonised by
P. aeruginosa but not in non-P. aeruginosa colonised patients. Anti-LPS IgA
antibodies were detected in some of both intermittently and non-colonised
patients. Immunoblot analysis of serum IgG and sputum IgA antibodies to
P. aeruginosa LPS revealed a response directed towards O-antigenic LPS in the
initial stages of pulmonary colonisation with non-mucoid P. aeruginosa and a
response towards common core LPS during subsequent chronic infection with
mucoid P. aeruginosa.
Flagellar preparations from P. aeruginosa strains were characterised and used
in ELISA and immunoblot studies to detect anti-P. aeruginosa flagellar anti¬
bodies in sera, saliva and sputum. Serum anti-flagellar IgG antibodies and
salivary and sputum anti-flagellar IgA antibodies were detected, particularly in
those CF patients intermittently or chronically colonised by P. aeruginosa.
Antibodies to both type-a and -b flagella were detected; in some patients a
pronounced antibody response to only one of the flagellar types was evident.
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Anti-P. aeruginosa LPS monoclonal antibodies (Mabs) were produced for use
in a sandwich ELISA for the detection of P. aeruginosa in respiratory secretions
of patients with CF. LPS defective mutants expressing only common core LPS
were used to immunise mice for preparation of Mabs. Antibodies were
screened in ELISA and the antigenic component(s) of LPS recognised by the
most P. aeruginosa cross-reactive Mabs was checked by immunoblotting. Five
IgG Mabs were characterised and found to recognise the core component of P.
aeruginosa LPS. Two of the Mabs were particularly reactive against core LPS
from all O-antigenic serotypes of P. aeruginosa and were included in the sand¬
wich ELISA for detection of P. aeruginosa LPS. A biotin-streptavidin amplifi¬
cation system was used to increase assay sensitivity. The sensitivity of the assay
was 0.1 ng/ml P. aeruginosa LPS; the assay was able to detect P. aeruginosa LPS
in the respiratory secretions from patients with CF.
The chemotactic response of P. aeruginosa towards various mucin preparations
and major amino acid and sugar components of mucin was investigated. Puri¬
fied CF mucin, chronic bronchitic mucin, normal salivary mucin, mucin glyco-
peptides as well as porcine mucin acted as chemoattractants for P. aeruginosa.
The degree of chemotaxis towards amino acids was also strain specific; opti¬
mum chemotaxis was observed towards serine, alanine, glycine, proline and
threonine. No strain showed chemotaxis to N-acetylneuraminic acid (NANA)
but a strain dependent chemotactic response to the sugars L-fucose, D-galac-
tose, N-acetyl-D-galactosamine and N-acetyl-D-glucosamine (GlcNAc) was
observed.
Transmission electron microscopy with a surfactant monolayer technique
demonstrated adhesion of P. aeruginosa to porcine gastric mucin and purified
CF mucin. A microtitre ELISA incorporating one of the characterised anti-
P. aeruginosa Mabs was also used to measure adherence of P. aeruginosa to
mucin. Strain dependent adhesion to various mucin preparations was
x
observed, particularly to normal salivary mucins and CF mucin glycopeptides.
Sugar inhibition studies indicated that GlcNAc and NANA may constitute the
binding site in mucin.
The relevance and significance of these studies is discussed.
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Cystic fibrosis (CF), otherwise known as mucoviscidosis or fibrocystic disease of
the pancreas, has been recognised as a disease since the late 1930s (Andersen,
1938), and is the most common lethal genetic disorder of the Caucasian
population (Wood et al, 1976; Davies & Di Sant' Agnese, 1980). CF is an inher¬
ited autosomal defect (Merritt et al, 1962; Danks et al, 1965; Rommens et al,
1989) and is thus manifested when two carriers produce a child inheriting the
mutant gene from both parents. The incidence of CF in the Caucasian popula¬
tion is approximately 1 in 2,000 live births with a calculated carrier frequency of
1 in 20 (Wood et al, 1976; Brunecky, 1982; Boat et al, 1989); there are
approximately 5,000 CF patients in the UK (Dodge et al, 1988). The inci¬
dence is less frequent in other racial groups (Romeo et al, 1989) although
occasionally detected, eg an incidence of 1 in 17,000 live births amongst negroes
in Washington D.C. (Kulczycki & Shauf, 1974).
1.2 CLINICAL FEATURES
There is considerable variability in the expression of CF and scarcely any organ
system is exempt from involvement (Fick, 1981). CF is characterised by dis¬
turbances in mucus secretion and electrolyte transport from exocrine glands and
secretory epithelia (Talamo et al, 1983; McPherson & Dormer, 1987; McPher-
son & Goodchild, 1988). CF pancreatic secretions contain precipitates leading
to ductal blockage, acinar cell degeneration and extensive fibrosis; the disease
was initially called cystic fibrosis of the pancreas, fibrotic cysts being observed in
post mortem pancreatic material from CF patients (Andersen, 1938; Talamo
et al, 1983). In addition to exocrine pancreatic insufficiency and concomitant
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digestive problems, perhaps the most important symptom of the disease is the
overproduction of abnormally viscid tracheobronchial mucus which results in
poor mucociliary clearance of the bronchial airways, and subsequent bacterial
colonisation, pulmonary inflammation, production of copious viscid sputum and
chronic obstructive pulmonary disease (McPherson & Dormer, 1987; Govan,
1988). The other consistent feature of CF is the elevated levels of sweat elec¬
trolytes and this forms the basis of the pilocarpine-stimulated sweat test used in
diagnosis of the disease (McPherson & Dormer, 1987).
Compared to the 1940s and 1950s when CF patients seldom survived infancy,
the average life expectancy and prognosis for a CF patient has increased con¬
siderably. In the UK 50% of patients with CF now survive to the age of 20
years, (Dodge et al, 1988). Meconium ileus (gastrointestinal blockage caused by
the inspissation of secretions), which used to be a primary cause of infant mor¬
tality in patients with CF, is becoming increasingly rare as a cause of death, due
to increased awareness and early diagnosis of CF, improved paediatric surgery
and neonatal intensive care, as well as improved patient management (Dodge
et al, 1988). Other developments over the last decade contributing to improved
patient prognosis include improvements in dietary supplements, effective physi¬
otherapy, use of increasingly potent antimicrobial agents and introduction of
heart lung transplants, (Dinwiddie, 1990; Govan & Glass, 1990). Today, pro¬
gressive pulmonary disease exacerbated by intermittent debilitating respiratory
infections presents the main threat to both quality of life and life expectancy in
CF patients (Govan & Glass, 1990).
1.3 THE CYSTIC FIBROSIS GENE
Intensive individual and collaborative studies contributed to the eventual
identification of the defective gene in individuals with CF (Rommens et al,
1989; Riordan et al, 1989). Initially linkage analysis based on a large number of
polymorphic DNA markers was used to localise the gene to a region in the
middle of the long arm of chromosome 7, between the flanking markers met
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and D7S8 (White et al, 1985; Beudet et aL, 1986). Novel gene cloning techniques
including chromosome walking and jumping, and complementary DNA
hybridisation enabled further refinement of the map and identification of the
relatively large CF gene extending over 250 kb of genomic DNA (Rommens
et aL, 1989). Messenger RNA transcripts, 6.5 kb in size constructed from 24
exons, were detected in various tissues of patients with CF including the pan¬
creas, lung, nasal polyps, sweat glands, colon and liver, but not in unaffected
tissue eg brain (Riordan et al, 1989). Further genetic analysis of the candidate
gene showed that 68% of CF patients have a single mutation resulting in a
deletion of three nucleotides encoding phenylalanine at position 508 of the
proposed protein (Kerem et aL, 1989). Work is currently underway to deter¬
mine the nature and extent of the other mutations (Scrambler, 1989).
The benefits of these advances include improved methods for screening of
heterozygous carriers and for prenatal diagnosis, as well as a confirmation of CF
in doubtful cases (Scambler, 1989; Knight & Hodson, 1990). A complete
description of all the CF mutations will aid towards a full understanding of the
pathophysiology of the disease and form a basis for the development of im¬
proved therapy (Kerem et al, 1989).
1.4 BIOCHEMICAL DEFECT AND PATHOPHYSIOLOGY OF CYSTIC
FIBROSIS
The discovery of the CF gene also made it possible to predict a likely structure
and function of the protein the gene encodes. Analysis of the sequence of
overlapping complementary DNA clones predicted a polypeptide gene product
of 1,480 amino acids. The main characteristics of the predicted protein
structure are two repeated motifs, each consisting of six membrane spanning
domains, and sequences resembling nucleotide (ATP) binding folds (Riordan
et al, 1989).
Available evidence suggests that the cystic fibrosis transmembrane regulator
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(CFTR) is likely to be involved in the transport of substances across the
membrane either by acting as an ion channel or regulating ion channel
activities. Since the CFTR appears to belong to a family of proteins, many of
which function as parts of multicomponent molecular transport systems, the
CFTR protein may be involved in other epithelial cell functions including
secretary activity (Riordan et al, 1989). Although the fundamental biochemical
defect in CF remains uncertain, available evidence suggests defective chloride
ion transportation in CF airway epithelia and in isolated sweat gland
reabsorptive ducts (Knowles et al, 1983; Quinton, 1983). The reduction in
chloride permeability resulting in a net decrease in the reabsorption of sodium,
is a likely explanation for the consistent observation of increased sodium,
potassium and chloride content of CF sweat and other secretions, including the
mucous secretions seen in CF (McPherson & Dormer, 1987). Recent work
suggests that the CF protein is not a chloride ion channel as was first thought
(Riordan et al 1989). Instead, researchers have proposed that the CFTR
transports a regulatory protein which in turn acts on the ion channels to produce
the characteristic chloride imbalance (Ringe & Petsko, 1990).
In the future, therapeutic stratagems may involve replacement of the
abnormally functioning protein by gene or protein therapy or remedying the
defect by drugs (Knight & Hodson, 1990). It is interesting to note available
evidence suggesting that transplanted lungs in CF patients do not acquire the
electrochemical defect (Alton et al, 1987).
A further consequence of the defect seems to be the overproduction of a
normal serum protein, the CF antigen (Bullock et al, 1982), which is located on
chromosome 1 (Van Heyningen et al, 1985). The deduced amino acid sequence
of the CF antigen revealed extensive similarity to several calcium binding
proteins eg calmodulin (Dorin et al 1987). One possibility is that the CF
antigen is part of a macromolecular signal-transducing complex coupled to the
chloride channel with the CF gene product occurring as another component of
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the complex (Dorin et al, 1987; Goodfellow, 1987).
A number of observations have indicated that cell calcium homeostasis may be
disturbed in CF (Case, 1984). Elevated calcium concentrations in CF cells and
in CF respiratory, intestinal and salivary secretions have been reported (Case,
1984; Katz et al, 1984). The increased anionic character of the mucous
glycoproteins in CF may promote increased sequestration and release of calci¬
um (Wood et al, 1976). In addition, abnormalaties in protein and calcium
concentrations in CF secretions (Katz et al, 1984) may contribute to observed
precipitations which eventually lead to blockage of exocrine gland ducts
(McPherson & Dormer, 1987). Calcium might also play a part in decreasing the
solubility of glycoproteins and Pseudomonas aeruginosa alginate in CF (Di
Sant' Agnese & Talamo, 1967; Govan et al, 1983).
1.5 PULMONARY INFECTION IN PATIENTS WITH CYSTIC FIBROSIS
Chronic, progressive lung disease exacerbated by intermittent, debilitating
respiratory infections is the major determinant of morbidity and mortality in
patients with CF (H0iby, 1984; Friend, 1986; Govan & Glass, 1990). Histologi¬
cally, the lungs of infants with CF are normal at birth and comparable with
those of non-CF infants (Wood et al, 1976; Oppenheimer, 1981). However,
soon after birth hypertrophy of bronchial glands, goblet cell hyperplasia,
metaplasia of the bronchiolar epithelium followed by mucopurulent plugging of
peripheral airways all contribute to the early pulmonary pathology of CF. The
sticky, mucopurulent, stagnant secretions gradually fill the bronchioles and
bronchi; bacterial colonisation follows, stimulating further mucus secretion and
bronchitis and bronchiolitis frequently result. A vicious cycle of obstruction,
chronic infection and further respiratory tissue damage develops, and
exacerbations resulting from viral or bacterial infection may lead to pneumonia.
Bronchiolectasis, bronchiectasis, peribronchial fibrosis and airway obstruction
result in the progressive loss of pulmonary function. Once bronchiectasis has
developed there are frequent exacerbations and eventually respiratory failure,
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cor pulmonale and death (Wood et al, 1976; Fick, 1981; Fick & Hata, 1989).
Pulmonary disease and remodelling in CF is usually diffuse but more
pronounced in the upper lobe segments of the lungs, especially the right (Wood
et al, 1976; Fick & Hata, 1989).
"The microbiology of lung disease in patients with CF is a sub speciality unto
itself' (Stutman & Marks, 1987). Microbial infections tend to be localised in
the lung with emphasis on the major and minor airways rather than the alveoli,
and localised infections at non-pulmonary sites or systemic infections are rare
(Govan & Glass, 1990). Although most infections associated with the chronic,
progressive lung disease and episodes of acute exacerbation of CF are due to
bacteria, infections with viruses, chlamydia, mycoplasma and fungi also con¬
tribute to a state of pulmonary deterioration (May et al, 1972; Friend, 1986;
Govan & Glass, 1990). The bacteria most commonly isolated from the sputum
in CF are Staphylococous aureus, Haemophilus influenzae and P. aeruginosa
(May et al, 1972; Mearns, 1980; H0iby, 1982; Friend, 1986; Govan & Glass,
1990). Susceptibility of individual CF patients to particular bacterial pathogens
is usually but not invariably age-related, the sequence usually beginning with
Staph, aureus colonisation in infancy, followed by H. influenzae (non¬
capsulated, non-group B) in the early years with the incidence of P. aeruginosa
becoming more frequent with increasing age (May et al, 1972; Mearns, 1980;
Govan & Glass, 1990).
In the early 1980s reports from several North American clinics cited an
increasing isolation (up to 20%) of Pseudomonas cepacia from CF patients
indicating that this species, possessing intrinsic resistance to many antimicro¬
bials, could present a significant problem (Isles et al, 1984). However, it is
possible that cross- infection and/or iatrogenic colonisation was responsible for
the reported increases in P. cepacia rather than the fact that the organism was
genuinely emerging as a major new pathogen in CF (Friend, 1986; Govan &
Glass, 1990). The current incidence of P. cepacia in CF patients in the UK is
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stable and currently less than 6% (Govan & Glass, 1990).
Staph, aureus exhibits a range of virulence factors and prior to the discovery of
antistaphylococcal agents many patients with CF succumbed to the acute
infectious complications caused by Staph, aureus (Marks, 1990). In the first
bacteriological study of CF lung disease Di Sant' Agnese & Anderson (1946)
noted the destructive potential of Staph, aureus. Their report based on 14
post-mortem examinations showed Staph, aureus from 12 patients, and single
isolations of H. influenzae and P. aeruginosa (Bacillus pyocyaneus) each in
conjunction with a predominant growth of Staph, aureus. Significantly all but
two of the cases involved patients less than one year of age and the single iso¬
late of P. aeruginosa was from one of the oldest patients who had died aged
three years. Since the introduction of effective anti-staphylococcal drugs in the
1950s the incidence of Staph, aureus infection in CF has declined whilst that of
P. aeruginosa has increased, although Staph, aereus remains an important
cause of respiratory damage and distress in CF patients (Wood et al, 1976;
Mearns, 1980; Friend, 1986; Govan & Glass, 1990).
The incidence of P. aeruginosa in CF patients typically increases with age and
most CF centres have experienced an inexorable rise in isolations over the last
four decades to a level of 70-80% in adolescent patients (Mearns, 1980; Govan
& Glass, 1990). There are, however, significant differences in the isolation rates
reported in individual centres (Friend, 1986; Bauernfeind et aL, 1987; Govan
et al, 1987; Govan & Glass, 1990) ranging from 30% in Edinburgh and
Melbourne clinics to 70-90% in the London and Munich clinics. The reasons
for the generally increased incidence of P. aeruginosa in CF patients, the
variation in the isolation rates for P. aeruginosa in different centres and the
influence of antistaphylococcal therapy on the subsequent colonisation by
P. aeruginosa are uncertain and controversial.
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Since P. aeruginosa has emerged as the predominant pathogen in the antibiotic
era it has been suggested that anti-staphylococcal therapy has caused the
increased incidence of P. aeruginosa in CF patients (Huang et al, 1961; Burns &
May, 1968; Kulczycki et al, 1978; Kulczycki et al, 1988; Govan & Glass, 1990).
In addition as an initial pathogen, Staph, aureus, may cause damage to the lung
rendering it susceptible to subsequent colonisation by P. aeruginosa (Burns &
May, 1968; Kilbourn, 1978). Alternatively, the switch from Staph, aureus to
P. aeruginosa and the increased incidence of P. aeruginosa could be due to a
change in patient population as a result of increased life expectancy (Mearns
et at, 1972). In the preantibiotic era the majority of children probably did not
live long enough for us to be certain that the switch would not have occurred
with age, perhaps as antistaphylococcal immunity developed (Ramphal &
Vishwanath, 1987). There have been cases reported where P. aeruginosa
was the first documented pathogen to be isolated from patients who have not
previously received antistaphylococcal treatment (Stern et al, 1977).
Prior lung damage may be a predisposing factor to P. aeruginosa colonisation.
However, H0iby (1982) observed that 50% of the CF patients attending the
Danish clinic were colonised with P. aeruginosa and that some, but not all had
impaired lung function at the time when P. aeruginosa was first isolated.
Since the frequency of P. aeruginosa in CF increases with age, clinics with high
adolescent populations would tend to yield a higher incidence than paediatric
clinics (Govan et al, 1987). In reality the factors underlying the incidence of
P. aeruginosa in any given CF clinic are likely to be multifactorial, reflecting
both age distribution of the CF population and the antibiotic policies employed
(Govan et al, 1987; Govan & Glass, 1990).
Lung infections in CF patients caused by Staph, aureus and H. influenzae can
be effectively treated with antibiotics (H^iby et al, 1982; Pier, 1985; Jensen
et al, 1989). In contrast, P. aeruginosa, despite significant increases in the
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potency of antipseudomonal antibiotics, is notoriously intractable to antibiotic
therapy, and once established, is seldom, if ever, eradicated (H^iby et al 1982;
Govan et al 1987).
An unusual feature of P. aeruginosa colonisation in CF is the very high
frequency of mucoid, alginate producing variants of P. aeruginosa which are
particularly associated with progressive chronic respiratory infection in CF
patients (Henry et al, 1982; H^iby, 1984; Pier 1985; Govan & Glass, 1990).
Although mucoid P. aeruginosa were first described by Sonnenschein in 1927,
the association of mucoid isolates with CF patients was first reported by Iacoc-
ca et al (1963) and by Doggett and colleagues (Doggett et al, 1964; Doggett
et al 1966; Doggett, 1969). In CF patients primary asymptomatic colonisation
is typically with non-mucoid P. aeruginosa strains, from which mucoid variants
later emerge (Doggett et al 1966; Govan, 1990).
Despite the isolation of P. aeruginosa from a wide range of environmental
niches and various tissue sites in infected hosts, strains of P. aeruginosa do not
typically produce mucoid colonies. In contrast, mucoid P. aeruginosa are iso¬
lated in up to 90% of CF patients colonised with Pseudomonas and can be
isolated in up to 40% of Pseudomonas-positive sputa from non-CF patients with
chronic obstructive lung disease and in up to 10% of patients with chronic
urinary tract infections (Govan, 1988; McAvoy et al 1989; Govan, 1990).
Respiratory colonisation by P. aeruginosa, especially by variants exhibiting a
mucoid phenotype, is the major cause of morbidity and mortality in CF and is
widely accepted as the major microbial challenge in CF lung disease (Pier, 1985;
Jensen et al, 1989; Govan & Glass, 1990). The isolation of mucoid
P. aeruginosa is almost diagnostic of CF in adolescents with chronic pulmonary
disease (Reynolds et al, 1976) and the emergence of the mucoid phenotype
following initial asymptomatic colonisation with non-mucoid P. aeruginosa has





The genus Pseudomonas comprises more than 200 species, many of which are
ubiquitously found in nature particularly in soil and water (Palleroni, 1984).
Members of the genus Pseudomonas are defined as Gram-negative, straight or
slightly curved unicellular rods, measuring 0.5-1 pm in diameter by 1.5-5.0 pm in
length, and motile by one or several polar flagella (Palleroni, 1975; Palleroni,
1984). Metabolism is strictly aerobic with oxygen as the terminal electron accep¬
tor, although in some cases nitrate can be used as an alternative electron accep¬
tor allowing growth to occur anaerobically (Palleroni, 1975; Palleroni, 1984). All
members of the genus are chemoorganotrophs and many exhibit great catabolic
versatility capable of attacking a large variety of organic compounds (Palleroni,
1975).
Present taxonomic classification of Pseudomonas species is based on both
ribosomal RNA and DNA homology studies, five groupings being defined on
the basis of rRNA homology (Palleroni et at, 1973; Palleroni, 1975; Palleroni,
1984). The rRNA homology group I contains the fluorescent species characte¬
rised by the production of water-soluble pigments (pyoverdins) and in some
species phenazine pigments (Palleroni, 1984). The type species and best de¬
fined member of the group is P. aeruginosa. Most P. aeruginosa strains can be
identified on the basis of the characteristic grapelike odour of aminoacetophe-
none, colonial morphology and production of pyocyanin, a blue, water soluble
non-fluorescent phenazine pigment. Indeed the name of the species refers to its
most striking and definitive characteristic, a colour resembling copper rust or
verdigris, ie green, due to the production of pyocyanin and the yellow-green
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fluorescent pigment pyoverdin. Individual colonies of P. aeruginosa can occur
as five distinct types ranging from dwarf colonies to a large mucoid type (Phillips,
1969); the commonest colonial type is large, low convex with an irregular surface
and an edge that is translucent in comparison with the pigmented centre. The
optimum growth temperature is 37°C, a characteristic which differentiates
P. aeruginosa from other fluorescent pseudomonads (Palleroni, 1975). Most
strains are motile and typically possess one polar flagellum per cell. The
organism, obligately aerobic except in media containing nitrate, is
physiologically versatile, having both simple nutritional requirements and the
ability to metabolize a variety of organic substances (Palleroni, 1984). In
addition P. aeruginosa is renowned for its innate resistance to a wide range of
anti-microbial agents.
22 HABITAT
Given the physiological versatility and adaptability of P. aeruginosa it is not
surprising that the organism is able to adapt and thrive in a spectrum of eco¬
logical niches (Rhame, 1980). P. aeruginosa, essentially an aquatic organism, is
found in almost any environment where moisture is present and is widely
distributed in soil, waterways and sewage (Hoadley, 1977). It is commonly
found in sinks, swimming pools and jaccuzis (Price & Ahearn, 1988) and is
particularly prevalent in niches in hospital environments including infusion
fluids, opthalmic solutions, in-use dilutions of disinfectants, distilled water
preparations, soaps, handcreams, respiratory ventilators and nebulizing
humidifiers (Favero et al, 1971; Favero et al, 1975; Neu, 1983; Morrison &
Wenzel, 1984). The organism can also be isolated from many plants, animals
and insects and may be found as a commensal in the intestinal and respiratory
tracts and on moist skin surfaces of a small proportion of healthy human
subjects. Stoodley & Thoma (1970) reported that 8% of normal humans carry
P. aeruginosa as part of their normal gut flora, whilst Rosenthal & Tager (1975)
found that only 2% of normal individuals carried P. aeruginosa as part of their
normal pharyngeal flora. Higher carriage rates of the organism can be found in
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hospitalised patients, particularly those being treated in an intensive care unit,
because of the greater exposure to reservoirs of the organism and the selective
influence of antibiotic therapy (Stoodley & Thoma, 1970; Neu, 1983). The
frequency of intestinal carriage in hospital patients may be as high as 75%
(Neu, 1983) and the oropharyngeal colonisation by P. aeruginosa and other
Gram-negatives also increases with severity of illness (Johanson et al, 1972).
2.3 CLINICAL INFECTIONS
Although P. aeruginosa is usually harmless towards most healthy, uninjured
individuals, the organism is an opportunistic pathogen par-excellence and
responsible for a diverse range of opportunistic infections in patients compro¬
mised by injury, underlying disease, chemotherapy or surgical procedure (Cross
et al, 1983; Sherertz & Sarubbi, 1983). Indeed the organism can infect almost
any external site or organ in the body (Young & Armstrong, 1972). Infection
often occurs in hospitalised patients after prior instrumentation or
manipulative procedures such as urethral catheterization, tracheostomies,
lumbar punctures and intravenous infusions of medications and fluids. Patients
debilitated by disease or by age and those undergoing treatments with
immunosuppressive agents, corticosteroids, antibiotics and radiation are also
particularly susceptible to P. aeruginosa infection.
Hospitalised patients may acquire the organism from common environmental
sources by contact with human or inanimate vectors or through airborne trans¬
mission. Nosocomial P. aeruginosa infections are common and varied (Geddes,
1980; Cross et al, 1983; Neu, 1983; Sherertz & Sarubbi, 1983), and include infec¬
tions of burns, eyes, ulcers and bedsores, urinary tract infections, acute pneu¬
monias and bacteraemia.
Certain occupational and recreational factors may also contribute to P.
aeruginosa infection of healthy individuals: serious eye infections may be
caused by contaminated contact lenses or eye drops, particularly to the injured
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eye; painful otitis externa in deep sea divers working in the high humidity and
poor sanitation is associated with saturation diving (Alcock, 1977); and the skin
condition folliculitis or Cjaccuzi rash' is associated with users of the warm,
aerated aqueous environment of the whirlpool or jaccuzi (Vogt et aL, 1982;
Ratman et aL, 1986).
2.4 RESPIRATORY INFECTIONS INVOLVING P. AERUGINOSA
Although P. aeruginosa is not a pathogen of the normal bronchial lining it is
associated with two major forms of respiratory tract infection: acute pneumonia
and chronic pulmonary disease. Primary or acute P. aeruginosa pneumonia is
one of the most common of the nosocomial infections caused by the organism
(Sherertz & Sarubbi, 1983). Factors that may predispose to the development of
acute pneumonia include tracheal intubation, immunocompromisation,
underlying chronic lung disease, thoracic surgery, prolonged treatment in an
intensive care unit and age greater than 70 years (Johanson et aL, 1972; Reynolds
& Fick, 1980; Celis et al, 1988). Involvement of P. aeruginosa in chronic
pulmonary disease is most commonly associated with patients with CF although
it may cause exacerbations in patients with non-CF chronic obstructive airways
diseases including chronic bronchitis and bronchiectasis (Doggett & Harrison,
1969; Fick, 1981; Rivera & Nicotra, 1982; Fick & Hata, 1989).
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CHAPTER 3
THE PSEUDOMONAS AERUGINOSA CELL ENVELOPE
The cell envelope of P. aeruginosa, and Gram-negative bacteria in general, is
complex in structure, conferring shape and rigidity on the bacterial cell and
functioning as a barrier through which a bacterium interacts with its environ¬
ment (Costerton et al 1974, Brown & Williams, 1985).
The Gram-negative cell envelope (Figure 1) is composed of three layers: a) an
outer membrane, b) the periplasmic space and c) the inner or cytoplasmic
membrane. In addition the surface of many Gram-negative bacteria may be
covered by a polysaccharide layer forming capsules or slimes (Sutherland, 1977;
Sutherland, 1985). The term glycocalyx describes all types of polysaccharide
material outwith, but adherent to the cell envelope (Costerton et al, 1981). The
alginate exopolysaccharide produced by mucoid P. aeruginosa is one such
glycocalyx.
3.1 STRUCTURE AND COMPOSITION OF THE OUTER MEMBRANE
The outer membrane of Gram-negative bacteria is an asymmetric bilayer struc¬
ture made up of phospholipids, proteins and lipopolysaccharide (LPS) (Coster¬
ton et al, 1974; Nikaido & Nakae, 1979; Lugtenberg & Van Alphen, 1983;
Hammond et al 1984; Nikaido & Vaara, 1985). The outer leaflet of the bilayer
is largely made up of LPS, the lipid component linking hydrophobically to the
phospholipids making up the inner leaflet, whilst the polysaccharide component
extends outwards from the cell surface. The outer membrane also possesses
protein components including lipoproteins, major and minor outer membrane








Figure 1. The cell envelope of a Gram-negative bacterium.




Lipopolysaccharides are a heterogenous collection of molecules unique to the
outer leaflet of the outer membrane of Gram-negative bacteria, sharing the
same general composition but showing heterogeneity in size (Muhlradt &
Golecki, 1975; Day & Marceau-Day, 1982). The LPS of P. aeruginosa is similar
in general structure to that of the enterobacteria in that it is an amphipathic,
tripartite macromolecule (Pitt, 1989). Integrated into the continuum of proteins
and phospholipids of the outer membrane is the hydrophobic lipid A region of
the LPS, consisting of fatty acids linked to glucosamine. Extending outwards
from lipid A is the common core region consisting of a short carbohydrate
chain. In smooth strains a longer, polymeric, carbohydrate side chain, known
as the O-specific side chain, is attached to and extends outwards from the core
oligosaccharide (Wilkinson, 1977; Wicken & Knox, 1980; Westphal et al, 1983;
Hammond et al, 1984). The composition and structure of the side chain are
variable but the lipid A and core regions are relatively conserved. Analysis and
fractionation of the LPS from P. aeruginosa indicate that they share many
features of typical enterobacterial LPS as well as possessing several distinctive
features (Wilkinson, 1983).
Lipid A
The Lipid A moiety of LPS from different species of Gram-negative bacteria
has a structure based on a phosphorylated £Sl-6 glucosamine disaccharide
backbone to which six or seven saturated fatty acids are attached by ester and
amide bunds (Westphal et al, 1983; Nikaido & Vaara, 1985). Lipid A is unique
among bacterial fatty acids in containing hydroxy fatty acids (Hammond et al,
1984). The lipid A of P. aeruginosa is similar to that of the enterobacteria but
differs in fatty acid composition and the unusual high degree of phosphoryla¬
tion (Wilkinson, 1983). Typically the fatty acid 3-hydroxytetradecanoic acid is
absent from the lipid A of P. aeruginosa whilst the fatty acids dodecanoic,
hexadecanoic, 3-hydroxydecanoic, 2-hydroxydodecanoic and 3-hydroxydode-
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canoic acid are present (Wilkinson & Galbraith, 1975; Wilkinson, 1983). In
addition minor amounts of palmitate, palmitoleate, stearate and oleate may be
found (Pier et al, 1981). The hydroxy fatty acids may be amide or ester linked to
glucosamine: in P. aeruginosa, the amino moities of the hexosamines are sub¬
stituted with 3-hydroxydodecanoate residues whilst 3-hydroxydecanoic, dode-
canoic and 2-hydroxydodecanoic acids are ester linked to the backbone or to
the hydroxy groups of the other fatty acids (Kropinski et al, 1985). LPS from
P. aeruginosa appears to be a less potent endotoxin than the LPS from other
Gram-negative bacteria (Sadoff, 1974; Kropinski et al, 1985) and this may be
due to the absence of 3-hydroxytetradecanoic acid.
Core oligosaccharides
P. aeruginosa LPS has a core structure which appears to differ significantly from
other described LPSs (Day & Marceau-Day, 1982). Reported observations
indicate heterogeneity in the core region (Wilkinson & Galbraith, 1975) and
that the core composition of the LPS varies with growth conditions (Day &
Marceau-Day, 1982).
The core oligosaccharide consists of inner and outer domains. The inner core
region contains heptose and the unique sugar 3-deoxy-D-manno-2-octulosonate
or keto-deoxy octanoic acid (KDO) which links the core polysaccharide to lipid
A via an acid labile bond (Wicken & Knox, 1980). The heptose constituent
contains equal amounts of L-glycero-D-manno-heptose and D-glycero-D-
manno-heptose (Hammond et al, 1984). In contrast to enterobacterial LPS
which contain about four phosphate residues in the inner core region and an
additional two or three in the lipid A, LPSs from P. aeruginosa may contain ten
or more residues per molecule (Kropinski et al, 1979; Wilkinson, 1983;
Kropinski et al, 1985). Inorganic orthophosphate is the major product of mild
acid hydrolysis, but small amounts of inorganic pyrophosphate and of
ethanolamine ortho-, pyro-, and triphosphates can also be detected (Wilkinson
& Galbraith, 1975; Wilkinson, 1983). The outer core of P. aeruginosa typically
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contains D-glucose, L-rhamnose, D-galactosamine and L-alanine (Wilkinson,
1983).
The composition of the core oligosaccharides from a number of P. aeruginosa
strains have been analysed and various structures proposed (Drewry et al, 1975;
Wilkinson & Galbraith, 1975; Rowe & Meadow, 1983). The major components
and their molar proportions in the core polysaccharide of P. aeruginosa strain
NCTC 1999 (National Collection of Type Cultures) were glucose (3-4), rham-
nose (1), heptose (2), KDO (1), galactosamine (1), alanine (1-1.5) and phosphorus
(6-7), (Drewry et al, 1975). However, the core oligosaccharide obtained and
analysed from P. aeruginosa PACIR differed in the glucose rhamnose ratio
(nearer to 3:1 than 4:1), the type of bonding and the number of heptose resi¬
dues from the core structure proposed for NCTC 1999 (Rowe & Meadow,
1983).
There are a number of controversial areas concerning the core structure of LPS
in P. aeruginosa (Kropinski et al, 1985). Evidence that L-alanine occurs mainly
in N-alanylgalactosamine residues needs to be reassessed in light of isolation of
a core defective LPS containing alanine but not galactosamine (Jarrell &
Kropinski, 1981). In addition the number of phosphate residues and their dis¬
tribution also requires reassessment (Kropinski et al, 1985). Allowing for
analytical imprecision, microheterogeneity in the core region, the presence of
smooth-rough products, and the effects of cultural conditions, it is likely that a
family of related core oligosaccharides exist for P. aeruginosa (Wilkinson,
1983).
O-side chains
The O-side chain component of LPS consists of repeating oligosaccharide
subunits. The side chains of most P. aeruginosa strains contain unbranched tri¬
or tetrasaccharide repeating units rich in N-acetylated aminosugars including
hexosamine, fucosamine and quinovosamine and occasionally bacillosamine
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(Wilkinson, 1983; Kropinski et al, 1985; Knirel et al, 1988). Neutral sugars
including glucose, rhamnose, xylose and ribose are not commonly found in P.
aeruginosa O-polysaccharides and only rhamnose is encountered frequently
(Knirel et al, 1988). Acidic monosaccharides are also found and two unique
bicyclic hexosamines have been isolated from certain O-side chains: an acety-
lated imidazoline derivative of 2,3-diaminomannuronic acid and a 6,3-lactam of
2,3-diaminoglucuronic acid. Other chemical characteristics of P. aeruginosa O-
side chain LPS include the presence of uronic acid residues in certain serotypes
and the lack of cis-vicinyl hydroxyls in the side chains (Kropinski et al, 1985).
Heterogeneity in the size of the P. aeruginosa LPS molecule have been reported
(Chester & Meadow, 1975; Rivera et al, 1988) and attributed to the variations in
the number of repeating units in the O-antigen. The number of repeating units
can show considerable variation under different physiological conditions
(Chester & Meadow, 1975; McGroarty & Rivera, 1990) and even within a
culture of one strain (Rivera et al, 1988). Such variation confers great variabili¬
ty on the molecular make up of the bacterial cell surface and there is evidence
to suggest that a strain may produce several different LPSs containing a
common polysaccharide (Chester & Meadow, 1975; Koval & Meadow, 1977;
Rivera et al, 1988; Lam et al, 1989; Rivera & McGroarty, 1989). Indeed analysis
of the LPS from PAOl revealed two antigenically and chemically distinct
molecules termed A- and B-band LPS (Rivera et al, 1988). B-band LPS is
generally composed of LPS with long-chain O-antigen and is the LPS respon¬
sible for the O-specificity of the organism, while A-band is composed of LPS
molecules consisting of only short-chain polysaccharides (Rivera et al, 1988)
and may be a common LPS antigen in all P. aeruginosa strains (Lam et al, 1989;
Rivera & McGroarty, 1989).
Compared to the enterobacteria the overall capping frequency of P. aeruginosa
LPS (ie the percentage of core LPS constituents covered with O-antigen) is
low, leaving a greater percentage of core determinants exposed at the cell
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surface (Kropinski et al, 1985). The percentage of smooth type molecules in
P. aeruginosa LPS have been reported at 0.2 - 13.7% (Hancock et al, 1983), 5-
11% (Wilkinson, 1983) and 8% ( Rivera, 1988). The unusually high amount of
phosphorus in the core of P. aeruginosa LPS may be due to the high proportion
of core molecules lacking O-side chains (Pitt, 1989).
The great variability in the chemical composition of the O-antigen subunit
forms the basis of immunological typing of P. aeruginosa strains (Chester et al,
1973; Bergan, 1975). The polysaccharides of different O-serogroups differ from
one another in monosaccharide composition and structure of their repeating
units (Knirel et al, 1988). Liu et al (1983) proposed a scheme comprising 17 O-
types, the International Antigenic Typing Scheme (IATS) which accounted for
the types in various previously described schemes (Pitt, 1988) including the
original 12 O-types of Habs (1957) and five antigens from other schemata.
Three new major somatic antigens of P. aeruginosa have recently been de¬
scribed and added to the other 17 IATS groups (Liu & Wang, 1990). Frequen¬
cies of individual serotypes in clinical specimens varies with country of investi¬
gation and source of the isolate (Pitt, 1988). Serotypes 0:6 and 0:11 together
account for about 40% of P. aeruginosa strains isolated worldwide (Pitt, 1989).
However, in chronic infections such as CF, bronchiectasis and urinary tract
infections, P. aeruginosa variants which are defective in their ability to synthe¬
size O-specific side chains often arise from parent O-typable forms (Pitt, 1989).
These variants are frequently polyagglutinable (ie agglutinated by more than
one antiserum towards unrelated O-antigens) and non-typable as a result of
loss of O-side chains (Hancock et al 1983; Fomsgaard et al, 1988a). Unlike
rough forms of enterobacteria, serologically rough strains of P. aeruginosa are
seldom colonially rough in appearance (Pitt, 1988). In addition to the loss of O-
serotype reactions, P. aeruginosa isolates from CF patients with chronic bron¬
chopulmonary infections also expressed a new somatic antigen called the
polyagglutinating antigen on their surface Penketh et al (1983). This antigen
may be related to the short-chain polysaccharide A-band LPS which has been
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suggested as the major LPS antigen in non-typable clinical isolates, as well as a
common antigen among other P. aeruginosa strains (Lam et al, 1989).
Biological properties of P. aeruginosa LPS
Numerous biological activities have been attributed to P. aeruginosa LPS
including pyrogenic, mitogenic and anti-tumour activity (Homma, 1971; Kro-
pinski et aL, 1985; Pitt, 1989). Injection of P. aeruginosa LPS into mice elicits the
classical symptoms of endotoxic shock (Homma, 1971) whilst antibody towards
LPS is highly protective both in man and experimental animal models (Pollack
& Young, 1979; Cryz et al, 1983). LPS plays a major role in the virulence of the
organism conferring resistance to the bactericidal action of complement in
normal human serum and protection of the bacterial cell against opsonization
and phagocytosis (Engels et al, 1985).
3.3 PROTEINS OF THE OUTER MEMBRANE
There are three major classes of protein found in the outer membrane including
lipoproteins, major outer membrane proteins (defined as components present
in sufficient quantity to be readily detected by simple staining of polyacrylamide
gels) and minor proteins which are inducible or derepressible and may, under
the appropriate environmental conditions, reach levels comparable with those
of the major proteins, eg iron regulated membrane proteins.
A number of proteins have been identified and characterised in the outer
membrane of P. aeruginosa (Hancock & Nikaido, 1978; Mizuno & Kageyama,
1978; Hancock & Carey, 1979). Many of the major outer membrane proteins
are pore proteins, porins, which form relatively non-specific, water filled pores
spanning the outer membrane for the passive entry of low molecular weight,
hydrophilic solutes present at relatively high concentrations (around 10'^M)
(Nikaido & Nakae, 1979; Nikaido & Vaara, 1985; Nakae, 1986). The porins also
serve as receptors for bacteriocins and bacteriophages (Lugtenberg & van
Alphen, 1983). Entry of essential solutes which are too large to pass through the
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porins and which are present at very low concentrations (down to 10'^M)
proceeds after binding of substrate or a substrate chelator complex to outer
membrane receptor proteins (Brass, 1986). It has been reported that a number
of the porins in P. aeruginosa are small in diameter (Yoshihara & Nakae, 1989)
and together with the tightly packed LPS (as a result of divalent cation binding
to the many phosphate residues), makes the outer membrane impermeable to
both hydrophobic and hydrophilic antibiotics (Nikaido & Hancock, 1986).
3.4 FLAGELLA
The single polar flagellum of P. aeruginosa is a major taxonomic characteristic
of the organism (Ansorg, 1978; Palleroni, 1984). Flagella are protein, filamen¬
tous cell surface appendages responsible for the motility and chemotaxis of
many bacteria (Doetsch & Sjoblad, 1980). Each flagellum is composed of three
parts:- (1) the basal body, (2) the hook and (3) the filament.
The basal body is the most morphologically and functionally complex region of
the bacterial flagellum containing at least ten distinct polypeptides (Doetsch &
Sjoblad, 1980; Hammond et al, 1984). It serves to anchor the flagellum to the
cell surface and provides the driving force for flagellar rotation. In Gram-
negative bacteria the basal body consists of a rod about 27 nm long bearing two
pairs of discs. The diameter of the discs is about 22 nm, whilst that of the rod is
7-10 nm. The rings have been named (DePhamphilis & Adler, 1971a & b) and
are located as follows:- embedded in the cytoplasmic membrane is the M
(membrane) ring, and this is closely associated with a second disc, the S
(supramembrane) ring lying between the cytoplasmic membrane and the
peptidoglycan layer. It is thought that the M-ring serves as a rotor, and the S-
ring as a stator during flagellar rotation (Berg, 1974; Hammond et al, 1984,
Macnab & Aizawa, 1984). The second pair of discs, the P (peptidoglycan) and
L (lipopolysaccharide) rings are tightly associated with the outer membrane.
Since P and L-rings are not present in Gram-positive bacteria it has been
suggested that they may serve as a bearing permitting rotation of the rod in the
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relatively mobile outer membrane (Berg, 1974; Hammond et al, 1984).
The hook structure serves as a universal joint between the basal body and the
filament. It is generally short, about 70-90 nm long, slightly curved, with a
diameter slightly greater than the filament, and consists principally of a single
polypeptide subunit (Doetsch & Sjoblad, 1980).
The filament, the distal section of the flagellum, is approximately 20 nm in
diameter and 10-20 nm long. This thin, helical propeller is made up of a single
protein called flagellin (Doetsch & Sjoblad, 1980). All flagellin antigen prepa¬
rations from P. aeruginosa consist of flagellin molecules with a common N-
terminal amino acid sequence and they all lack the amino acids proline, cysteine
and histidine (Rotering & Dorner, 1989). It has been reported that the rpoN
gene product, an alternative sigma factor of P. aeruginosa, is required for
expression of a set of diverse genes, including the flagellin gene (Totten et al,
1990). Flagella from P. aeruginosa can be categorised into two major groups
designated type-a and -b, based on agglutination (Lanyi, 1970) and
immunofluorescence assays (Ansorg, 1978), and the molecular weight of the
flagellar antigens (Allison et al, 1985). Type-a flagella belong to a heterologous
group which can be further subdivided into five partial antigens aq, ap ^ a^,
a^, (Ansorg, 1978) with Ms ranging from 45,000 to 52,000 (Allison et al, 1985).
These are found in 16 possible combinations in P. aeruginosa flagella, the
partial antigen aq being present in all a-types with usually one or more of the
additional flagellin subtypes (Ansorg, 1978). The b-types comprise a
homologous group having a Mr of 53,000 (Allison et al, 1985). Based on this
typing scheme Ansorg (1978) could ascribe 17 possible flagella serotypes to
95% of clinical isolates of P. aeruginosa with about 60% of the isolates having
b- type flagella. Molecular weight analysis by electrophoretic separation
(Allison et al, 1985), and amino acid analysis (Rotering & Dorner, 1989) of
flagella with the serotype aq, failed to discriminate them from flagella of
serotype b. The presence of the b or aq epitope on all 17 flagella serotypes
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described by Ansorg (1978) as well as common N-terminal amino acid
sequences, indicate that immunological cross-reactions exist between
P. aeruginosa flagella of different serotypes (Anderson & Montie, 1987;
Rotering & Dorner, 1989).
Chemotaxis
P. aeruginosa swim by the rotation of the polar flagellum enabling the organism
to seek out nutrients and find a suitable environment in which to grow. Many
bacteria including P. aeruginosa are able to respond to their environment by a
process known as chemotaxis which includes the ability to respond and swim
towards attractants and away from noxious repellents (Adler, 1987). Chemotaxis
may be defined as the biased migration of cells in response to a chemical
gradient (Lauffenburger et al, 1987). Positive chemotaxis describes movement
towards a chemical gradient whereas negative chemotaxis denotes movement
away from a chemical gradient (Chet & Mitchell, 1976).
Flagellate bacteria use the proton-motive force across the cytoplasmic
membrane to drive the rotation of the semi-rigid helical flagella (Berg et al,
1982). The bacterial movement generated by the flagellar apparatus can be
followed by the aid of a tracking microscope, and is characterised by sequences
of steps called runs, during which speed and direction are fairly constant,
separated by tumbles in which the cells stop and change direction (Berg, 1971).
Runs are relatively long lasting for a duration of a few seconds, while tumbles
last for only a fraction of a second (Lauffenburger et at, 1987). When the flagel¬
lum rotates counterclockwise the organism swims smoothly, whilst clockwise
rotation of the flagellum causes the organism to tumble, making possible a
change in direction (Larsen et al, 1974; Simon et al, 1989). When smooth
swimming resumes it will be in a new, randomly chosen direction (Berg &
Brown, 1972). Bacterial flagellar rotation and hence bacterial motility is
modulated by attractant and repellent chemotactic stimuli. Attractants in¬
crease the counterclockwise bias of flagella, with a resultant prolonged swim-
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ming in rather straight lines, whilst repellents increase the clockwise bias of the
flagella, resulting in tumbling (Berg & Brown, 1972; Macnab & Koshland, 1972;
Larsen et al, 1974; Lapidus et aL, 1988).
Chemotaxis results from a decrease in the tumbling probability for a cell moving
up a concentration gradient of attractant or down a concentration gradient of
repellent (Brown & Berg, 1974; Lauffenburger, et al, 1987). Thus when the
bacterium proceeds, during a smooth swimming period, from a region of low
attractant concentration to a region where attractant is more prevalent,
tumbling response is suppressed and the bacterium continues to swim in the
same direction. When the cell encounters decreased concentrations of attract¬
ant however, the frequency of tumbling increases. After a brief period of
tumbles, the organism resumes smooth swimming until further changes in the
concentrations of attractants or repellents are encountered. Thus the cell
executes a biased random walk with net movement up the spatial gradient of an
attractant, and vice versa in the case of a repellent (Berg & Brown, 1972; Brown
& Berg, 1974). Bacteria respond to spatial gradients of attractants or repellents
by monitoring the change in concentration of chemicals over time as they swim
from one place to another ie swimming cells perceive spatial gradients indirectly
through a chemosensor, sensing only the overall temporal change in
concentration as they move in the presence of both temporal and spatial gradi¬
ents (Macnab & Koshland, 1972; Lauffenburger et al, 1987). Monitoring con¬
centration with respect to space would not be possible since bacteria are too
small to reliably detect spatial gradients across their own dimensions (Macnab
& Koshland, 1972). In nature, bacteria experience temporal concentration
gradients as they swim through spatial gradients formed by diffusion from
chemical sources. Immediately after the presentation of a temporal stimulus
constituting an attractant, bacteria will demonstrate prolonged periods of
smooth swimming, the duration of the response being proportional to the
magnitude of the concentration change (Macnab & Koshland, 1972 ; Spudich &
Koshland, 1975). After the initial excitation response the cell behaviour adapts,
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and even in the continued presence of an attractant the tumbling frequency
returns to normal (Berg & Brown, 1972; Macnab & Koshland, 1972; Spudich &
Koshland, 1975). This process of desensitization or adaptation is specific for a
chemoattractant since the bacteria still respond to other unrelated attractants.
Adaptation is an essential part of the chemotactic response allowing bacteria to
respond to changes in concentration and therefore to prolong swimming when
moving in a favourable direction. In the absence of the adaptation process the
bacteria would be stimulated indefinitely by just one compound and unable to
respond to other, potentially nutritionally useful, attractants
Bacteria detect chemicals in the environment by specific chemoreceptors
(transducers) (Adler, 1987). About twenty different chemosensors are known for
various attractants and repellents (Adler, 1987). Chemoreceptors may either be
periplasmic proteins or integral parts of the cytoplasmic membrane (Hammond
et al, 1984; Brass, 1986). Many of the latter appear to be transmembrane
proteins and are proposed to have an N-terminal sensing domain located in the
periplasm as well as a C-terminal signalling domain in the cytoplasm (Nixon
et al, 1986; Bourret et al, 1989). For each sensor protein there is a corresponding
regulator protein and it is proposed that these proteins are involved in a two
component regulatory system of chemotaxis (Bourret et al, 1989; Simon et al,
1989). Each chemoreceptor is highly specific, binding only one specific
chemical or its closely related analogue (Hammond et al, 1984). Many of the
chemoreceptors serve as both receptors and help to mediate the transport of
specific chemicals across the plasma membrane. Ability to move towards higher
chemical concentrations is advantageous only if that compound can be
efficiently transported and metabolised (Hammond et al 1984).
The major components of the chemotaxis information processing network of
E. coll have been identified, although the detailed molecular mechanisms of
signal transduction remain elusive (Bourret et al, 1989). The discovery that
methionine is required for chemotaxis led to the discovery of transmembrane
26
proteins called methyl-accepting chemotaxis proteins (MCP) (Springer et al
1979). There are four distinct MCPs known, each serving a different set of
attractants and repellents: in most cases the transmembrane protein acts as a
receptor for a specific ligand or ligand binding protein in the periplasmic space
(Bourret et al 1989). A derivative of methionine, S-adenosylmethionine, a
potent methylating agent is thought to methylate MCPs. The level of methyla-
tion is increased by attractants and decreased by repellents (Springer et al,
1979). Protein methyltransferase, the product of CheR gene progressively
methylates glutamyl residues in the methylation regions until the attractant-
induced signal is cancelled and the cell is adapted in the presence of the attract-
ant (Springer et al 1979). Thus the level of methylation will remain at the new
level as long as the attractant is present. When the attractant is removed the
respective MCP is demethylated by a methylesterase, the product of the CheB
gene, until the signal is returned to the prestimulus state (Stock & Koshland,
1978). Chemotaxis of P. aeruginosa towards amino acids is mediated by dynamic
methylation and demethylation of MCPs analogous to those of the enteric
bacteria (Craven & Montie, 1983).
Since MCPs are anchored in the cell membrane they cannot transmit the
message across the inside of the cell to the flagellum. One candidate for a
mediator of signalling between the receptors and the flagellar apparatus is
protein phosphorylation (Hess et al 1987; Bourret et al 1989; Simon et al 1989).
ATP has been shown to be required for the chemotaxis of P. aeruginosa
(Armitage & Evans, 1983). The excitation pathway involves a number of pro¬
teins which ultimately determine the direction of rotation of flagella. Some of
these proteins, CheA and CheY can be phosphorylated and interact with the
MCPs. CheA is an autophosphorylating protein kinase (Hess et al, 1987;
Bourret et al, 1989). Phosphorylated CheA can then transfer the phosphoryl
group to either CheB (methylesterase) or CheY (Hess et al 1988). Genetic and
biochemical evidence suggest that CheB and CheY proteins are activated by
























Figure 2. a) Model for the mechanism of excitation and adaptation during bacterial chemotaxis.
(Figure modified from Simon et aL, 1989, see text for description).
b) The mechanism of bacterial chemotaxis. CCW = counterclockwise rotation of the flagella;
CW = clockwise rotation; MCP = methyl- accepting chemotaxis protein. (Figure modified from
Adler, 1987).
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response (CheY) or effecting the adaptation response (CheB) (Simon et al,
1989). Phosphorylation of the CheB protein would increase its methylesterase
activity allowing it to change the sensibility of the receptor (Simon et al, 1989).
It has been suggested CheY-phosphate might cause clockwise rotation of flagel-
la and be the tumble signal (Simon et al, 1989). Phosphorylation is transient,
and dephosphorylation of CheY is catalyzed by the CheZ protein (Hess et al,
1988). In addition, the receptor activated-state of another protein CheW may
regulate the CheA dependent phosphorylation of CheB and CheY (Hess et al,
1988). A model for bacterial chemotactic signalling which incorporates the
observations outlined above has been proposed (Bourret et al, 1989; Sanders
et al, 1989; Simon et al, 1989) (Figure 2a). During the response to an increase
in attractant concentration the receptors deactivate the CheW protein. CheA
dependent phosphorylation of the CheB and CheY proteins is thereby reduced
and results in the suppression of receptor demethylation and tumbling (clock¬
wise flagella rotation). The attractant induced receptor conformational change
increases the activity of the CheR methyltransferase and decreases the activity
of the CheB methylesterase thus raising the level of receptor methylesterifica-
tion and effecting adaptation. The more highly methylated receptor would
activate CheW protein until its levels were high enough to once again stimulate
CheA dependent phosphorylation of the CheB and CheY proteins to the level
achieved before the increase in attractant concentration. An increase in CheY-
phosphate induces clockwise rotation of flagella (tumbling).
Catalytic enhanced desphosphorylation of the CheY protein by the CheZ pro¬
tein will counteract the excitation signal.
3.5 PILI
The pili (fimbriae) of P. aeruginosa have been shown to be polar located
(Bradley, 1972). Pili serve as an attachment site for various Pseudomonas spe¬
cific bacteriophages (Bradley & Pitt, 1974) and are responsible for twitching
motility (Bradley, 1980). Pili may assist in the attachment of organisms to var-
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ious cell surfaces: they have been reported to be involved in the binding of
P. aeruginosa to human buccal epithelial cells (Woods et al, 1980b; McEachran
& Irvin, 1985; Doig et al, 1988), acid injured mouse tracheal cells (Ramphal &
Pyle, 1983a; Ramphal et al, 1984), tracheobronchial mucins (Ramphal et al,
1987) and damaged corneal epithelial cells (Reichert et al, 1983). Transferable
plasmids have been shown to determine conjugative pili, which are also
receptors for donor specific phages (Bradley, 1983).
Fimbriation is a reversible trait, most likely to be determined by chromosomal
genes, and has been shown to be under the control of the rpoN gene product
(Totten et al, 1990). Pili are expressed in relatively small numbers, 2-12 per
pole (Bradley, 1972), and are proteinaceous appendages about 6 nm wide,
composed of a single monomer termed pilin (Sastry et al, 1985). The pili puri¬
fied from P. aeruginosa strain K have been extensively characterised and the
primary amino acid sequence determined (Sastry et al, 1985). Pilin from
P. aeruginosa K (PAK) was found to be built up of subunits of Mr 17,800, whilst
the serologically distinct pili of P. aeruginosa O (PAO) possessed smaller
subunits (Mr 15,500) (Sastry et al, 1985).
3.6 EXOPOLYSACCHARIDE
Despite the isolation of P. aeruginosa from a wide range of environmental
niches and various tissue sites in infected hosts, the organism is not typically
associated with a mucoid colonial morphology and alginate biosynthesis at
readily detectable levels (Govan, 1988). Thus the organism tends to appear non-
mucoid when cultured on an agar media (Govan, 1990). However, as previously
mentioned, respiratory isolates from patients with CF frequently exhibit the
mucoid phenotype (Govan, 1988). It is important at this point to make the
distinction between the alginate exopolysaccharide produced by mucoid
P. aeruginosa, and slime, produced by most P. aeruginosa. Slime is a loosely
defined material with variable composition depending on the strain, cultural
conditions, and method of analysis (Govan, 1990). The term mucoid is restrict-
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ed to those strains producing the large, watery colonial type 5 of Phillips (1969)
within 24 hours on agar based media, and whose mucoid appearance results
from the copious production of the polyuronide, alginate (Govan, 1990).
The observation that P. aeruginosa was able to synthesize an alginate-like
polysaccharide was first reported by Linker & Jones (1964). Alginate produced
by mucoid P. aeruginosa is a strongly anionic polysaccharide, composed of
linear 1-4 linked chains of p-D-mannuronic acid and its C5 epimer a-L-
guluronic acid (Evans & Linker, 1973; Gacesa & Russell, 1990). The uronic
acids are monosaccharides which have been oxidised at C6 to produce a car-
boxylate group and therefore are negatively charged (Gacesa & Russell, 1990).
A distinctive feature of alginates from mucoid P. aeruginosa is that the man-
nuronate residues are O-acetylated (Sherbrock-Cox et al, 1984). The two
different uronic acids may be arranged in different ways within the alginate
molecule to form block structures. There may be homopolymeric regions ie
poly {3 -D-mannuronate or poly a-L-guluronate, or heteropolymeric regions in
which there is a random arrangement of the monomers (Russell & Gacesa,
1989; Gacesa & Russell, 1990). Since alginate is polyanionic it is able to bind
? 4- 7 4-
cations, particularly of the divalent kind eg Ca^ and Mg^"1" (Russell &
Gacesa, 1989).
A significant property of alginate from mucoid P. aeruginosa is the absence of
polyguluronate blocks (Sherbrock-Cox et aL, 1984). In addition alginates derived
from P. aeruginosa and other pseudomonads show a predominance of the
heteropolymeric random block structures. Alginate produced by mucoid
P. aeruginosa tends to be highly viscous and flexible, with the capacity to bind
large quantities of water (Gacesa & Russell, 1990). The alginate displays the
ability to form rigid, stable gels in the presence of divalent cations, particularly
Ca^+ (Rees, 1972). Culture of mucoid P. aeruginosa in the presence of 3 mM
Ca^+ causes the normal mucoid colonial form to assume a more compact
gelatinous appearance on agar media and the formation of bacterial microgels
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which rapidly sediment in liquid culture (Govan & Harris, 1986). Electron
microscopy shows the microgels as cotton-wool like meshes enclosing the bacte¬
rial cells (Govan & Harris, 1986).
Evidence obtained in vitro by the use of NMR spectroscopy on the polysaccha¬
rides produced by mucoid and non-mucoid isolates from both CF and non-CF
patients indicates that alginate is not restricted to the mucoid colonial pheno-
type: non-mucoid P. aeruginosa and revertants of mucoid isolates have been
found to produce alginate but at very much lower levels than in mucoid variants
(Anastassiou et aL, 1987). Thus the mucoid phenotype is thought to result from
the derepression of a normal regulatory system resulting in a shift from low,
barely detectable levels of alginate in non-mucoid strains to high levels in the
mucoid phenotype (Govan, 1990).
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CHAPTER 4
PATHOGENESIS OF P. AERUGINOSA IN CYSTIC FIBROSIS
Pathogenicity is the capacity of microorganisms to produce disease in sus¬
ceptible hosts (Smith, 1977). Not all pathogens have an equal chance of causing
infection and disease, and in particular instances disease occurs or is prevented
depending on the outcome of interactions between the microbe and the host
(Smith, 1977; Finlay & Falkow, 1989). While some pathogens regularly cause
disease in a proportion of non-immune individuals with intact host defences,
others, including P. aeruginosa, do not (Finlay & Falkow, 1989). As discussed
earlier P. aeruginosa can infect compromised individuals and cause disease but
presents little danger to those with intact host defences. Indeed probably any
miroorganism which has the capacity to sustain itself in humans will occasion¬
ally cause disease in compromised individuals and act as an opportunistic
pathogen (Finlay & Falkow, 1989).
Essential requirements for pathogenicity are: 1) ability to enter the host; 2)
multiply in host tissues; 3) resist or not stimulate host defences; 4) cause
damage to the host (Smith, 1977; Finlay & Falkow, 1989; Smith, 1990). Microbial
factors responsible for these processes are the determinants of pathogenicity or
virulence factors, and include both cell-associated and extracellular products
(Smith, 1977). Since pathogenesis is a multifactorial process, potential
pathogens usually require a number of virulence factors, the absence of one
member of the full complement resulting in considerable attenuation of the
organism concerned (Smith, 1977).
P. aeruginosa manifests a variety of cellular and extracellular products, many of
which have been implicated as virulence factors in the pathogenesis of the
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organism in CF. In turn, the CF patient appears to respond to cellular and
extracellular products of P. aeruginosa with an array of host defences (H0iby
et aL, 1975; Schi0tz, 1982) yet P. aeruginosa is never eliminated from the respira¬
tory tract, nor does it spread systemically beyond this site in CF patients to
cause non-pulmonary infections.
4.1 PULMONARY HOST DEFENCES
The respiratory tract possesses an elaborate array of non-specific and specific
defence mechanisms which coordinate to remove a variety of noxious sub¬
stances, particles and microorganisms and prevent injury to the mucosa and
delicate alveolar surface (Reynolds, 1989). These protective mechanisms may
be classified as follows:-
a) Mechanical: including the cough reflex and the mucociliary clearance
mechanism which is important between the posterior two-thirds of the nasal
cavity and the nasopharynx, and the larynx to the terminal bronchioles
(Newhouse et al, 1976).
b) Anatomical: including the nose, epiglottis, larynx and respiratory branch
which are responsible for directing airflow. Branching and angulation of
airways are important in causing aerosolised particles to impact on the
mucosa, after which mucociliary clearance and other mechanisms on the
mucosal surface can aid removal or inactivation of offending particles
(Reynolds, 1989).
c) Non-specific factors: including lysozyme; anti-proteinases including a^-
proteinase inhibitor, antileukoproteinase and c^-macroglobulin; iron-
binding proteins, lactoferrin and transferrin; anti-bacterial activity of lung
surfactant; phagocytosis by alveolar macrophages and polymorphonuclear
leucocytes; bacterial cell lysis and enhancement of phagocytosis
(opsonophagocytosis) by the alternative complement pathway.
d) Specific immunological mechanisms: including the initiation of a humoral
antibody and a cellular response; opsonisation of microorganisms with
antibody enhances phagocytosis and initiates the classical complement
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pathway involved in the antibody lysis of cells as well as the attraction and
enhancement of the function of phagocytic cells.
The normal respiratory host defences outlined above combine to provide
surveillance and protection of the respiratory tract under normal circumstances.
However, if a sufficiently large bacterial inoculum reaches the lower respiratory
tract or if particularly virulent microorganisms are inhaled, the alveolar macro¬
phage system, for example, may be overwhelmed (Reynolds, 1983; Reynolds,
1989). In such circumstances the lung parenchyma mounts an extensive inflam¬
matory response that may be perceived as clinical illness (Reynolds, 1983).
Polymorphonuclear leucocytes may be recruited from the intravascular spaces
providing a secondary supply of phagocytes. A number of factors may initiate
the influx of polymorphonuclear leucocytes into the alveoli, including chemotax-
ins produced by alveolar macrophages, lymphokines produced by immune T-
lymphocytes, and the potent leucoattractant C5a, one of the complement pro¬
teins (Reynolds, 1983; Fick, 1989). In addition, alteration of the permeability of
the alveolar surface as a result of inflammation allows the entry of immunologic
factors from the plasma including extra complement, additional antibodies
including IgM, and other immune constituents including protease inhibitors
(Reynolds, 1983; Reynolds, 1989).
4.2 INITIAL COLONISATION OF THE CYSTIC FIBROSIS
RESPIRATORY TRACT
Initial colonisation by P. aeruginosa is an important predisposing factor in the
acquisition of pulmonary infection. The transition from asymptomatic
P. aeruginosa colonisation to chronic and progressive pulmonary infection is
difficult to define and may vary from one patient to another (H0iby, 1974).
Typing of P. aeruginosa including pyocin typing (Fyfe et al, 1984; Govan, 1988),
and a method based on Southern blotting and hybridisation with a DNA probe
derived from the exotoxin A gene (Ogle et al, 1987), have proved useful
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epidemiological tools and indicated the following:- 1) cross infection between
patients is rare, except between CF siblings; 2) the majority of CF patients
remain colonised with a single strain of P. aeruginosa which eventually exhibits
the mucoid phenotype (Govan, 1990).
The presence of non-mucoid strains of P. aeruginosa in the CF respiratory tract
has previously been deemed of no clinical significance (Henry et al, 1982).
However, non-mucoid strains probably play a critical role as a microbial reser¬
voir to allow the emergence and selection of more adaptable mucoid
phenotypes associated with progressive lung disease (Govan et al, 1984; Govan,
1988). The time taken for the emergence of mucoid P. aeruginosa in individual
patients is difficult to monitor since conversion is insidious and may occur in the
time interval between bacteriological investigations, and in many patients both
non-mucoid and mucoid forms are isolated on initial sputum culture (Govan,
1990). Epidemiological studies have indicated that the time interval between
initial colonisation with a typical non-mucoid strain and the emergence of a
mucoid form can be as short as three months (Govan, 1990).
4.3 SITES OF INITIAL COLONISATION
The precise mechanism of colonisation and the nature of the sites of early
asymptomatic colonisation with P. aeruginosa remain obscure. It has been
suggested that colonisation of the upper respiratory tract may precede aspira¬
tion of the organism into the lower airways where colonisation is established
(Komiyama et al, 1985; Lindemann et al, 1985; Baker, 1990). Reports of upper
respiratory tract colonisation sites include maxillary sinuses (Shapiro et al,
1982), tongue, buccal mucosa, saliva (Komiyama et al, 1985; Lindemann et al,
1985) and dental plaque (Komiyama et al, 1985). The difficulty of identifying
oral colonisation and distinguishing it from sputum contamination because of
the high concentration of bacteria in sputum was stressed by Lindemann et al
(1985). The average age of the patients in the studies of Lindemann et al (1985)
and Komiyama et al (1985) were 19 and 13.5 years respectively and therefore
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likely that many of the patients had chronic P. aeruginosa lung colonisation.
Since neither study reported examination of patients before they became
sputum positive, the presence and significance of P. aeruginosa isolated from
the oral cavity is uncertain. Indeed Iacocca et al (1963) reported that isolation
of an organism from deep throat or nasopharyngeal swabs of ten CF patients
reflects the presence of the organism below the larynx. In a recent report
Taylor et al (1990) were unable to demonstrate the presence of P. aeruginosa in
the upper respiratory tract of patients with an absence of pulmonary involve¬
ment, even in the case of a child who became sputum positive during the study.
Support for an oral reservoir of P. aeruginosa has been reported in a series of
investigations by Komiyama and colleagues. Komiyama & Gibbons (1984)
demonstrated interbacterial adhesion between strains of Actinomyces viscosus
indigenous to the human oral cavity and P. aeruginosa of non-CF origin. In a
later study interbacterial adhesion between P. aeruginosa (non-mucoid and
mucoid) and indigenous oral bacteria (including Streptococcus sanguis, Strepto¬
coccus mitis, A. viscosus and Actinomyces naeslundii) all of which were isolated
from the oral cavity of CF patients, was reported (Komiyama et al, 1987a). The
coaggregation reactions were dependent upon heat and protease sensitive
components of Pseudomonas, indicating that the interbacterial adhesion was
mediated by adhesins on the P. aeruginosa cell which bind to complementary
receptors on the cell surfaces of oral bacteria. It was suggested that interbacte¬
rial adhesion between P. aeruginosa and the oral bacteria had a possible role in
oral colonisation of CF patients and thereby influenced susceptibility of the host
to infection (Komiyama et al, 1987a).
Further studies also demonstrated the saliva-mediated aggregation of
P. aeruginosa, the authors speculating that this mechanism may have a role in
colonisation of patients with CF (Komiyama et al, 1987b; Komiyama et al, 1989).
The increased aggregation of P. aeruginosa by saliva from patients with CF was
directly related to the sialic acid content present, suggesting that this acidic
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molecule acts as the salivary receptor for P. aeruginosa (Komiyama et al, 1987b).
The sero-mucous products of the submandibular gland of patients with CF were
shown to have enhanced P. aeruginosa aggregation activity, and proposed to
have a role in the mechanisms by which the organism colonises or is cleared
from the oral cavities of patients with CF (Komiyama et al, 1989).
The possibility that colonisation of the gastrointestinal tract might act as a
reservoir of non-mucoid P. aeruginosa in CF has also been investigated
(Agnarsson et al, 1989). Faecal isolation of P. aeruginosa was observed in eight
of ten patients who at the time of sampling exhibited colonisation of the respira¬
tory tract. Thus in this group of patients it was not possible to determine
whether gut colonisation preceeded, or resulted from, colonisation of the respi¬
ratory tract. In contrast, P. aeruginosa cells were isolated at low frequency
(9.1%) from the stools of 44 patients with no previous history of chronic coloni¬
sation. The incidence for this latter group of CF patients was within the normal
range for both non-hospitalised patients (Rhame, 1980) and the 20-54% isola¬
tion rate reported for hospitalised patients (Bodey, 1970, Young & Armstrong,
1972). These observations led the authors to conclude that the gastrointestinal
tract is not a significant reservoir of P. aeruginosa prior to pulmonary
colonisation.
4.4 THE ROLE OF ADHERENCE IN COLONISATION
The first major interaction between a potential pathogenic microorganism and
its host, entails attachment to a eukaryotic cell surface (Finlay & Falkow, 1989).
Some microorganisms multiply at and remain on the surface whilst others use
attachment as the first essential step before proceeding to deeper tissue or other
locations. Adherence of P. aeruginosa to a number of cell surfaces has been
reported and implicated as one of the factors for colonisation and establishment
of the organism in the CF respiratory tract.
38
Adherence to buccal epithelial cells
An initial in vitro study on the adherence of P. aeruginosa revealed adhesion of
the organism to buccal epithelial cells (Johanson et al, 1979). Enhanced
adhesion was observed with buccal cells obtained from non-CF patients colo¬
nised with Gram-negative bacilli or after prior treatment of buccal cells with
trypsin (Johanson et al, 1979). Inhibition of adherence by purified pili and anti¬
serum to pili indicated the role of pili in adherence of P. aeruginosa to buccal
epithelial cells (Woods et al, 1980b). Subsequent in vitro studies showed
adherence of P. aeruginosa to buccal cells obtained from patients with CF,
increased adherence being associated with decreased amounts of the cell sur¬
face glycoprotein, fibronectin, and increased levels of salivary proteases (Woods
et al, 1980a; Woods et al, 1981). Normal resistance of upper respiratory tract
epithelial cells to Gram-negative colonisation is believed to be associated with
the presence of fibronectin (Woods et al, 1983). Fibronectin is thought to mask
Gram-negative bacterial receptor sites on the epithelial cell surface. Since
fibronectin is highly sensitive to proteases such as trypsin (Woods et al, 1981) and
since salivary protease levels in CF patients are significantly elevated over those
of controls, it would be reasonable to assume that increased levels in secretions
which bathe mucosal surfaces, may be responsible for the decreased levels of
fibronectin exposing receptors for adhesion to buccal cells (Woods et al, 1980a).
Although these in vitro observations suggested that buccal cells may form the
reservoir for colonisation of the CF respiratory tract this step has been difficult
to observe in vivo and would require frequent screening of patients. In vivo
observations reported by Govan (1988) showed that Pseudomonas was cultured
on only two occasions from buccal cells obtained directly from 88 CF patients.
Indeed a comparison of the adherence of P. aeruginosa to ciliated cells and
buccal cells revealed that nasal and tracheal cells bound more bacteria per cell
than did buccal cells (Niederman et al 1983). More recent in vitro studies have
further demonstrated pilus mediated adhesion of non-mucoid P. aeruginosa to
buccal epithelial cells (Doig et al 1988; Doig et al 1990). Investigations into the
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nature of the receptors indicate that they may consist of carbohydrate moieties.
Adherence of P. aeruginosa and P. cepacia to glycolipids on thin-layer chro-
matograms demonstrated binding to gangliotetraosylceramide (asialo GM1)
and gangliotriasylceramide (asialo GM2) (Krivan et al, 1988). In addition
Baker (1990), and Baker et al (1990) reported adherence of P. aeruginosa to a
number of sialylated glycolipids. Terminal or internal N-acetyl-p-D-galacto-
samine (1-4) p-D-galactose sequences were implicated as the minimal, specific
binding site (Krivan et al, 1988). Studies by Doig et al (1989) showed that
periodate oxidation of buccal epithelial cell blots eliminated pilus binding,
indicating that a carbohydrate molecule was necessary for receptor activity.
Sugar inhibition studies showed that sialic acid and L-fucose prevented pilus
binding to the buccal cells.
The initial adhesion studies by Woods et al (1980a) indicated that mucoid
strains did not adhere to normal or trypsinated buccal cells. This difference in
adhesion between non-mucoid and mucoid strains was thought to possibly
account for the common observation that initial Pseudomonas colonisation of
the CF respiratory tract was by non- mucoid P. aeruginosa (Woods et al, 1980a).
However, more recent evidence has shown that mucoid strains could also
adhere to buccal cells (McEachran & Irvin, 1985). Two classes of receptors
were identified:- 1) a high affinity, low copy number site, present after
trypsination and hypothesized to be the receptor for pili; 2) a low affinity, high
copy number, trypsin sensitive site proposed to be the receptor for alginate
(McEachran & Irvin, 1985). In a later study the binding of mucoid P. aeruginosa
to buccal and tracheal epithelial cells was shown to be strain dependent
reflecting structural diversity in P. aeruginosa alginates (Doig et al, 1987).
Adherence to cells of the lower respiratory tract
Initial colonisation of P. aeruginosa in the upper respiratory tract has been
proposed to precede aspiration into the lower respiratory tract where they
colonise epithelial cells or tracheobronchial mucins (Baker, 1990). Adherence
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studies of P. aeruginosa to hamster tracheal explants revealed that mucoid
organisms were more adherent than the non-mucoid isolates (Baker & Marcus,
1982). Mucoid organisms were usually found in microcolonies adhering to cilia,
transmission electron microscopy revealing interaction of the bacterial
glycocalyx with the glycocalyx on the cilia (Baker & Marcus, 1982). Quantitation
of adherence by the tracheal perfusion model further indicated the greater
affinity of mucoid strains of P. aeruginosa for tracheal epithelium isolated from
hamsters, mice and guinea pigs (Marcus & Baker, 1985; Marcus et al, 1989).
Scanning electron microscopy again revealed the presence of microcolonies of
mucoid organisms attached to cilia and associated with the mucus layer cover¬
ing the epithelium (Marcus & Baker, 1985). Adherence of mucoid isolates to
cilia of human tracheal cells has also been observed (Franklin et aL, 1987).
A number of experimental observations indicated that the adhesin for mucoid
strains was alginate including inhibition by the positively charged polymer poly-
L-lysine, inhibition by anti-alginate antibodies (Marcus et al, 1989; Baker, 1990),
and by the ability of purified alginate to bind to the cilia of human epithelial
cells (Doig et al, 1987). Sugai inhibition studies with the perfused-trachea
model showed that N-acetylglucosamine, galactose and N-acetylneuraminic acid
were the best inhibitors of mucoid strains of P. aeruginosa and may represent
important components of receptors on cilia or mucins (Marcus et al 1989).
Adherence to damaged epithelium
Ramphal & Pyle (1983a) have shown that both non-mucoid and mucoid strains
of P. aeruginosa could adhere to acid-injured tracheal epithelium from mice.
Previous work also showed that the organisms could adhere to tracheal
epithelium injured by influenza virus or by intubation (Ramphal et al, 1980).
Additional studies using the acid-damaged tracheal model showed that the
adherence of mucoid and non-mucoid strains was inhibited by N-acetylneura-
minic acid and mucin (Ramphal & Pyle, 1983b). Purified pili and anti-pilus
antibodies inhibited the adherence of non-mucoid strains to injured epithelium,
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but had no effect on adherence of mucoid strains (Ramphal et al, 1984). In
contrast antibodies against alginate inhibited the binding of mucoid strains to
damaged epithelium but had no effect on the adherence of non-mucoid strains
(Ramphal & Pier, 1985). Further studies on the tracheal receptor for P.
aeruginosa indicated that both non-mucoid and mucoid strains bound to sialic
acid containing glycolipids, probably a ganglioside (Ramphal & Pyle, 1985;
Krivan et al, 1988).
Whilst the specific interaction between injured tracheal cells and P. aeruginosa
is apparent, it is uncertain whether this is necessarily relevant to chronic
colonisation in CF (Ramphal & Vishwanath, 1987). It is possible to speculate
that cells injured by viruses or mycoplasmas during exacerbations could
become colonised. In support of this theory Kubesch et al (1988) reported
greater binding of P. aeruginosa to buccal cells from patients who had acute
upper airway viral infection of their upper airways. Non-mucoid strains of P.
aeruginosa do not adhere well to normal ciliated epithelial cells (Ramphal &
Pyle, 1983a) indicating that prior damage may be necessary for colonisation.
Morphological studies of the respiratory epithelium of CF patients who had not
had any documented infections indicated that the epithelium was not abnormal
(Sturgees, 1981).
Mucociliary clearance and adherence to mucins
The mucociliary transport apparatus of the respiratory tract is responsible for
clearing natural cellular debris and inhaled particulate material, including
bacteria, from the respiratory mucosa and is thought to play a major role in
prevention of respiratory infections (Reynolds, 1983). The two major compo¬
nents of this mechanism are the mucus blanket and the underlying cilia whose
beating motion provides the means for mucus flow up the respiratory tract.
Mucus is a complex secretion from secretory cells of the submucosal layer and
surface epithelium, locally produced substances and tissue fluid transudate
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(Lopez-Vidriero, 1981; Reynolds, 1983). Mucus is composed of 95% water with
the glycoprotein, mucin as the major macromolecular component (Lopez-
Vidriero, 1981). Other components of respiratory mucus include lipids, immu¬
noglobulins, lactotransferrin, nucleic acids, proteolytic enzymes and protease
inhibitors (Roussel, 1984). Respiratory mucins, secreted by the submucosal
glands and goblet cells of the surface epithelium (Rose et al, 1984), are respon¬
sible for the Theological and sticky properties of mucus (Lopez-Vidriero, 1981).
These high molecular mass, filamentous glycoproteins contain several hundred
oligosaccharide chains in glycosidic linkages to serine and threonine residues of
the polypeptide chain (Rose et al, 1984; Slayter et al, 1984). The highly gly¬
cosylated regions are resistant to proteases, whilst the naked regions devoid of
carbohydrate chains are susceptible to proteolytic degradation.
The question of an inherited abnormality in mucins from patients with CF is
uncertain although increased levels of sulphation of the carbohydrate chains has
been reported (Boat et al, 1976; Chace et al, 1985). Some characteristic features
of CF mucin including increased acidity and a decreased proportion of neutral
glycopeptides (Houdret et al, 1989) and the apparent lower molecular mass of
CF respiratory mucins (Rose et al, 1987) have been attributed toAgradation by P.
aeruginosa, including degradation by both P. aeruginosa and neutrophil
proteases (Rose et al, 1987; Houdret et al, 1989; Poncz et al, 1988). In addition
both elastase and alkaline proteinase from P. aeruginosa have been shown to
stimulate mucin secretion by rabbit tracheal epithelium (Klinger et al, 1984).
Since the increased production of mucin and production of viscid respiratory
secretions are basic characteristics of CF and play an important part in its
pathophysiology, the influence of bacterial and other proteases may exacerbate
the condition.
In healthy individuals mucociliary clearance is mediated by a complex series of
interactions between mucus, cilia and the intervening watery periciliary fluid
lying below a thick layer of mucus (Greenstone & Cole, 1985). Mucus is re-
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leased onto the surface of the ciliated epithelium as droplets and these are
drawn out into strands by the action of the cilia which beat in the periciliary
zone of fluid of low viscosity (Sleigh, 1981). Driven by the coordinated beating
of the cilia the mucous blanket is moved at a rate of 0.5-1.5 cm/min towards the
larynx where the mucus is either swallowed or expectorated (Greenstone &
Cole, 1985, Hingley et al, 1989). If the periciliary zone of fluid is too shallow or
too deep the propulsion of mucus will be severely restricted or may cease
altogether (Sleigh, 1981). In addition, if the mucus layer is too thick uncoupling
may occur within it so that the inner part is transported by ciliary beating but
the outer part, to which bacteria may adhere, remains stationary (Cole &
Wilson, 1989). In general, both the rate of ciliary beat and proportion of ciliat¬
ed cells in the epithelium increase from smaller to larger airways so that the
role and efficiency of mucus propulsion increases as it ascends the mucociliary
escalator (Sleigh, 1981).
Malfunction of mucociliary clearance may result from intrinsically defective
cilia, from infections that are ciliolytic (Mycoplasma pneumoniae) or actually
destroy the cilia-containing epithelial cells (viral agents), and from abnormal
mucus secretion (Reynolds, 1983). The term ciliary dyskinesis is used to de¬
scribe congenital abnormalities in the structure and function of cilia. Patients
suffering from such a condition are prone to recurrent chest infections, and
coughing is a prominent symptom in an attempt to remedy mucus stasis caused
by impaired mucociliary clearance (Greenstone & Cole, 1985).
In CF, mucus secretions are copious, inspissated and stagnant, mucociliary
clearance is slowed and mucopurulent plugging of peripheral airways forms part
of the early pathologic lesion (McPherson & Dormer, 1987; Fick, 1989). The
stagnation of mucus in CF implies a defect or interference in the mucociliary
system. The presence of an increased depth of tenacious and dehydrated
mucus, as well as dehydrated periciliary fluids may contribute to reduced
mucociliary transport in CF (Wood et al, 1976; Fick, 1989). Wood et al (1976)
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reported that mucociliary clearance was five to ten-fold lower than in normal
controls. A reduced mucus transport rate in 14 adult CF patients was also
reported by Wanner (1981) although no correlation between transport rate and
clinical status was found. However, Yeates et al (1976) observed abnormal
mucociliary transport in some, but not all CF patients, and Rutland & Cole
(1981) noted that in vitro ciliary beat frequency of nasal epithelium was normal
in patients with CF. The presence of a ciliotoxic factor in the serum of patients
with CF has been described, but is also present in unaffected heterozygotes
(Spock et al, 1967).
Viral and mycoplasmal infections may damage the mucociliary system in CF,
and inactivation of ciliary beat by extracellular products of P. aeruginosa and
H. influenzae has also been reported (Wilson et al, 1985). In particular
P. aeruginosa rhamnolipid, pyocyanin and proteases have been implicated as
important ciliostatic factors released by P. aeruginosa which act on the
membrane and the axoneme of respiratory cilia (Hingley et al, 1989; Wilson
et al, 1989). By interfering with normal ciliary function these ciliostatic factors
might enable P. aeruginosa to more easily colonise the respiratory tract
(Hingley et al, 1989).
Microorganisms may become entrapped in mucus (prior to subsequent removal
by cephalad ciliary movement in normal individuals) because of its stickiness or
because of a specific interaction between receptors in mucin and surface
components of bacteria (Vishwanath & Ramphal, 1985).
P. aeruginosa has been shown to adhere to mucin strands in mouse trachea
(Ramphal & Pyle, 1983a). A microtitre plate assay developed by Vishwanath &
Ramphal (1984) for the study of adherence of P. aeruginosa to human tracheo¬
bronchial mucin demonstrated that P. aeruginosa binds preferentially when
compared to other Gram-negative organisms. Adherence of both mucoid and
non-mucoid strains was reported (Vishwanath & Ramphal, 1984) and, as for
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other adherence studies, the adhesins appeared to be different. Purified alginate
attached to mucins and antibodies to the exopolysaccharides, blocked
adherence of mucoid strains to mucin (Ramphal et al 1987). Purified pili and
antibodies to pili blocked adherence of non-mucoid, but not mucoid strains to
mucins (Ramphal et al, 1987). The adherence of both groups of organisms was
sensitive to periodate oxidation, to neuraminidase treatment of mucin, and to
pretreatment of the bacteria with N-acetylneuraminic acid or N-acetylglucosa-
mine (Vishwanath & Ramphal, 1985). These amino-sugars were proposed to
form important constituents of the binding sites for P. aeruginosa on human
tracheobronchial mucin (Vishwanath & Ramphal, 1985). A recent report by
Ramphal et al (1989) suggested that CF mucins may be altered after infection
with P. aeruginosa is established, resulting in less binding to some fragments.
Sulphated fractions showed no binding of P. aeruginosa leading to the
suggestion that sulphation may be a mechanism to reduce binding (Ramphal
et al 1989).
Since the clearance of mucus is defective in CF, binding of P. aeruginosa to
mucins may play an important step in colonisation of the CF respiratory tract
(Ramphal & Vishwanath, 1987). The association of P. aeruginosa with mucin
and its relevance to colonisation in CF has been supported by other observa¬
tions: Simel et al (1984) and Jeffery & Brain (1988) observed the association of
P. aeruginosa with surface mucous secretions rather than with the underlying
epithelia in scanning electron microscopy studies of CF lung tissue. Indeed the
binding of P. aeruginosa to mucin has been hypothesized to protect the organ¬
ism from opsonophagocytic killing and may be responsible, in part, for its
persistence in the CF respiratory tract (Ramphal & Vishwanath, 1987).
4.5 ADAPTATION OF P. AERUGINOSA TO THE LUNG
ENVIRONMENT
The ability of P. aeruginosa to colonise and cause significant morbidity in CF
patients is due to a combination of innate and adaptive properties (Govan,
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1990). As indicated previously, the isolation of mucoid P. aeruginosa in sputum
is almost diagnostic of CF in adolescent patients with chronic pulmonary dis¬
ease, and is the major cause of morbidity and mortality (H0iby, 1984; Govan,
1988; Govan & Glass, 1990).
The possibility that environmental factors within the CF bronchial secretions
might induce or switch on the production of alginate and hence influence the
emergence of mucoid P. aeruginosa has been proposed and several attendant
factors proposed: the presence of dipalmitoyl-phosphatidylcholine, the major
lung surfactant (Govan, 1975); increased osmolarity (Berry et al, 1988; Govan,
1990); effects of individual cations (Boyce & Miller, 1982a); nutrient limitation
(Govan, 1990; Speert et al, 1990); selection by phage (Govan, 1975) and
antimicrobial pressure (Govan, 1976; Govan & Fyfe, 1978; Deretic et al, 1986).
P. aeruginosa is associated with intrinsic resistance to many antimicrobial
agents, a property held responsible for the emergence of the species as a signifi¬
cant opportunistic pathogen (Govan, 1989). However, in the CF lung, isolates of
P. aeruginosa may exhibit the paradoxical characteristic of antibiotic hypersus-
ceptibility (May & Ingold, 1972; Irvin et al, 1981; Fyfe & Govan, 1984). The
degree of enhanced susceptibility is most evident with carbenicillin and be¬
comes less significant as the anti-pseudomonal activity of the antibiotic in¬
creases: with ciprofloxacin, hypersusceptible variants are only 2.5 fold more
susceptible than normal isolates (Govan, 1989).
Although alginate biosynthesis and hypersusceptibility are frequently present in
the same isolate, the two chromosomal mutations (bis and tps) which encode
hypersusceptibility are distinct from those involved in alginate biosynthesis
(Fyfe & Govan, 1984). Hypersusceptibility is almost exclusively confined to
respiratory isolates of P. aeruginosa (Irvin et al, 1981), the frequency of such
isolates increasing in patients with established pseudomonal colonisation
(Govan, 1989). Paradoxically, hypersusceptible P. aeruginosa are not
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eliminated during antibiotic therapy and may even increase during anti-
pseudomonal therapy (Govan, 1989). Hypersusceptibility together with alginate
biosynthesis must confer significant advantages for bacterial growth and
survival in the respiratory environment (see 4.6 The Microcolony Mode of
Growth).
Another common feature of P. aeruginosa strains isolated from patients with
CF is that of serum sensitivity (Thomassen & Demko, 1981; Hancock et al, 1983;
Penketh et al, 1983). In a survey of 109 CF isolates, 87 sputum isolates from
non-CF patients and 118 isolates from other clinical sources, Penketh et al
(1983) showed that 53.2% of the CF isolates were serum sensitive which was
significantly greater than in either of the control groups. In addition 68% of the
CF strains could not be serotyped due to loss of the O-type reaction and 50.5%
showed multiple agglutination reactions with O-antisera (ie polyagglutinable)
and expressed the polyagglutinating (PA) antigen. Although there was close
correlation between serum sensitivity, loss of O-type reaction and expression of
PA antigen (Penketh et al, 1983; Pitt et al, 1986), some intermediate strains were
identified with some, but not all of these features (Penketh et al, 1983). In
addition these phenotypic characteristics were also seen in non-CF isolates
suggesting that they are not specific to CF, but perhaps relate to chronic
colonisation by the organism.
The above study also revealed that patients recently colonised by P. aeruginosa
had strains of the organism similar in characteristics to those from other clinical
sources. In contrast, patients chronically colonised by the organism tended to
express all three characteristics, whilst patients infected by organisms of an
intermediate type were often more severely affected by the disease. These
observations led the authors to suggest that in chronic bronchopulmonary
infection with P. aeruginosa in CF the organism undergoes an environmental
adaptation marked by changes in somatic antigens and serum sensitivity, and
that during the period of adaptation the condition of some patients may greatly
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deteriorate.
In a similar study by Hancock et al (1983) a strong correlation between the
apparent numbers of O-side chains, sensitivity to serum, and non-typability was
reported for isolates from patients with CF. The relationship between polyag-
glutinability and loss of serum resistance in P. aeruginosa strains from CF was
further reported by Pitt et al (1986). Evidence for the role of LPS in serum
resistance was the finding that the LPS of serum resistant variants derived from
serum-sensitive parents were heterogenous and contained O-side chains, whilst
serum-sensitive counterparts contained primarily lipid A/core polysaccharide
components (Schiller et al, 1984). Fomsgaard et al (1988a) showed immuno¬
chemical similarities between LPS core/lipid A antigens in typable and polyag-
glutinable strains from CF lungs indicating that this region of the molecule is
conserved when O-antigenic units are lost. However, LPS integrity may not be
the only factor in determining serum resistance in P. aeruginosa. Pitt (1989)
reported that a number of LATS serotype strains as well as some serotypable
clinical isolates were serum sensitive and suggested that a 32-kilodalton outer
membrane protein previously identified by Schiller et al (1984) may play a role
in serum killing.
The role of antibody and both the classical and alternative complement path¬
ways in serum killing of serum sensitive strains of P. aeruginosa have been
investigated. Whether complement-mediated killing is a normal host defence in
sputum is unknown since many of the complement proteins are difficult to
identify in respiratory secretions (Fick, 1989). Several investigators have pre¬
sented evidence suggesting the importance of the classical complement pathway
activated by antibodies in the killing of P. aeruginosa strains (Thomassen &
Demko, 1981; Borowski & Schiller, 1983). Other reports have stated that certain
strains are killed by complement activated via the alternative complement
pathway in the apparent absence of antibodies (Pier & Ames, 1984): lipid
A/core polysaccharide is known to activate the alternative complement path-
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way in the absence of antibody (Morrison & Kline, 1977). The exposure of these
components in O-side chain deficient strains of P. aeruginosa perhaps counts for
their serum sensitivity. In an examination of seven serum sensitive strains
obtained from the sputa of patients with CF, Schiller (1988) found that bacteri¬
cidal killing could occur via either of the complement pathways, although
maximum killing of four of these strains required the function of both pathways.
In addition, antibodies in pooled normal human serum specific for rough-type
LPS on serum-sensitive strains are able to mediate bacterial killing via the
classical complement pathway (Schiller, 1988).
Antigenic variation of P. aeruginosa in the respiratory tract may well suppress
the development of an effective antibody response to the organism (Penketh
et al, 1983) whilst the high incidence of serum sensitive strains could account for
the low incidence of septicaemia in CF patients (Hancock et al, 1983).
However, Thomassen & Demko (1981) demonstrated that some CF sera
contained blocking antibodies which neutralised the bactericidal activity of a
patient's serum for the homologous P. aeruginosa strain.
Engels et al (1985) showed that with respect to P. aeruginosa strains PAC1 and
PAC605, the lack of an O-side chain in the latter resulted in increased
sensitivity to serum and decreased virulence. The authors concluded that the
structure of the O-antigen polysaccharide side-chain of LPS is of crucial
importance for evasion of host defence mechanisms by P. aeruginosa, able to
resist serum killing by shedding the C5b-9 complement complexes even in the
presence of antibodies. Indeed, studies by Cryz et al (1984) showed that an LPS-
defective, serum sensitive variant was approximately 1,000 fold less virulent
than the parent strain. However, the ability of an opportunistic organism like
P. aeruginosa to modify the LPS structure, perhaps under the influence of
environmental factors (Day & Marceau-Day, 1982), may give the organism a
survival advantage and help it persist within the CF lung.
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4.6 THE MICROCOLONY MODE OF GROWTH
Direct microscopic examination of tissue from acute P. aeruginosa infections,
including burn and acute lung infections, reveals the organism to be widely
dispersed throughout the specimen (Costerton et aL, 1990). In contrast the
mucoid P. aeruginosa present in the CF-post mortem lung (Lam et al 1980) and
in CF sputum (H0iby, 1982; Govan & Harris, 1986) can often be seen as large
microcolonies adhering to bronchial mucosa. In the study of Lam et al (1980)
direct electron microscopic examination of post mortem lung material from CF
lungs revealed large, coherent microcolony structures in which alginate
occupied more space than the enclosed P. aeruginosa cells themselves. Further
experiments showed that the microcolonies could be duplicated in in vitro
cultures and in animal model experiments involving pulmonary infections of
rats by the agar bead method developed by Cash et al (1979).
The microcolony form of growth, also applicable for growth of P. aeruginosa in
natural and other pathogenic environments (Costerton, et al, 1990), has been
used to construct a model which takes account of the unusual properties of
P. aeruginosa and the survival and pathophysiology of pseudomonal infection
in the CF lung (Govan & Harris, 1986; Govan, 1988) (see Figure 3). Once
initial adhesion to a surface is complete the adherent cells produce large
amounts of alginate and divide to produce polysaccharide enclosed
microcolonies of sister cells. A coherent biofilm is eventually produced when
cell division and alginate production cause adherent microcolonies to coalesce,
the process being further accelerated by adhesion of motile, planktonic
bacterial cells. Organisms within the glycocalyx matrix are protected from
external antibacterial influences although motile, planktonic cells may leave
the biofilm and adhere to new surfaces and initiate the formation of new
biofilm communities (Costerton et al 1990).















STIMULATED BY Fc RECEPTOF








I by bacterial protease (P)
Figure 3. Microcolony mode for survival and pathogenesis of mucoid P. aeruginosa within a CF
lung. (See text for description; from Govan, 1988). ss = serum sensitivity; pa = polyagglutinating
antigen; A = alginate matrix; P = protease; muc = mucoid phenotype; alg = alginate.
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of the pseudomonal alginate coupled with the raised Ca^+ and DNA levels
found in the CF lung (Govan & Harris, 1986; Govan, 1988). As discussed earli¬
er, the alginate may be responsible for adherence of mucoid P. aeruginosa to
tracheal epithelum or mucosal material. Indeed, provided the bacterial alginate
is not removed by centrifugation and washing, evidence from intratracheal
inoculation into rat lungs indicates that mucoid P. aeruginosa are removed less
rapidly than isogenic non-mucoid strains (Govan et al, 1983).
It has been proposed that motility would not be a major factor in the survival of
pathogens within the microcolony (Costerton et al, 1990). In the case of the
microcolonies found in CF this theory is supported by the observations of
Luzar et al (1985) who reported that rough strains from patients in poor clini¬
cal condition either lacked flagella, as determined by electron microscopy, or
demonstrated weak motility both in soft agar and by the capillary assay. Alter¬
ations in the synthesis of LPS were proposed to favour non-flagellated
P. aeruginosa strains in patients who had harboured the pathogen for prolonged
periods of time, since a basal body ring of the flagellum is associated with the
LPS in the outer membrane of the cells.
Within the microcolony the decreased susceptibility of mucoid P. aeruginosa to
antibiotics (in the absence of bis and tps mutations) is probably not due to a
diffusion barrier or binding by the alginate but possibly from antagonism of p-
lactams and aminoglycoside antibiotics by the high electrolyte content of the
alginate gel structure (Slack & Nichols, 1981), modification of the alginate gel
structure, or other biofilm associated mechanisms (reviewed by Govan, 1989).
Protection afforded by the microcolony may also account for the apparently
paradoxical characteristics of serum sensitivity and hypersusceptibility to
antibiotics. In vivo the selective advantage for the bis and tps mutations may he
in conferring greater permeability for the limited nutrients within the alginate
matrix (Govan & Harris, 1986; Govan, 1988).
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The microcolony mode may account for the inability of the normally highly
efficient pulmonary immune system to remove P. aeruginosa from the CF lung
(Govan, 1988). With other exopolysaccharide producing pathogens, including
Streptococcus pneumoniae and Klebsiella pneumoniae opsonisation by specific
antibodies assists ingestion and killing by phagocytic cells. However, in the CF
lung the size and gelatinous nature of the alginate microcolony would present a
formidable and persistent target (Govan, 1988). It has been estimated that
microcolonies may reach 60 pm in diameter and are thus considerably larger
than the surrounding phagocytic cells (10 pm) Govan, 1990).
The possible antiphagocytic nature of alginate has been reported by a number
of investigators although the subject is controversial and has been disputed by
others. In a study by Schwartzmann & Boring (1971) alginate containing extra¬
cellular material from mucoid P. aeruginosa inhibited the killing of bacteria by
rabbit neutrophils, whilst Oliver & Weir (1983) reported that alginate inhibited
the binding of an isogenic non-mucoid revertant to mouse peritoneal and
pulmonary macrophages. Experiments by Simpson et al (1988) showed that
purified exogenous alginate inhibited both the uptake and subsequent degrada¬
tion of non-mucoid P. aeruginosa by mouse peritoneal macrophages. The
authors concluded that evasion of host defences is probably due to the physical
rather than the chemical properties of the alginate, including both size and
viscoscity characteristics. Further evidence presented by Simpson et al (1989)
demonstrated that the scavenging properties of P. aeruginosa alginate may
protect the bacterium from free radicals generated by phagocytes and hence
interfere with the killing mechanisms of phagocytes.
Both Cabral et al (1987) and Krieg et al (1988) showed that alginate from
mucoid P. aeruginosa may render the organism resistant to non-opsonic
phagocytosis, the former suggesting that this property may give a survival
advantage in the early course of pulmonary infection before opsonic antibody
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and complement are present in respiratory secretions.
Baltimore & Mitchell (1980) found that a higher concentration of antiserum
was required to achieve a ten-fold reduction in viable mucoid P. aeruginosa
compared to isogenic non-mucoid strains. However, these observations were
not confirmed by LeBlanc et al (1982) who could find no difference between
mucoid and non-mucoid strains in a chemiluminescence assay with CF serum.
Indeed, the antiphagocytic effect ascribed to mucoid exopolysaccharide was not
confirmed by Pier (1989) who suggested that variation in technique and source
of assay components was likely to account for some of the discrepancies.
The term "frustrated macrophage" has been applied to phagocytes which would
normally phagocytose P. aeruginosa (Govan & Harris, 1986; Govan, 1990).
Frustrated phagocytic cells, particularly pulmonary neutrophils stimulated by
immune complexes or altered immunoglobulins, release elastase and toxic
oxygen radicals which may explain the considerable evidence for immune
mediated damage in CF lungs (see Chapter 5).
4.7 EXTRACELLULAR VIRULENCE FACTORS OF P. AERUGINOSA
AND THEIR ROLES IN PATHOGENESIS OF CYSTIC FIBROSIS
Indirect evidence for the production in vivo of exoenzymes by CF strains of
P. aeruginosa have come from the observation that significant levels of anti¬
bodies to the bacterial exoenzymes have been detected in sera of infected
patients (Granstrom et al, 1984; Doring et al, 1985; Hollsing et al, 1987). In
addition, many CF isolates of P. aeruginosa are able to produce the respective
exoenzymes in vitro (Woods & Sokol, 1986).
P. aeruginosa produces two proteases alkaline phosphatase and elastase, both of
which are metalloproteases (Kharazmi, 1989). There is considerable evidence
from in vitro studies that P. aeruginosa proteases inhibit the function of phago¬
cytes, natural killer cells and T cells, probably by cleavage of receptors involved
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in cell function. The proteases also inhibit the biological activities of interleu-
kin-1 and interleukin-2, and inactivate immunoglobulins and complement
(reviewed by Kharazmi, 1989). Baker (1982), utilising hamster tracheal organ
culture, concluded that the elastase (and other exoenzymes) of P. aeruginosa
may be responsible for much of the destruction of respiratory tissue in
Pseudomonas infections. In CF, P. aeruginosa elastase has been implicated in
the cleavage of IgG, secretory IgA and the complement proteins C3 and C5, and
therefore hinders opsonophagocytosis of the organism (Fick, 1989; Bainbridge &
Fick, 1989).
The bulk of the proteolytic activity in bronchial secretions has been attributed
to the neutrophil serine elastases including elastase, collagenase and
cathepsin G (Suter et al, 1984). However, although the Pseudomonas elastase
contribution to the total proteolytic activity present in CF airway fluids is small
(Suter et aL, 1984), the potency of P. aeruginosa elastase for the substrate elastin
far exceeds that of human neutrophil elastase, and the bacterial exoprotein is
likely to be present in higher concentrations in the local milieu immediately
surrounding the microcolony (Bainbridge & Fick, 1989). In addition, the major
proteinase inhibitors of the human airway, a-^-proteinase inhibitor and
antileukoproteinase are inactivated by the bacterial proteinase (Fick, 1989).
The only airway proteinase inhibitor with reported neutralizing activity versus
Pseudomonas elastase is o^-macroglobulin which is usually present at only very
low levels in airway secretions (Bainbridge & Fick, 1989).
The exoproteinases of P. aeruginosa are believed to support bacterial
colonisation at the onset of infection by impairing antimicrobial defence
mechanisms of the CF host, whereas during later stages of infection they
become inactivated by neutralising antibodies; the same is also believed to be
true of exotoxin A (Doring et al, 1985). In a study of P. aeruginosa from CF
patients in good clinical condition, 72% of strains demonstrated proteolytic
activity, whereas 60% of isolates from patients in poor clinical condition were
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not proteolytic (Luzar & Montie, 1985). The observation that mucoid strains
produce less extracellular proteolytic activity than their isogenic non-mucoid
revertants (Ohman & Chakrabarty, 1982) also supports the hypothesis that
following alginate conversion in the lungs of CF patients, low level production
of proteinases may contribute to the unique ability of mucoid P. aeruginosa to
maintain chronic infections. Experiments by Goldberg & Ohman (1987)
indicate transcriptional control over proteinase genes when alginate production
is activated.
Pseudomonal alginate has been reported to enhance exolipase activity in a time
and concentration dependent manner (Wingender & Winkler, 1984). It remains
to be investigated whether lipase contributes as a virulence factor to the
persistence of mucoid P. aeruginosa in chronic lung infections eg by the
destruction of lung tissue or surfactant.
Both exotoxin A, the most toxic exoenzyme of P. aeruginosa, and exoenzyme S,
which function as distinct ADP ribosyl transferases, are produced by only a
minority of isolates from CF patients (Vasil, 1986). Their mode of action is
similar to the diphtheria toxin in that both transfer the ADP ribose moiety to
elongation factor-2 thereby inhibiting eukaryotic protein synthesis (Fick, 1981).
The biosynthesis of exotoxin A, as well as proteases, has been shown to be
enhanced in iron-deficient culture (Vasil, 1986) and recent studies demonstrate
that this regulation is at the level of transcription (Grant & Vasil, 1986). Use of
animal models has indicated the involvement of exotoxin A in histopathological
change and respiratory tissue destruction (Baker, 1982; Cash et al, 1983), and a
possible role in CF. Evidence that exoenzyme S may play a role in lung injury
during P. aeruginosa infection has been provided by light and electron micro¬
scopic characterisation of lung injury after intratracheal instillation of purified
exoenzyme S which could reproduce the pathological changes described for
P. aeruginosa in lung infection (Woods et al, 1988).
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The haemolysins, phospholipase C, rhamnolipid, and phenazine pigment, have
also been postulated to play a role in the pathogenesis of P. aeruginosa in CF.
In view of the high phospholipid content in the respiratory tract, phospholipase
C has been postulated as a potential pseudomonal colonising factor, giving rise
to the early phospholipase antibodies observed by Hollsing et al (1987). The
enzyme may be involved in the degradation of lung surfactant and lung tissue
(Liu, 1974).
Kownatski et al (1987) found rhamnolipids (heat-stable haemolysin) in sputum
from CF patients chronically colonised with P. aeruginosa, high concentrations
correlating with poor clinical status; the rhamnolipids were absent in non-colo¬
nised patients. Rhamnolipids are small detergent like substances which may aid
solubilisation of phospholipids, and are also known to inhibit the action of cilia
(Hingley et al, 1989; Wilson et al, 1989).
Bacteria adherent to the mucosa of the CF airway require iron for growth (Fick,
1989). However, in the aerobic environment of the lung, iron is oxidised to
*1 I
FeJ_r forming insoluble ferric hydroxide. In addition most of the iron in the
respiratory tract is strongly bound by the glycoproteins transferrin, and lactofer-
rin, the primary iron binding protein on human mucosal surfaces (Fick, 1989;
Fick & Hata, 1989).
In situations of iron deprivation P. aeruginosa responds by the production of
high molecular outer membrane proteins (Brown et al, 1984; Cochrane et al,
1988a) which may act as receptors for the low molecular weight iron chelators
(siderophores) pyochelin and pyoverdin also produced under iron stress condi¬
tions (Fick, 1989). In addition the blue, phenolic, phenazine pigment, pyocyanin
is also produced to reduce Fe^+ to the more soluble Fe^+ form, and thus
make iron available for bacterial growth (Fick, 1989). The anionic alginate
matrix, shown to be stabilised in iron deficient conditions (Boyce & Miller,
1982a) may serve to concentrate iron and siderophores (Shand et al, 1989). As
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previously indicated pyocyanin may act as a ciliostatic factor (Hingley et aL,
1989; Wilson et al 1989).
It is a common observation that antibiotic treatment of pulmonary exacerba¬
tions due to P. aeruginosa in CF patients results in improved lung function and
reduction in the levels of the acute phase protein CRP (C-reactive protein) to
normal, even when numbers of P. aeruginosa present in sputum remains high
(Glass et al, 1988). This beneficial effect of antibiotics may be due to suppres¬
sion of pseudomonal virulence and tissue damaging enzymes (Govan et al,
1987). In addition, subinhibitory concentrations of antipseudomonal agents
have been shown to inhibit adherence of mucoid P. aeruginosa to tracheobron¬
chial mucin (Vishwanath et al 1987) and intact hamster tracheal epithelium
(Geers & Baker, 1987).
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CHAPTER 5
ANTIBODY RESPONSE TO P. AERUGINOSA IN CYSTIC FIBROSIS
No specific primary defect in the immunological defence mechanisms of CF
patients has been demonstrated (Schi^tz, 1982; Fick, 1989). CF patients exhibit
a normal systemic humoral response to various vaccinations (H^iby, 1977) as
well as various bacterial, viral, dietary and drug protein antigens (Wallwork
et aL, 1974). In fact the available evidence suggests that antibodies may actually
participate in various immunopathological mechanisms which contribute to the
pathogenesis of P. aeruginosa lung infection in CF (H0iby & Schi^tz, 1982;
H0iby et al, 1986; Dasgupta et al, 1981)
5.1 SERUM AND MUCOSAL ANTIBODIES
Compared with normal children CF patients have normal or increased numbers
of circulating B lymphocytes (H^iby & Mathiesen, 1974). Upon antigenic
stimulation B lymphocytes are induced to produce immunoglobulin specific for
that particular antigen. Immunoglobulins are the major glycoproteins of the
humoral immune system and five different classes are recognised: IgG, IgA,
IgM, IgD and IgE. In serum, IgG may account for up to 80% of the total
immunoglobulin concentration followed by IgA (10-15%), IgM (10%) and less
than 1% and 0.01% of IgD and IgE, respectively (Pedersen et al, 1989b).
Immunoglobulins have a dual function, the Fab region of the molecule
constituting the antigen binding site, whilst the Fc region binds to complement
and to various host cells, such as neutrophils and macrophages, and mediaties
immune reactions including opsonsophagocytosis and the classical complement
pathway. In addition, binding of immunoglobulins to their respective target may
mediate immunological protection by neutralization (eg toxins, enzymes) and
may include precipitation of soluble antigens, or agglutination of insoluble
antigens.
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The major mediator of humoral immunity on mucosal surfaces is IgA
(Bienenstock & Befus, 1980; Kilian et al, 1988) although IgG appears to be the
principal opsonin in normal respiratory secretions (Reynolds & Thompson,
1973). IgM antibodies are largely restricted to the bloodstream and are found
only in miniscule amounts in the respiratory tract (Kazmierowski et al, 1977)
probably due to size constraints preventing diffusion across the blood-alveolar
barrier (Reynolds, 1989). Secretory IgA is synthesized by local plasma cells as a
dimer containing a joining polypeptide J-chain. Another polypeptide, the
secretory component, is synthesized in epithelial cells and binds to dimeric IgA
forming secretory IgA which is released via the apical membrane to the mucosal
surface (Bienenstock & Befus, 1980). Secretory IgA tends to be present in high
concentrations in the upper and large airways but diminishes in relative
concentration in distal portions of the lung (Reynolds, 1983). This may reflect
its importance in the nasopharynx and large airways where it forms part of the
mucosal barrier preventing adherence of microorganisms, neutralization of
toxins, and inhibition of antigen penetration through the mucosa (Reynolds,
1983; Kilian et al, 1988). Because of its less efficient opsonizing potential and
uncertain interaction with the complement system (Reynolds & Thompson,
1973; Reynolds, 1983) secretory IgA may be less important in the peripheral
airways and alveoli. IgG is the predominant antibody found in these regions
(Reynolds, 1983; Bienenstock, 1984; Reynolds, 1989) and is essential to the
optimal clearance of P. aeruginosa from the distal human airway (Fick & Hata,
1989). Increased levels of IgG in respiratory secretions may be associated with
transudation from serum, particularly during respiratory infection (Bienen¬
stock, 1984).
Many studies of the immunoglobulin levels in CF patients have been reported.
Schwartz (1966) found that serum IgA and IgG were significantly elevated
compared to normal values, whereas IgM and IgD levels were normal; IgA was
very high in those patients who subsequently developed pulmonary complica-
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tions. In a study of 106 patients, serum IgA and IgG levels were higher in
patients who had recently experienced a major episode of chest infection
compared to those CF patients without such episodes (Turner et al, 1978).
Pressler et al (1988) reported that a large proportion of both young and old CF
patients had increased levels of IgG, whereas IgA and IgM were seen less fre¬
quently in patients less than 10 years old. Data from various studies (H0iby
et al, 1975; Matthews et al, 1980; Moss & Lewiston, 1980; Cukor et al, 1983;
Wheeler et al, 1984) indicates that the majority of CF patients have normal or
elevated levels of immunoglobulins and that P. aeruginosa is associated with
increased levels of IgA and IgG and a poor clinical condition.
5.2 ANTIBODY RESPONSE TO P. AERUGINOSA ANTIGENS
CF patients are capable of mounting an antibody response against cellular and
extracellular pseudomonal antigens (H0iby, 1977; Pedersen et al, 1987). Use of
purified P. aeruginosa antigens has demonstrated antibodies to the extracellu¬
lar antigens alkaline, protease, elastase, exotoxin A, phospholipase C and
exoenzyme S (Doring & H0iby, 1983; Granstrom et al, 1984; Doring et al, 1985;
Hollsing et al, 1987; Woods et al, 1989). Antibodies to cellular components
including alginate (Pier et al, 1987), LPS (Fick et al, 1986; Jacobson et al, 1987;
Cochrane et al, 1988b; Fomsgaard et al, 1988b), outer membrane proteins
(Hancock et al, 1984); pili (see Pedersen et al, 1989b for references) and flagella
(Anderson et al, 1989) have been demonstrated.
Antibodies against P. aeruginosa can be detected by a variety of immunological
methods including crossed immunoelectrophoresis (H0iby, 1977), radioimmu¬
noassay (Doring & H0iby, 1983), enzyme-linked immunosorbent assay (ELISA)
(Brett et al, 1986b; Pedersen et al, 1987) and immunoblotting (Shand et al,
1988b). Determination of antibodies against P. aeruginosa are useful to
diagnose progression from superficial colonisation with P. aeruginosa to
invasive infection, giving an insight into the mode of pathogenesis of the
organism in lung infection (H^iby, 1977; Hollsing et al, 1987; Pedersen et al,
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1987).
In a longitudinal study by Doring & H0iby (1983) the immune response in¬
creased in nearly all patients after the onset of chronic P. aeruginosa infection,
showing increases in antibody titres to proteases and increases in the number of
precipitins to a water-soluble standard antigen-preparation of P. aeruginosa.
•These results suggested that the action of elastase and alkaline protease are
important only at the onset of chronic infection, after which time they are
neutralized by specific antibodies. In a related study by Hollsing et al (1987)
antibodies to a number of P. aeruginosa exoproteins were detected, serum
antibodies to phospholipase C developing first, at an average of three months
after initial colonisation. In contrast Shand et al (1989) observed that
antibodies to iron regulated membrane proteins occur late in the disease and
may reflect a change in the physiological conditions under which P. aeruginosa
grows in the infected lung.
ELISA studies, with whole cells (Brett et al, 1986a & b) or a sonicated mixture
of P. aeruginosa antigens (Pedersen et aL, 1987) for the detection of serum IgG
antibodies, showed high titres of antibodies in patients chronically colonised by
P. aeruginosa, antibodies increasing with the duration of infection and
correlating with a deterioration in clinical state. In a recent study by Brett et al
(1990) elevated serum IgA antibodies to P. aeruginosa whole cells were particu¬
larly associated with patients who were chronically infected by P. aeruginosa.
In a longitudinal study of serum antibodies to Pseudomonas LPSs during the
course of chronic lung infection, a good positive correlation between anti-LPS
IgG antibodies and the number of precipitins to Pseudomonas sonic extracts
was found (Fomsgaard et aL, 1988b). Earher studies by H0iby (1977) and H0iby
et al (1977) showed that high and rapidly increasing numbers of Pseudomonas
precipitins determined by crossed immuno-electrophoresis, were associated
with a poor prognosis including impaired respiratory function, and severe
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changes on chest radiographs. A later examination of anti-LPS antibodies in CF
patients showed that IgG and IgA anti-LPS antibodies increased significantly at
the onset of chronic infection and continued to increase to very high levels in
the later stages of infection (Fomsgaard et al, 1989). IgM anti-LPS levels also
rose at the onset of chronic infection but did not increase further (Fomsgaard
etal, 1989).
In some patients, antibodies can be detected in serum before sputum
bacteriology becomes positive for P. aeruginosa (Brett et al, 1987; Brett et al,
1988; Fomsgaard et al, 1988b; Shand et al, 1988b; Brett et al, 1990). Brett et al
(1988) found that 73% of CF patients had increased IgG titres up to two years
before the first isolation of P. aeruginosa from sputum. In a subsequent report,
measurement of IgA antibodies was shown to be better than IgG measurement
at predicting the reappearance of P. aeruginosa after apparent erradication and
also gave an earlier indication of the presence of P. aeruginosa in the
respiratory tract (Brett et al, 1990).
Pier et al (1987) reported an association between opsonophagocytic killing
antibodies in the sera of relatively healthy CF adolescents directed against
alginate and a lack of detectable colonisation. Although patients chronically
colonised with P. aeruginosa demonstrated high titres of serum opsono¬
phagocytic killing antibodies than did the older non-colonised patients, these
antibodies were not specific to the mucoid exopolysaccharide, suggesting a role
v for opsonic killing antibody specific to alginate in resistance to colonisation with
P. aeruginosa in CF. Other studies have also reported the detection of alginate
antibodies in sera from patients with CF (Bryan et al, 1983; Pedersen et al,
1989a; Pedersen et al, 1990). In a recent study Pedersen et al (1990) observed
that patients responded to P. aeruginosa infection with an early IgA and IgG
antibody response to alginate although these antibodies did not prevent
development of chronic infection, poor lung function correlating significantly
with increased levels of IgA and IgG antibodies to alginate. Elevated titres of
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anti-alginate antibodies were also found in patients colonised by non-mucoid P.
aeruginosa indicating that alginate may be produced in vivo by apparently non-
mucoid organisms.
The presence of P. aeruginosa specific antibodies in CF sputa, particularly in
those patients chronically colonised by the organism, have been reported by a
number of investigators (Schi0tz et al, 1979; Przyklenk & Bauernfeind, 1988). In
the study of Przyklenk & Bauernfeind (1988) patients chronically colonised by
P. aeruginosa had significantly higher secretory IgA antibody levels against LPS
and elastase compared to non-colonised patients, increases in secretory IgA
correlating well with acute exacerbations attributable to P. aeruginosa. The
ELISA studies of Cochrane et al (1988b) demonstrated very low sputum titres of
IgG antibodies against LPS. The authors were unable to detect these anti¬
bodies in immunoblots of sol phase of sputum, and suggested that LPS-specific
antibodies in sputum may be bound to LPS forming immune complexes. Hann
& Holsclaw (1976) found that P. aeruginosa in CF sputum were coated with
IgA, IgG, IgM and complement factor C3 by using a fluorescent technique and
that staining was most intense with IgA. In another study bacteria in autopsy
lung sections were coated with IgA, IgG and C3, but not IgM (Speert et al,
1987).
5.3 IMMUNE DEFECTS IN CYSTIC FIBROSIS
In CF it would appear that despite an apparently competent and often hyper¬
immune response which protects the host from systemic bacterial invasion, the
P. aeruginosa specific antibodies are unable to eliminate the organism from the
lungs. The implication is therefore that the organism, which may remain
localised at the mucosal surface of the respiratory tract for up to 15-20 years
(Pedersen et al, 1989b), is able to evade the opsonophagocytic host defences.
An important function of IgG is to act as an opsonin for phagocytosis and it has
been found that CF serum is able to inhibit the phagocytosis of P. aeruginosa by
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alveolar macrophages obtained from a number of sources including rabbits and
individuals with and without CF (Thomassen et al, 1979). However, this
inhibition did not affect phagocytosis of P. aeruginosa by peripheral monocytes,
and neutrophils (Thomassen et al, 1982). Fick et al (1981) demonstrated a
superior affinity of CF derived IgG opsonins to bind to bacteria when compared
to other immune opsonins. However, the antibody attachment to alveolar
macrophage membrane Fc receptors appeared less avid for the CF specimens
and led to the conclusion that CF IgG opsonins acted in an inhibitory fashion
(Fick et al, 1981). In a study by Eichler et al (1989) LPS specific non-opsonic
antibodies were detected in some sera from CF patients colonised by
P. aeruginosa and shown to inhibit the neutrophil oxidative response.
In the lung the presence of secretory IgA antibodies, less able than IgG to
mediate opsonization (Reynolds, 1983), may also contribute to the persistence
of infection by blocking the bactericidal and opsonizing effect of IgG (Pedersen
et al, 1989b). The inability of IgG antibodies to kill P. aeruginosa may also be
caused by the development of blocking antibodies which have been
demonstrated in serum (Thomassen & Demko, 1981) and sputum (Schiller &
Millard, 1983) from CF patients.
Based on the presence of free J-chain and altered electrophoretic mobility of
secretory component isolated from CF sputa, Wallwork & McFarlane (1976)
suggested that there may be an abnormality in the synthesis and/or assembly of
secretory IgA molecules in patients with CF. However, such reports of a
primary deficiency in secretory IgA remain unsubstantiated.
In sputum a defect in the opsonizing ability of IgG as well as IgA, may be
caused by the fragmentation of antibody (Fick et al, 1984) caused by the proteo¬
lytic activity of P. aeruginosa elastase (Fick et al, 1985) or elastase from poly¬
morphonuclear leucocytes (Doring et al, 1986). These enzymes may also
inactivate opsonizing complement components such as C3 (Suter et al, 1984).
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The bacterial elastase is able to cleave IgG in the hinge region (Fick et al,
1985), the F(ab)2 and Fc fragments generated closely resembling those detected
in the respiratory secretions of CF patients (Fick et al, 1984; Bainbridge & Fick,
1989). The polypeptide fragments are unable to promote opsonophagocytosis
and are actively inhibitory to pulmonary macrophage and polymorphonuclear
leucocyte phagocytic cell uptake of P. aeruginosa (Fick et al, 1984; Bainbridge &
Fick, 1989).
The discovery that immunoglobulins from CF patients have a lower content of
galactose and sialic acid compared to non-CF individuals (Margolies & Boat,
1983) may also be due to P. aeruginosa induced alteration rather than a primary
defect. The organism may produce a glycosidase which secondarily alters the
carbohydrate containing hinge region (Fick, 1989). Hypoglycosylated
immunoglobulins are cleared less rapidly from the circulation and may con¬
tribute to the elevated levels of IgG and immune complexes commonly found
in older CF patients (Margolies & Boat, 1983). In addition, alteration in the
IgG carbohydrate components may influence intracellular bactericidal
processes and serve to protect P. aeruginosa within phagocytes (Schoderbek &
Fick, 1987). Indeed, it is postulated that it is from this protected intracellular
pool that Pseudomonas airway infections relapse (Fick, 1989).
5.4 ANTIBODY SUBCLASS AND RELATED IMMUNOLOGICAL
IMPLICATIONS IN CYSTIC FIBROSIS
There are four different subclasses of IgG each with characteristic biological
functions (Pedersen et al, 1989b). IgG subclasses in serum and normal bron-
choalveolar fluid have similar subclass proportions in which IgGl accounts for
65% of total IgG, IgG2 about 30% and IgG3 and IgG4 combined contribute
about 5% (Reynolds, 1989). Complement activation is most efficient with IgGl
and IgG3 which also bind well to phagocyte membrane receptors, whereas IgG2
and IgG4 bind complement poorly and are non-opsonic (see Pedersen et al,
1989b for references).
67
The proteolytic activity of P. aeruginosa elastase has been shown to be signif¬
icantly more active on IgGl and IgG3 (Fick et al, 1985), whilst the IgG response
to Pseudomonas LPS is largely restricted to IgG2 (Fick et al, 1986). Indeed, the
opsonic index (IgGl + Ig3/IgG2 + IgG4) has been found to be inverted in CF
compared to normal (Fick et al, 1986) with a pronounced shift to IgG2 in CF
airway secretions demonstrated (Hornick & Fick, 1987). IgG4 levels have been
shown to be significantly increased in CF patients and to correlate with disease
severity (Shakib et al, 1976). The relative surplus of non- opsonic IgG2 and
IgG4 antibodies will therefore contribute poorly to phagocytic clearance (Fick
et al, 1986) and may present a significant impediment to IgG opsonin-mediated
phogocytosis of P. aeruginosa ie by acting as blocking antibodies as described by
Thomassen & Demko (1981). Such a scenario may be particularly relevant in
the initial stages of infection before proteases are neutralised by specific anti¬
bodies (Doring & H^iby, 1983).
Since the antibody response to polysaccharide antigens such as LPS is
predominantly restricted to IgG2 subclass (Siber et al, 1980) it would seem that
a major determinant in terms of protection is the host's ability to generate a
sufficient amount of IgG2 antibody that will be protective (Reynolds, 1989). An
IgG2 deficiency in CF patients has been suggested by Moss et al (1986b) who
found that some infected CF patients had a deficient IgG2 antibody response to
P. aeruginosa LPS. In contrast however, Albus et al (1989) could find no im¬
paired IgG2 response to alginate polysaccharide, and reported significantly
elevated levels of all four subclasses to both protein and polysaccharide anti¬
gens.
Moss (1987) found that hypergammaglobulinemia associated with CF was
mainly due to increased levels of IgG2 and IgG3 and that the striking increases
in IgG2 correlated significantly with IgG2 antibodies against LPS. Similarly
Pressler et al (1988) have found that an elevation of IgG2 and IgG3 correlated
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significantly with poor lung function and chronic P. aeruginosa infection. It has
been postulated that poorly cleared IgG2-bacterial antigen complexes may
contribute to immune complex-mediated destruction of the CF airways (Fick,
1989). Current evidence suggests that IgG2 is present in significant quantities in
CF immune complexes (Hornick & Fick, 1987).
5.5 IMMUNE COMPLEXES AND IMMUNE MEDIATED TISSUE
DAMAGE
Immune complexes, formed by the interaction of antigen and antibody, play an
important role in host defences against bacterial infection (Kronborg et al,
1989). The immune response and localised inflammatory reactions act together
to eliminate the offending pathogen and to neutralize bacterial toxins. If
elimination is not accomplished, chronic infection may result which, in turn,
may be associated with immunopathological disease. The simultaneous
presence of P. aeruginosa and the sensitised host's humoral and cellular
immune responses suggest that hypersensitivity reactions may contribute to the
Pseudomonas initiated pathologic-lung-lesion in CF (Fick, 1981; Fick, 1989).
The formation of immune complexes and a subsequent type III hypersensitivity
reaction appears to correlate strongly with increasing titres of antibody in
serum and sputum from patients with chronic lung infection and is associated
with decreasing pulmonary function and poor patient prognosis (H^iby &
Axelsen, 1973; Moss & Lewiston, 1980; Schi^tz, 1982; H0iby & Schi^tz, 1982;
, Moss et al, 1986a; Dasgupta et al, 1987). Immune complexes have been detected
in CF lung fluids, various tissues and serum by many investigators (Moss &
Lewiston, 1980; Doring et al, 1984; Dasgupta et al, 1987). Pulmonary colonisa¬
tion by P. aeruginosa would result in the formation of immune complexes ini¬
tially in the lungs, the rate and nature of their further formation depending on
the antigenic load, rate of formation of antibodies and the efficiency of the
lung's immunologic clearance systems (Dasgupta et al, 1987). Circulating
immune complexes are believed to be derived as a spill-over effect of immune
69
complexes from the lungs when the pulmonary clearance mechanisms are
saturated or overwhelmed (Schi^tz, 1981; Dasgupta et al, 1987). A number of
pseudomonal antigens are believed to be present in CF immune complexes
including LPS and proteases (Doring et al 1984; Moss et al, 1986a).
The biological properties of immune complexes and their ability to participate
in type III hypersensitivity reactions is determined by their ability to activate
complement and to interact with other host cells (H0iby & Schi^tz, 1982). The
activation of complement leads to liberation of the complement anaphylatoxins
C3a and C5a which in turn attract neutrophils to the lungs, as indicated by the
presence of high numbers of these cells in sputum (Hjftby & Schi0tz, 1982; Suter
et al, 1984). Accumulation of neutrophils may also be enhanced by the presence
of other chemoattractants including P. aeruginosa endotoxin and the
leucotrienes D and B (Kharazmi et al, 1986).
Bronchoalveolar lavage from CF airways reveals the greatly increased numbers
of cells and a very abnormal cell differential: 30-90% neutrophils in CF lavage
compared to 3% neutrophils in normal individuals (Fick & Reynolds, 1983).
The neutrophils moving into the distal airways contribute to the proteolytic
damage initiated by Pseudomonas, by release of elastase, collagenase and
cathepsin G which are able to destroy important structural proteins of the lung
and its airways, including elastin, collagen and proteoglycans (Suter et al, 1984).
The release of other lysozomal enzymes, and of toxic oxygen radicals released
during the oxidative burst of activated neutrophils, also contribute substantially
to lung damage in CF (Fick, 1981; H0iby et al, 1986; Kharazmi et al, 1987). The
report of Auerbach et al (1985) that systemic steroids have a beneficial effect on
CF patients indirectly supports the view that immune complex mediated
damage is important.
Intermittent immune complex mediated inflammatoiy exacerbations superim¬
posed on the insidious, chronic lung disease gradually leads to impaired lung
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function and eventually the death of the CF patient (H^iby & Schi^tz, 1982).
Characteristically the lungs of such patients at autopsy are severely consoli¬
dated, containing an abundance of purulent material with high numbers of
mucoid P. aeruginosa and large numbers of neutrophils (H^iby & Schi^tz,
1982).
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AIMS OF THE THESIS
Pulmonary colonisation of patients with CF by P. aeruginosa represents a
complex, multi-faceted example of bacterial adaptation and pathogenesis. The
objective of this thesis was to investigate various aspects of the host-bacterium
interaction with a particular focus on the initial colonisation stages with non-
mucoid P. aeruginosa.
The areas of research covered include:-
1) Detection of anti-F. aeruginosa antibodies in serum, saliva and sputum from
patients with CF. The response to P. aeruginosa LPS and flagellar antigens
was investigated. The development of a simple ELISA system based on
more defined LPS antigenic preparations than those used in previous pub¬
lished studies, and its suitability for the detection of antibodies against all
serotypes of P. aeruginosa was considered.
2) Production of anti-P. aeruginosa LPS monoclonal antibodies (Mabs) able to
recognise all O-antigenic serotypes of P. aeruginosa. The underlying
objective of this study was to use the Mabs in a capture ELISA system for
the detection of P. aeruginosa LPS in CF respiratory secretions as a means
of facilitating early identification of respiratory colonisation by non-mucoid
P. aeruginosa.
3) Investigation of the mucinophilic properties of non-mucoid P. aeruginosa
and their possible contribution to the initial stages of pulmonary





1.1 PATIENTS AND SPECIMENS
Patients
Specimens of sera, saliva and sputum were obtained from patients with CF
attending the paediatric and adult CF clinics in Edinburgh. For the purposes of
this thesis, CF patients (age range <1-27 years) were classified on the basis of
degree of colonisation with P. aeruginosa: a) non-colonised patients ie those
patients from whom P. aeruginosa had never been isolated, b) intermittently
colonised patients, P. aeruginosa having been isolated from sputum on one or
more occasions but no recognizable pulmonary symptoms attributable to the
organism, and c) chronically colonised patients, P. aeruginosa having been
isolated continuously from their sputum specimens.
Serum, saliva and sputum specimens
Serum obtained from CF patients was aliquoted into micronic tubes (Alpha
Laboratories, Eastleigh, Hants) and stored at -20°C until analysis. Control
serum was also obtained from blood donors at the Blood Transfusion Centre,
Edinburgh. Saliva and sputum specimens obtained from CF patients were
v stored at -70°C. Prior to storage of sputa, 1.0 ml aliquots in 1.5 ml micro¬
centrifuge tubes (Elkay Products Inc., Shrewsbury, MA, USA), were
centrifuged in a microcentrifuge (Micro Centaur, MSE, Crawley, Surrey) at




Bacteriology of routine sputum specimens was performed by Mrs C. J. Doherty
(Department of Bacteriology, University Medical School, Edinburgh). Sputa
were homogenized in sputalysin (Behring) and following appropriate dilutions,
were cultured quantitatively on blood agar, Hartley broth agar (incorporating
bacitracian) and Pseudomonas Isolation Agar (PLA). These procedures allow
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the detection of P. aeruginosa at concentrations as low as 10 CFU/ml
sputum. Cultures were identified as P. aeruginosa by growth on PIA,
production of blue-green pigmentation and where necessary by biochemical
tests performed with API 20 E strips (API Laboratories Ltd., Basingstoke,
Hants).
Pvocin typing and serotvping of P. aeruginosa
Pyocin typing of P. aeruginosa strains was by the spotting method described by
Fyfe et al (1984). Serotyping was performed by the slide agglutination method
of Lanyi & Bergan (1978).
Maintenance of bacterial strains
Bacterial strains were maintained at -70°C in 10% (w/v) skim milk (Oxoid
L31, Oxoid Ltd., Basingstoke, Hants.). Bacterial suspensions were prepared by
emulsifying several single colonies in 1.0 ml volumes of skim milk contained in
2.0 ml plastic screw top vials (Elkay). Four 1.0 ml aliquotes were prepared for
each strain. Fresh maintenance cultures were prepared at approximately four
monthly intervals.
Bacterial strains
Bacterial strains used in this thesis are shown in Table 1. All other bacterial
strains, including clinical isolates of P. aeruginosa, P. cepacia, P. maltophilia,
H. influenzae and H. parainfluenzae are indicated in the relevant section of the
Results. All bacterial strain numbers prefixed with JN were isolated from
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Table 1. Bacterial Strains.
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sputum of patients with CF.
1.3 CHEMICALS, MEDIA AND REAGENTS
Chemicals
Unless otherwise indicated all chemicals were Analar grade (BDH Chemicals
Ltd., Poole, Dorset), and all solutions were prepared in double distilled water.
Complex media
a) Nutrient yeast broth (NYB) was Oxoid No.2 supplemented with 0.5% (w/v)
yeast extract (Oxoid).
b) Nutrient agar (NA) was Columbia agar base (Oxoid).
c) Pseudomonas Isolation Agar (PIA) (Difco Laboratories, Detroit, Michigan,
USA).
d) Tryptone Soya Agar (TSA) for pyocin typing studies was Oxoid CM131.
e) Semi-solid agar for motility studies consisted of:-
0.1% (w/v) tryptone (Difco), 0.3% (w/v) yeast extract (Oxoid),
0.5% (w/v) sodium chloride (BDH), 0.4% (w/v) Bacteriological Agar
(Oxoid) and 1 litre of distilled water.
f) Hartley broth agar (incorporating bacitracin) (Oxoid) - for growth of
H. influenzae and H. parainfluenzae.
All commercial media were prepared by the Bacteriology Media kitchen
according to manufacturers' instructions. Media were sterilised by autoclaving




a) MALKA minimal medium used for growth studies was prepared as follows:-
Solution A Na2HPC>4 (73.4 mg/ml); KH2PO4 (32.4 mg/ml)
Solution B MgS04.7H20 (20.5 mg/ml)
Solution C Sodium succinate (4.0 mg/ml)
Solution D FeSC^.TF^O (1.83 mg/ml) in sterile distilled water to which one
drop of concentrated hydrochloric acid (HC1) was added.
Solution E (NH4)2S04 (50.0 mg/ml)
All chemicals were from BDH. Solutions were prepared with sterile distilled
water and were filter sterilised. All solutions except C were stored over
chloroform.
To prepare 1 litre ofMALKA, 20 ml A, 20 ml B, 20 ml C, 1 ml D and and 20 ml
E were added to 919 ml sterile distilled water. Variations in the MALKA
medium used in the growth experiments are described later.
b) Minimal medium employed for growth of P. aeruginosa for chemotaxis
assays was made according to Moulton & Montie (1979) and contained
(per litre of distilled water): K2HPO4 (7.0 g); KH2PO4 (3.0 g),
(NH4)2S04 (1.0 g); MgS04.7H20 (0.05 g) and FeCl2.6H20 (2.5 mg) and
was supplemented with sodium succinate (0.4% w/v). All chemicals were
from BDH.
c) Chemotaxis medium (CM) was made according to Moulton & Montie
(1979) and consisted of 0.05 M potassium phosphate buffer at pH7.0
supplemented with 0.005 M MgC^.b^O (BDH), and 0.1 mM disodium
ethylenediamine tetraacetic acid (EDTA) (Sigma Chemical Co., Poole,
Dorset).
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Amino acids, sugars, mucins and lipopolvsaccharides
a) Amino acids used in chemotaxis assays included alanine, aspartic acid,
cysteine, glutamic acid, glycine, proline, serine and threonine (all from
BDH).
b) Sugars used in chemotaxis studies and/or growth experiments included L-
fucose (Sigma); D-galactose (BDH); D-glucose (BDH); N-acetyl-D-
galactosamine (GalNAc) (Sigma); N-acetyl-D-glucosamine (GlcNAc)
(BDH); and N-acetylneuraminic acid (NANA) (Koch-Light, Haverhill).
All amino acid and sugar solutions were filter sterilised through 0.2 pm-pore
size membrane filters (Schleicher & Schuell, Dassell, W. Germany).
c) Mucin preparations. Purified porcine gastric mucin was from BDH.
Purified human mucins were obtained from Dr J.K. Sheehan and Dr D.J.
Thornton (Department of Biochemistry and Molecular Biology, University
of Manchester) and included the following: CF tracheobronchial mucin
(gel fraction - Mr 10-12 x 10^); CF tracheobronchial mucin (gel fraction -
Mr 4-30 x 106) fractioned by gel chromatography into fractions A, B, C and
D; CF tracheobronchial mucin (sol fraction - Mr 4 x 10^); chronic
bronchitic mucin (Mr 20 x 10^), normal salivary mucins - large -
(approximate Mr 20 x 10^) and small (Mr 250,000); asthmatic mucin; CF
mucin glycopeptides derived from mucins-sol and gel (Mr 300,000-
500,000). The CF mucins were derived from the sputum of a female CF
patient, who was 16 years old and infected with P. aeruginosa.
All human mucins were supplied and stored as solutions in 4 M guanidinium
chloride at 4°C. Prior to use in chemotaxis assays mucins were diluted in CM
(100 pg/ml), added to dialysis tubing (previously boiled for 10 min in a water
bath) and dialyzed with stirring against 1 litre of CM at 4°C for 24 h.
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d) Lipopolysaccharides. LPS was prepared from P. aeruginosa strains as
described below. Additional LPS, including peparations from E. coli R1
and Salmonella typhimurium 1542 were obtained from Dr I.R. Poxton
(Department of Bacteriology, University Medical School, Edinburgh).
Polyvalent Pseudomonas LPS extract vaccine PEV-02, which is comprised
of cell wall LPS extracts of sixteen IATS O-serotypes of P. aeruginosa, was
a gift from Dr P. Hambleton (Porton International). The individual
vaccine O-serotype components IATS 0:1-0:16 (Pseudomonas vaccine
antigens PVA) were obtained from Dr G. R. Barclay (Regional Blood
Transfusion Centre, Edinburgh).
Antisera
Antisera for O-serotyping corresponded to the International Antigenic Typing
Scheme (IATS) (Lanyi & Bergan, 1978) and were donated by Dr T.L. Pitt
(Division of Hospital Infection, Central Public Health Laboratory, Colindale).
The rabbit anti-flagellar type-a and -b antisera, and the rabbit anti-flagella
type-b monoclonal antibody (Mab) were kindly provided by Dr G.H. Shand
(Statens Seruminstitut, Copenhagen, Denmark).
1.4 EQUIPMENT
Equipment and apparatus used in the experimental studies is indicated in the




2.1 MEASUREMENT OF BACTERIAL CONCENTRATIONS
a) Viable counts Serial ten-fold dilutions of bacteria were prepared in sterile
physiological saline and volumes of 100 pi were plated on NA plates. Plates
were incubated at 37°C for upto 24 h and colonies enumerated using a colony
counter (Gallenkamp, Loughborough, Leics.).
b) Measurement of optical density Measurements of absorbance were made at
470 nm (spectrophotometer, Spectronic 20, Bausch & Lomb, supplied by
Gallenkamp). An aliquot of suspending medium was retained for use as a
blank and as a diluent for optical density (OD) measurements. A standard
curve of log bacterial numbers (as determined by viable counts) against OD470
was constructed. An optical density of 1.0 at 470 nm indicates a concentration
of approximately 10^ cells of P. aeruginosa /ml.
2.2 CULTURE OF BACTERIA
Most bacteria were cultured at 37°C. The Pseudomonas spp, excluding
P. aeruginosa were cultured at 30°C. Bacteria were streaked onto NA or PIA
(as appropriate) from skim-milk maintenance cultures. Subculture of bacteria
onto fresh plate media was performed no more than seven days after the
previous subculture and was performed for up to a maximum of three
subcultures. After this time fresh cultures were prepared from maintenance
cultures.
Bacteria were inoculated into 10 ml liquid medium to prepare a starter culture,
which when required could be inoculated into larger volumes for further
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growth. All liquid cultures were incubated in an orbital incubator
(Gallenkamp) at 100-120 rpm.
2.3 PREPARATION OF SMOOTH LIPOPOLYSACCHARIDES
Extraction of LPS from P. aeruginosa strains expressing the S-LPS phenotype
was based on the aqueous phenol method of Westphal & Luderitz (1954). Two
litre flasks (ten) containing 1 litre of NYB were inoculated with 2.0 ml of an
overnight preculture grown in NYB. The flasks were then incubated in an
orbital incubator (120 rpm) at 37°C overnight. Bacterial cells were harvested
by centrifugation at 15,000 g using a KSB continuous flow system (Dupont UK
Ltd., Stevenage, Herts.). Cells were then washed twice in phosphate buffered
saline (PBS) with centrifugation (Sorval RC-5B refrigerated superspeed
centrifuge, Dupont) at 10,000 g for 10 min. The bacterial pellet was frozen at
-20°C, freeze dried (Edwards Modylo freeze dryer, Edwards High Vacuum
Ltd., Crawley, Surrey) and weighed.
The lyophilized bacterial pellet was finely divided, resuspended to a
concentration of 5% w/v in distilled water and heated to 67°C in a water bath.
Meanwhile 90% w/v aqueous phenol was prepared by dissolving 90 g of phenol
(BDH) in 10 ml of distilled water at 45°C and then making the volume up to
100 ml with distilled water. A volume of phenol solution equal to that of the
bacterial suspension was heated to 67°C in a water bath. The prewarmed
bacterial suspension and phenol solution were mixed and stirred at 67°C for 15
min. The mixture was transferred to 50 ml centrifuge tubes and cooled in an
ice bath to allow separation of the phenol and aqueous phases. The tubes were
then centrifuged at 10,000 gfor 15 min to complete separation of the phases.
The upper (aqueous) phase containing the LPS was carefully removed and the
extraction procedure repeated on the lower phenol phase. The two aqueous
phases were pooled, transferred to dialysis tubing (previously washed and
boiled for 10 min in distilled water) and dialysed against running tapwater
overnight, until the smell of phenol was no longer detectable. The solution was
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centrifuged twice for 15 min at 10,000 g to remove any insoluble deposit. The
dialysed extract was then concentrated by rotary evaporation (Buchi
Rotavapor-RElll, Switzerland) to approximately one-fifth of its original
volume. After this the solution was ultracentrifuged (Sorval ultracentrifuge -
OTD65B, Dupont) at 100,000 g for 3 h. The gelatinous pellet obtained was
resuspended in distilled water with the aid of a syringe fitted with 23-gauge
needle and recentrifuged. The final pellet was then suspended in a small
volume of distilled water (pyrogen free), freeze dried and weighed. The LPS
was stored at -20°C until required.
2.4 PREPARATION OF ROUGH LIPOPOLYSACCHARIDES
The aqueous phenol, chloroform, petroleum ether (PCP) method of Galanos
et al (1969) incorporating the diethyl ether precipitation of LPS described by
Qureshi et al (1982), was used to prepare LPS from P. aeruginosa expressing
the R-LPS phenotype. Bacteria were cultured and lyophilized as described for
S-LPS preparations.
The extraction solvent (PCP) consisted of 90% phenol (BDH - see above),
chloroform (BDH) and petroleum spirit (boiling point 40°- 60°C) (BDH) in
the proportions 2:5:8 by volume. Dried bacteria were resuspended in PCP at
25% w/v, stirred for 2 min below 20°C and then centrifuged at 10,000 g for 15
min. The supernate was filtered through Whatman No. 1 filter paper into a
round-bottomed flask. The centrifuged pellet was re-extracted by the same
procedure and then the filtered supernates pooled. The supernate was rotary
evaporated to remove the petroleum spirit and chloroform.
In order to precipitate the LPS (Qureshi et al, 1982) six volumes of diethyl
ether/acetone (BDH) in the ratio of 1:5 by volume, were added to one volume
of the phenol solution. After leaving to stand for at least 1 h the LPS was
sedimented by centrifugation at 5,000 g for 10 min. The centrifuge tubes were
drained and the pellet washed three times with diethyl ether/acetone, the
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pellet being recovered by centrifugation each time. The final pellet was dried
under vacuum until the smell of ether/acetone was no longer detectable. The
dried pellet of LPS was resuspended in 5 ml of distilled water with the aid of a
syringe and 23-gauge needle and recovered by ultracentrifugation at 100,000 g
for 4 h. The LPS was then taken up in a minimum amount of distilled water,
lyophilized and stored at -20°C until used.
2.5 PROTEINASE K DIGESTION OF BACTERIA FOR THE
PREPARATION OF LIPOPOLYSACCHARIDES
The proteinase K digestion of bacteria (Hitchcock & Brown, 1983), suitable for
both R- and S-LPS types, was used to prepare LPS for analysis by
polyacrylamide gel electrophoresis (PAGE) and immunoblotting. Bacteria,
from a 10 ml overnight culture, were harvested by centrifugation and washed
twice in PBS. The bacteria were resuspended in PBS to give an absorbance
between 0.5 and 0.6 at 525 nm as measured on a spectrophotometer. 1.5 ml of
bacteria suspension was transferred to an Eppendorf tube (Elkay) and the
bacteria sedimented in a microcentrifuge at 1,000 g for 3 min. The pellet was
resuspended in 50 pi of single strength PAGE sample buffer (see page 85) and
heated at 100°C for 10 min. Once cooled 10 pi of sample buffer containing
25 pg of proteinase K (Sigma protease Type XI) (2.5 mg/ml in sample buffer)
was added followed by incubation in a 60°C water bath for 60 min. Samples
were stored at -20°C.
2.6 PREPARATION OF FLAGELLA
For flagellar antigen preparation, 2 litre flasks containing 1 litre of NYB were
inoculated with 2.0 ml of an overnight preculture grown in NYB. The flasks
were incubated in an orbital incubator (120 rpm) at 37°C for overnight culture.
Bacterial cultures were then harvested by centrifugation at 10,000 g for 15 min
at 4°C and washed twice in PBS. Each bacterial pellet was suspended in 20 ml
of PBS and blended with a commercial blender for 2 min. Bacterial cells were
removed by up to twelve cycles of centrifugation (10,000 g for 10 min at 4°C).
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Removal of cells was monitored at intervals by microscopy and culture of the
supernatant. The cell free supernatant was ultracentrifuged at 100,000 g for 2 h
at 4°C, and the resultant pellet washed twice in distilled water. The pellet was
then resuspended in 0.5 ml distilled water, dialysed overnight against distilled
water at 4°C and stored at -20°C until required. The amount of protein in
each sample was determined by the method of Lowry et al (1951).
Flagella were classified into P. aeruginosa flagellar types-a or -b based on their
mobility in polyacrylamide gels (12% acrylamide), and by ELISA and
immunoblot analysis with rabbit anti-flagellar type-a and -b antisera.
2.7 ELECTRON MICROSCOPY OF FLAGELLA
Flagellar preparations were examined by electron microscopy and were
prepared in two ways:
a) Negative-staining with phosphotungstic acid (PTA4 Formvar-coated 400
mesh copper grids were floated onto a drop (approximately 5 pi of flagellar
sample, previously diluted 1:10 in distilled water. Excess moisture on the grids
was removed by lightly blotting with filter paper (Whatman No. 1). Grids were
then touched onto a drop of 2% w/v PTA before drying with filter paper and
allowing to dry fully in a desiccator.
b) Shadowing with platinum Grids were prepared with flagella as above.
Prior to shadowing grids were allowed to dry fully in a desiccator for at least 30
min. Grids were then shadowed with platinum in an Edwards vacuum coater
model 306 (Edwards High Vacuum).
All grids were viewed with a Hitachi 12A electron microscope at 75 KV.
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2.8 PREPARATION OF SAMPLES FOR POLYACRYLAMIDE GEL
ELECTROPHORESIS
Sample buffer (pH6.8) contained 0.0625 M Tris (BDH) at pH6.8 in which 2.0%
w/v sodium dodecyl sulphate (SDS) (BDH Specially Pure), 10% v/v glycerol
(BDH), 1% v/v 2-mercaptoethanol (BDH) and 0.001% bromophenol blue
(BDH) were present. Double strength sample buffer (pH6.8) was made as
above except concentrations of all constituents were doubled.
a) Protein samples The protein concentration of flagellar preparations was
determined by the method of Lowry et al (1951) and adjusted to 1.0 mg/ml with
distilled water. Samples were then mixed with an equal volume of double
strength sample buffer and were denatured by heating at 100°C for 10 min in a
water bath.
b) Lipopolvsaccharide samples Proteinase K digests were prepared as
described above and added to gels at 10 pi per track. Samples of extracted LPS
(1.0 mg/ml), were mixed with an equal volume of single strength buffer and
heated at 100°C for 10 min before electrophoretic analysis. Samples were
added at 10 pg LPS per track.
2.9 POLYACRYLAMIDE GEL ELECTROPHORESIS (PAGE)
PAGE was performed with the buffer system of Laemmli (1970). PAGE of
proteinase K samples for subsequent immunoblotting was carried out with SDS
free gel buffers (Pyle & Schill, 1985). The following buffers and solutions were
used in PAGE:
a) Electrode buffer (pH8.3) consisted of 0.025 M Tris (BDH), 0.192 M glycine
(BDH Chromatographically Homogeneous) and 0.1% w/v SDS (BDH).
b) Separating gel buffer (double strength, pH8.8) consisted of 0.75 M Tris-HCI
at pH8.8 to which 0.2% w/v SDS was added. (SDS omitted for SDS-free
buffer).
c) Stacking gel buffer (double strength, pH6.8) consisted of 0.25 M Tris-HCI at
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pH6.8 to which 0.2% w/v SDS was added (SDS omitted for SDS-free
buffer).
d) Acrylamide stock solution (40% w/v) contained 100 g acrylamide (BDH
Electrophoresis Grade) and 2.7 g methylene bis acrylamide (BDH
Electrophoresis Grade) and made up to 250 ml with distilled water.
The separating gel was prepared as described in Table 2, with deaeration under
vacuum prior to addition of TEMED (NNN'N'- tetramethyl-l,2-diaminoethane
(BDH Electran) and ammonium persulphate (BDH). The gel solution was
poured between clean (with methanol) glass plates (160 mm x 125 mm x 1.5
mm) of the slab gel electrophoresis equipment. The gel was overlayed with
water saturated butan-2-ol (BDH) and allowed to set. After removal of butan-
2-ol the stacking gel, prepared in a similar manner (Table 2), was poured onto
the separating gel. A comb was inserted and the gel allowed to set. On
removing the comb the gel was fitted into an electrophoresis tank (Jencons
Scientific Ltd., Leighton Buzzard, Beds.) and the electrode buffer added.
Samples, prepared as described above, were loaded into the wells of the
stacking gel. Samples were electrophoresed through the stacking gel at a
constant 60 V and through the separating gel at a constant 150 V until the dye
front had run 80 mm. After electrophoresis samples were analysed by staining
or by immunoblotting after transfer to nitrocellulose.
v 2.10 SILVER STAINING OF POLYACRYLAMIDE GELS FOR
LIPOPOLYSACCHARIDE
An adaptation of the methods of Tsai & Frasch (1982) and Hitchcock & Brown
(1983) was used to visualise LPS in polyacrylamide gels. The following reagents
and solutions were used in the silver staining procedure:
a) Fixative consisted of 7% v/v acetic acid (BDH General Purpose) and
propan-2-ol (BDH General Purpose).
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Table 2. Preparation of polyacrylamide gels.







Distilled water 5.2 3 . 45 3.5
Separating buffer 17.5 17 . 5 -
Stacking buffer - - 5.0
Acrylamide solution
(40% w/v) 10.5 12.25 1.0
TEMED 0.05 0 . 05 0 . 02
Ammonium persulphate
(15mg/ml) 1.75 1 . 75 0 . 5
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b) Oxidising solution contained 1.05 g periodic acid (BDH General Purpose) in
150 ml of distilled water to which 4 ml of fixative was added.
c) Ammoniacal silver nitrate solution was made up by mixing 1.4 ml ammonia
solution (BDH General Purpose) with 21 ml of 0.36% w/v sodium
hydroxide (BDH) and the slow addition of 4 ml silver nitrate (BDH)
accompanied by vigorous agitation. Volume was made up to 100 ml with
distilled water.
d) Developing solution consisted of 0.019% v/v formaldehyde (BDH) solution
containing 0.005% w/v citric acid (BDH).
Post-electrophoresis the gel was placed in fixative and left overnight at room
temperature. Fixative was poured off and the gel oxidised for 5 min with a
freshly prepared solution of periodic acid. The gel was then washed in at least
four changes of 200 ml distilled water over 4 h. Silver staining was carried out
by addition of fresh ammoniacal silver nitrate solution. After staining for 10
min the gel was washed with at least four changes of distilled water (200 ml)
over 40 min. LPS was visualised by the addition of 200 ml of the freshly made
developing solution. Once the desired staining intensity had been obtained (5-
10 min) the gel was washed repeatedly in large volumes of distilled water. The
gel was stored in the dark. (All the above reaction steps were shaken).
2.11 COOMASSIE BLUE STAINING OF POLYACRYLAMIDE GELS
FOR PROTEIN
The Coomassie blue stain described by Hancock & Poxton (1988) was used.
The solutions used were made up in distilled water and included:
a) Solution 1-25% v/v propan-2-ol (BDH General Purpose), 10% v/v acetic
acid (BDH General Purpose) and 0.05% w/v Coomassie brilliant blue R-
250 (BDH).
b) Solution 2 - 10% v/v propan-2-ol, 10% v/v acetic acid and 0.005% w/v
Coomassie blue.
c) Solution 3 -10% v/v acetic acid and 0.0025% w/v Coomassie blue.
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d) Solution 4 - 40% v/v methanol (BDH General Purpose) and 10% v/v acetic
acid.
e) Solution 5 -10% v/v acetic acid.
The gel was placed in solution 1 overnight and then sequentially through
solutions 2-5, each for 45-60 min at room temperature with gentle shaking
throughout.
2.12 IMMUNOBLOTTING
Bacterial cell components separated in PAGE were transferred to
nitrocellulose (NIC) paper (pore size 0.2 pm ) (Schleicher & Schuell, Dassel,
W. Germany) for immunochemical analysis. A modification of the method of
Towbin et al (1979) was used.
The following reagents and solutions were used:
a) Electrode transfer buffer (pH8.3) - contained 12 g Tris (BDH General
Purpose), 57.68 g glycine (BDH Chromatographically Homogeneous) in 4
litres distilled water and 1 litre methanol (BDH General Purpose).
b) Tris buffered saline (pH7.5) (TBS) - contained 4.84 g Tris (BDH) 58.48 g
sodium chloride (BDH) and 2 litres distilled water.
c) Tween-Tris-buffered saline (pH7.5) (TTBS) - as for TBS containing
0.025% v/v Tween 20 (Sigma).
d) Blocking solution - as for TBS containing 3% w/v gelatin (Bio-Rad ELA
Purity Grade, Bio-Rad Laboratories Ltd., Watford, Herts.).
e) Antibody/conjugate diluent - as for TBS containing 1% w/v gelatin (Bio-
Rad).
f) Horse radish peroxidase (HRP) colour solution. The development solution
was made up fresh immediately before use. 30 mg HRP colour reagent
(Bio-Rad ELA Purity Grade) was dissolved in 10 ml methanol (BDH) and
added to 50 ml TBS containing 50 pi hydrogen peroxide (BDH General
Purpose).
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Electrophoretic transfer of antigens from polvacrvlamide gels to nitrocellulose
The gel was removed from the PAGE apparatus and placed in the
Scotchbrite^^ pad cassette of the blotting apparatus (made in-house by Mr J.
Duffus, Dept. of Bacteriology, University Medical School, Edinburgh). The
gel was then covered with a sheet of NIC presoaked in transfer buffer. The
cassette was then closed sandwiching the gel and NIC paper between the two
Scotchbrite pads. The assembly was then placed into the immunoblotting tank
containing transfer buffer, ensuring that the gel was placed towards the cathode
and the NIC towards the anode. A constant current of 40 mA was applied
overnight at 4°C.
Visualisation of antibody-antigen reactions
After transfer the NIC was removed and washed in TBS for 10 min before
placing in blocking solution for 30-45 min. Once blocked the NIC was
transferred into antibody buffer containing an appropriate dilution of sample
(serum, saliva, sputum or Mab) and incubated for 3 h at room temperature.
The NIC was then rinsed briefly in distilled water and washed for two 10 min
periods in TTBS, following which it was incubated with HRP-conjugated
secondary antibody suitably diluted in antibody diluent. The type of conjugate
used depended upon the particular investigation (see Results) and included the
following: anti-human IgA; anti-human IgG; anti-mouse Ig; anti- rabbit IgG (all
from ICN Biomedicals Limited, High Wycombe, Bucks.). The NIC was treated
for 60 min with the secondary antibody followed by rinsing in distilled water and
washing in TTBS (as above). The binding of antibody to separated antigenic
determinants was visualised by addition of HRP colour solution to the NIC.
The colour was allowed to develop for up to 30 min and then stopped by
washing in several changes of distilled water. The blot was dried and stored in
the dark. (The above processing stages involved gentle shaking throughout).
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2.13 ENZYME-LINKED IMMUNOSORBENT ASSAY (ELISA)
Polystyrene microplates (Immulon M129A) (Dynatech Billingshurst, Sussex)
and polystyrene microwell strips (Polysorb F8) (Nunc, Inter Med, Kamstrup,
Roskilde, Denmark) were used in the ELISA experiments. Frame-modules were
used to hold strips to form a 'plate'. Mini-sorb tubes (Nunc) were used for
making antigen dilutions. The following diluents and buffers were used during
the various ELISA procedures:
a) Coating buffer (pH9.6) consisted of 0.05 M carbonate/bicarbonate buffer
(6.2 g/litre Na2C03H20 and 4.2 g/litre NaHCOj) plus 0.05% w/v sodium
azide (Sigma).
b) Post-coat buffer consisted of PBS (pH7.2) containing 5% v/v bovine serum
albumin (BSA) (ICN Biomedicals) and 0.05% w/v sodium azide.
c) Wash buffer consisted of PBS (pH7.2) containing 0.05% v/v Tween-20
(Sigma) and 0.05% w/v sodium azide.
d) Dilution buffer consisted of PBS (pH7.2) containing 0.05% v/v Tween-20,
4% w/v polyethylene glycol 6,000 (Sigma) and 0.05% w/v sodium azide.
ELISA coating procedures
a) Coating with LPS-polvmvxin complex (Scott & Barclay, 1987)
Stock solutions of LPS and polymyxin were made up in distilled water and were
sonicated (Microson, Ultrasonic Cell Disruptor, Heat Systems-Ultrasonics Inc,
NY, USA) for 30 s prior to mixing. Complexes were formed by adding
polymyxin B sulphate (Sigma) at a concentration of 0.2 mM with LPS at a
concentration of 0.1 mM and then sonicating for another 30 s. The mixture was
then transferred to cellulose dialysis tubing with a 2,000 molecular weight cut
off (Spectrum Medical Industries Inc. Los Angeles, USA) and dialysed
overnight at 4°C against distilled water (containing 0.05% w/v sodium azide)
to remove unbound polymyxin. Complexes were stored in mini-sorb tubes at
-20°C until required. Molarity of P. aeruginosa R- and S-LPS was calculated
from the estimated molecular weights of LPS as determined by Morrison &
91
Jacobs (1976) as shown in Table 3.
To coat microwell strips or microtitre plates, complex was diluted 1:50 in
coating buffer and added at 100 pi per well. Strips and plates were coated
overnight at room temperature and washed four times with wash buffer
(Microwash 2, Skatron, Traby, Lier, Norway). Wells were post-coated with
post-coat buffer at 100 pi per well overnight at room temperature. After being
washed four times with wash buffer, strips and plates were rinsed in distilled
water and stored at -20°C until used.
Cocktails of different LPS-polymyxin complexes (see Results) were constituted
by mixing equal volumes of the relevant complexes. The coating procedure was
as described above.
b) Coating with Pseudomonas extract vaccine (PEV-02) and individual vaccine
serotype components fPVA)
PEV-02 was diluted 1:500 in coating buffer giving a final carbohydrate
concentration of 1 pg/ml. The individual vaccine O-serotype components
(stock solutions 0.1 mg/ml in distilled water) were diluted 1:100 in coating
buffer giving a final concentration of 1 pg/ml. Both were added to wells at
100 pi per well. Incubation, washing and post-coating was carried out as
described for LPS- polymyxin coating.
c) Coating with whole bacteria
Bacteria were grown overnight in NYB, harvested and washed twice with PBS.
Cells were resuspended to a density of 10^ cells/ml (determined
spectrophotometrically) in coating buffer and added at 100 pi per well. Plates
were then centrifuged at 1,365 g for 5 min to sediment bacteria to the wells.
Following overnight coating at room temperature the procedures were as
described for LPS-polymyxin coating.
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Wild type (smooth) 15,000 Serotype strains
Ra and Rb type 4, 500 PAC557 PAC608
PAC556 PAC611
Rc type 4, 150 PAC605
Rd and Re type 3, 100
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d) Coating with P. aeruginosa flagellar antigens
Flagellar antigen preparations were diluted in coating buffer to a concentration
of 1 pg/ml and added to microwell strips at 100 pi per well. The coating
procedure was as described above.
ELISA experimental procedures
The coated microwell strips/plates were used in a number of ELISA studies
which will be described individually for ease of reference:
a) Detection of serum IgG anti-P. aeruginosa LPS antibodies
Plates coated with PEV-02, R-LPS/polymyxin complexes, and whole cells, and
strips coated with the above, plus vaccine components PVA 0:1-0:16 were
used in these studies. Sera were diluted 1:200 in dilution buffer and added at
100 piper well in triplicate. Plates were incubated at 37°C for 90 min before
washing four times with wash buffer. Urease-conjugated anti-human IgG (Sera
Lab Ltd., Crawley Down, Sussex) was diluted 1:500 in diluent, added at 100 pi
per well and plates incubated for a further 90 min at 37°C. Plates were washed
four times and rinsed with distilled water before substrate (Sera Lab) at 100 pi
per well was added. Plates were incubated for 30 min at room temperature and
reactions stopped by adding 1% w/v thimerosal in distilled water (20 pi per
well). The OD of wells was read at 590 nm on an automated microplate reader
(Titertek Multiskan/MC, Flow Laboratories Ltd., Irvine). Final results were
expressed after subtraction of the OD of negative control wells (coated only
with BSA - post coat) for each serum.
b) Detection of salivary and sputum IgA and IgG anti-F. aeruginosa LPS
antibodies
Plates coated with PEV-02 and R-LPS/polymyxin samples were used in these
studies. Dilutions of saliva and sputum were made in dilution buffer and added
at 100 pl/well in triplicate. Plates were incubated at 37°C for 90 min before
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washing four times with wash buffer. HRP-conjugated anti-human IgA and
IgG (both ICN) were diluted 1:1000 and added at 100 pi per well and plates
incubated for a further 90 min at 37°C. Plates were washed four times and
rinsed with distilled water before substrate at 100 pi per well was added.
Substrate consisted of 0.1 M sodium acetate (BDH)/citrate (Sigma) buffer
(pH6.0) containing 1 mg/ml 3,3-,5,5-tetramethyl-benzidine (ICN) made up in
dimethylsulphoxide (BDH) and 0.015% v/v hydrogen peroxide (BDH General
Purpose). Plates were incubated for 60 min at room temperature and reactions
stopped by adding 2 M sulphuric acid at 25 pi per well. The OD of wells was
read at 450 nm on a microplate reader. Final results were expressed after
subtraction of the OD of negative control wells (as above).
c) Detection of serum, salivary and sputum IgA and IgG anti-P. aeruginosa
flagellar IgA and IgG antibodies
As for b) above.
d) Screening of mouse sera and Mabs antibodies for anti-.P. aeruginosa LPS
activity
Sera from mouse tail bleeds were diluted 1:100 in diluent. Supernatant from
hybrids and clones were screened for Mab at a dilution of 1:5. Screenings
included microwe 11 strips coated with LPS/polymyxin complexes, PEV-02, PVA
serotype vaccine components, and whole cell preparations. 'Antibody' samples
were added at 100 pi per well and plates incubated at 37°C for 90 mins before
> washing four times with wash buffer. Urease-conjugated anti-mouse Ig, IgG or
IgM (all Sera Lab) (used as appropriate - see Results) were diluted 1:500,
added at 100 pi per well, and plates incubated for a further 90 min at 37°C.
Plates were washed and rinsed before substrate (Sera Lab) at 100 pi per well was
added. Plates were incubated for 60 min at room temperature and reactions, if
required, stopped by thimerosal (as for a) above). OD of wells was read at 590
nm on a microplate reader and results expressed after subtraction of negative
controls (as above).
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2.14 ABSORPTION OF CLINICAL SPECIMENS
a) Absorption of sera with whole cells
Sera from CF patients were subjected to a series of absorptions with
P. aeruginosa whole cells. Overnight cultures of bacteria grown in NYB were
harvested by centrifugation (4,600 g for 15 min), washed twice in PBS and
resuspended to a density of 10^ cells/ml. Bacterial suspension (1 ml) was
added to a 1.5 ml Eppendorf tube and bacteria harvested at 1,365 g for 5 min
using a microcentrifuge. After removal of supernatant, bacteria
were resuspended in serum diluted 1:200 in dilution buffer, incubated for 15
min at room temperature, and recentrifuged. The supernatant was then added
to another pellet of cells and the process repeated. This step was repeated at
least three times for each absorbing cell type to ensure maximal absorption of
antibodies by bacteria. Serum anti-pseudomonal LPS IgG antibodies in
absorbed and unabsorbed sera were assayed by ELISA.
b) Absorption of clinical specimens with extracted LPS
To avoid immunological detection of anti-LPS antibodies in the flagella
experiments, due to any contaminating LPS (Poxton et al, 1985), specimens
were preabsorbed with LPS. Sera, saliva and sputa (100 pi) were mixed with an
equal volume of extracted LPS at 1 mg/ml. (The LPS was from the strain used
to prepare the corresponding flagella). Samples were incubated for 60 min at
37°C followed by incubation overnight at 4°C. Afterwards samples were
suitably diluted prior to use in ELISA and immunoblot studies. Removal of
LPS antibodies was confirmed by ELISA against the relevant LPS.
2.15 PRODUCTION OF ANTI-P. AERUGINOSA LPS MONOCLONAL
ANTIBODIES
a) Preparation of cells for mice vaccinations
Bacteria were cultured overnight in NYB, harvested by centrifugation (4,600 g
for 15 min) washed twice with PBS and resuspended in PBS (pH7.2) to a density
of 108 cells/ml. Cell suspensions were then dispensed in 10 ml aliquots into
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sterile universal bottles and were heat-killed by heating at 100°C for 5 min.
Bacterial culture of the heat-killed preparations was used to ensure total
bacterial killing. Samples were frozen at -20°C and used as required.
b) Mice vaccinations and Mab production
All animal manipulations were performed by Mr J. Verth (Animal House,
University Medical School, Edinburgh) and production of Mabs was by Dr L.R.
Micklem (Dept. Surgery, University Medical School, Edinburgh). BALB/c mice
were immunised with 0.1 ml of the heat-killed cell preparations (equivalent to
107 cells/ml) as follows: day 1, 2, 3, 8, 9, 10 with PAC608; day 22, 23, 24 with
PAC605. Blood from the mice was taken at: pre- inoculation day 1, and day
20, 31 and 38. The bloods were allowed to clot overnight at 4°C and then
centrifuged at 13,000 gfor 30 s in a microcentrifuge. The supernatant serum
was collected and stored at -20°C.
The nature of the antibody response to P. aeruginosa LPS was measured by
ELISA. A mouse showing a strong, cross-reactive antibody response to
P. aeruginosa LPS was selected (see Results). The mouse was boosted
intravenously with 0.1 ml heat-killed cells of PAC608 and killed 3 days later to
obtain spleen cells. Mouse spleen cells were fused with cells of the NS-1 (NS-
1/1-Ag4-1) plasmacytoma cell line. Resulting hybrids were screened for anti-
P. aeruginosa LPS antibodies by ELISA. Antibody positive hybrids were cloned
by limiting dilution and were also screened in ELISA (see Results). Clones
producing Mabs of particular interest were grown in bulk (1 litre) for the
concentration and partial purification of the Mabs.
c) Concentration of Mabs from bulk growths
Culture supernatent from bulk growth (1 litre) of Mab producing clones was
centrifuged at 10,000 g for 10 min to remove cellular debris. The supernatant
containing Mabs was concentrated 20-fold by a Minitan tangential-flow system
(Millipore, Bedford, MA, USA) employing Minitan pore filters (Millipore) with
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a molecular weight cut-off of 30,000. The system was purged with copious
amounts of pyrogen free distilled water and 0.1 M sodium hydroxide (BDH)
and primed with a small quantity of RPMI (Gibco, Paisley, Renfrewshire)
between each concentration. Activity of the Mabs was checked by ELISA.
d) Ammonium sulphate precipitation of immunoglobulins
The method used was a modification of that described by Hardy (1986).
Immunoglobulin was precipitated by the addition of crystalline ammonium
sulphate (Sigma Grade III) to the concentrated solution containing Mab to give
50% saturation (equivalent to a final concentration of 0.313 g/ml). Thus 3.13 g
of ammonium sulphate was added slowly, with stirring to 10 ml of the Mab
preparation. The ammonium sulphate was allowed to dissolve and the
precipitate was stirred for 2 h at room temperature. The precipitate was
harvested by centrifugation at 10,000 g for 60 min at 4°C and the pellet
resuspended in 10 ml of 0.1 M NaHCC^ (BDH). The solution was
reprecipitated, recentrifuged and resuspended as above. The ammonium
sulphate was removed by dialysis for 20 h at 4°C with stirring, against at least
three changes of 0.1 M NaHCO^ buffer containing 0.05% w/v sodium azide
(Sigma). Activity of the Mabs was checked by ELISA.
2.16 AGAROSE GEL ELECTROPHORESIS
Mabs prepared by ammonium sulphate precipitation were analysed by agarose
gel electrophoresis based on a modification of the method described by
Carlstrom & Johansson (1983). The solutions and reagents required included:
a) Tris-glycine-vernal buffer (TGV) (pH8.6). 25.75 g of barbitone and 16 g of
sodium barbitone (both BDH) were dissolved in 1 litre of distilled water
and added to a further 1 litre of water containing 17 g of glycine (BDH
Chromatographically Homogeneous) and 13.75 g of Tris (BDH). The
mixture was stirred, 37.2 g of disodium EDTA (Sigma) added and the
mixture made up to a final volume of 5 litres.
b) Agarose gel. A 1% w/v solution of agarose (Bio-Rad standard low- Mr) in
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TGV was prepared with the aid of a boiling water bath. After allowing to
cool 60°-70°C, 22.2 ml was poured onto the hydrophilic surface of a sheet
of Gelbond^M (Bio-Rad) (125 mm x 100 mm) supported on a glass plate
on a levelling table (Bio-Rad). The gel was allowed to set at room
temperature for 5 min and then placed in a fridge for 30 min to harden.
c) Picric acid fixative. A warmed (60°C), filtered solution of 1.4% w/v picric
acid (BDH) in water was mixed with glacial acetic acid (BDH) in a ratio
of 5:1 (v/v).
d) Staining and washing solution for protein. Methanol, acetic acid (both BDH
General Purpose) and distilled water were mixed in 9:2:9 ratio (v/v). The
dye free solvent was used for the washing solution. Coomassie brilliant
blue R-250 (BDH) was added at 0.2% w/v for the staining solution.
The area of the gel to be used for placement of the applicator foil was lightly
blotted with Whatman No. 1 filter paper to remove surface moisture. The
applicator (containing a series of regularly arranged slots for diffusion of
samples into the gel) was then placed on the gel. Samples (2 pi), previously
diluted 1:2 in 0.1% w/v bromophenol blue in TGV, were applied to slits using
microcapillaries. Samples were left for 5 min after the last application in order
to allow diffusion into the gel. After diffusion excess sample was removed from
the applicator which was then removed. The gel was placed in the
electrophoresis cell tank (Model 1415, Bio-Rad) and the wicks (five layers of
Whatman No. 1 filter paper) were put in place to serve as contacts between each
end of the gel and the respective TGV buffer reservoirs. A glass plate was then
placed on top to prevent the wicks becoming detached from the gel surface.
Cooled water at 10°C from a temperature control unit (Model RTE-5DD,
Jencons Scientific) was circulated through the gel tank at a flow rate of 1 litre
per min. The gel was run at a constant 300 V until the dye front had travelled
55 min.
The gel was placed in picric acid fixing solution for 15 min and then dryed by
99
covering with six sheets of filter paper and pressing for 5 min. Drying was
completed by placing in a 60°C oven for 15 min. The thin gel film was briefly
rinsed in distilled water and stained for 10 min. After staining the gel was
washed twice with dye free solvent until a colourless background was obtained.
2.17 BIOTINYLATION OF MONOCLONAL ANTIBODIES
Biotinylation of Mabs was based on the procedure described by Guesdon et al
(1979). Aminohexanoyl-biotin-N-hydroxysuccinimide ester (AH- BNHS)
(Zymed Laboratories Inc., San Francisco, California, USA) was used to
covalently bind biotin to the Mabs. The protein concentration of Mab
preparations was determined by the method of Lowry et al (1951). Calculations
of quantities of reagents were based on a value of 90 free amino groups per
gamma globulin molecule as reported by Habeeb (1966). Various molar ratios
(1:1, 2:1, 4:1) of AH-BNHS and free amino groups of gamma globulin Mab
molecules were reacted together to determine the optimal binding ratio. To
react a 1:1 molar ratio of AH-BNHS with the free amino groups of Mab,
27.5 pi of AH-BNHS (10 mg/ml dissolved in dimethylformamide BDH) was
added to 1 ml of Mab (1 mg/ml in 0.1 M NaHCC^). Reactions were
performed in Reactovials TM (Pierce Chemical Co., Rockford, Illinois, USA)
and were vigorously stirred for 2 h at room temperature. The reaction mixture
was dialysed for 24 h at 4°C with stirring, against several changes of PBS
(pH7.2) containing 0.05% w/v sodium azide (Sigma). After dialysis an equal
volume of glycerol (Sigma) was added and the biotinylated Mabs (bio-Mabs)
stored at -20°C. The bio-Mabs were analysed by ELISA.
2.18 ISOTYPING OF IMMUNOGLOBULINS
Mouse Mabs were isotyped by a blotting detection kit for mouse antibodies
(RPN2?) (Amersham International pic, Amersham, Bucks.).
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2.19 STREPTAVIDIN-BIOTIN ELISA SYSTEMS
ELISA studies of bio-Mabs included comparison of immunoassay detection
systems involving different streptavidin-labelled enzymes as well as an
amplification system incorporating streptavidin-biotin-enzyme complexes.
Buffers, reagents and methodologies used in these ELISA studies were as
previously described unless otherwise indicated.
a) Enzyme labelled reagents. Some or all of the following enzyme-labelled
reagents were used in the various experiments: i) urease conjugated
streptavidin (Sera Lab) diluted 1:200; ii) alkaline phosphatase conjugated
streptavidin (Zymed) diluted 1:1000; iii) biotinylated alkaline
phosphatase-streptavidin (BAPS) complex made up by the addition of
10 pi of biotinylated alkaline phosphatase (1 mg/ml) (Zymed) and 20 pi
of streptavidin (1 mg/ml) (Zymed) to 5 ml diluent. The dilution buffer
described previously (see page 91 ) was used for i) and ii). PBS buffer
(pH7.2) containing 0.05% v/v Tween 20 (Sigma) was used for iii).
b) Substrates i) Urease substrate (Sera Lab) was used for the urease-
conjugated streptavidin; ii) substrate for the alkaline phosphatase
labelled reagents was prepared by dissolving one p-nitrophenyl phosphate
tablet (Sigma 104 phosphatase substrate tablets) per 5 ml of substrate
dilution buffer (pH9.8 - containing 0.05 M sodium carbonate/bicarbonate,
0.002 M magnesium chloride).
Bio-Mabs were serially diluted (or as appropriate) in diluent and added to
coated microwell strips at 100 pi per well. In some of the investigations
(checkerboard titrations) strips were coated with a series of different antigen
concentrations. Plates were incubated for 90 min at 37°C and then washed.
Enzyme-labelled reagents were added at 100 pi per well and plates incubated
for a further 90 min prior to washing and then rinsing with distilled water. The
relevant substrate was added (100 pi per well) and plates incubated for 60 min
at room temperature prior to reading the OD - 590 nm for urease and 405 nm
for alkaline phosphatase.
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2.20 MONOCLONAL ANTIBODY COMPETITION STUDIES
An ELISA competition assay was devised to compare the antigen binding sites
of different Mabs. Buffers, reagents and methodologies were as previously
described. A dilution series of unlabelled Mab was prepared in dilution buffer
and added to coated microwell strips at 100 pi per well. Following incubation
(90 min at 37°C) bio-Mab (the same or different to the unlabelled Mab)
serially diluted in diluent, was added on top of the unlabelled Mab at 100 pi
per well ie in checkerboard fashion. Plates were shaken for 15-30 s to mix
Mabs, incubated (90 min at 37°C), and then washed prior to addition of 100 pi
per well streptavidin alkaline phosphatase (1:1000). Following incubation (90
min at 37°C) plates were washed, rinsed and substrate added at 100 pi per
well. After incubation (60 min at room temperature) the OD was read at
405 nm.
A standard curve was established by titrating one Mab against itself ie the
same Mab used for both the label and competitor. The capacity of other
unlabelled Mabs to inhibit the binding of the labelled Mab was titrated. The
results were plotted and the concentrations necessary to achieve 50% inhibition
of binding were compared.
2.21 CAPTURE ELISA
A capture ELISA was developed for the detection of P. aeruginosa LPS in
solution. Solutions, reagents and basic methodologies were as previously
described.
The wells of microwell strips were coated with Mab diluted, as appropriate (see
Results), in coating buffer. Plates were coated overnight at room temperature
and then washed, post-coated and subsequently stored as previously described.
A series of dilutions of P. aeruginosa LPS, whole-cells and heat-killed cells
were made in dilution buffer and added at 100 pi per well. Plates were
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incubated at 37°C for 2 h before washing. Bio-Mab, diluted as appropriate
(see Results), was added at 100 pi per well and plates incubated at 37°C for 90
min. After washing, BAPS complex (see page 101) was added at 100 pi per
well and plates incubated for 30 min at 37°C. Plates were then washed and
alkaline phosphatase substrate added at 100 pi per well. Following incubation
(60 min at room temperature) the OD of wells was read at 405 nm.
The above method was used for detection of LPS in saliva and sputum
specimens. Prior to use in the assay samples were deproteinised by heating
(100°C for 5 min) as recommended by Doskeland & Berdal (1980). Samples
were then diluted 1:2 in diluent and added at 100 pi per well to Mab coated
wells. The remainder of the assay was as described above.
2.22 BACTERIAL CHEMOTAXIS ASSAY
Bacterial chemotaxis was measured by the capillary tube assay described by
Adler (1973) incorporating the minimal medium and chemotaxis medium (CM)
described by Moulton & Montie (1979). One millilitre of an overnight
preculture grown in minimal medium was inoculated into 9 ml of minimal
medium and incubated at 37°C for 3 h in an orbital incubator at 120 rpm. The
exponentially growing cells were harvested by centrifugation at 4,600 g for 15
min and washed twice with 10 ml of CM before suspension to a density of 2 x 10^
CFU (OD 0.25 at 590 nm).
The capillary tube assay was set up and performed as follows: A small
chamber was formed by placing a cover slip on a U-shaped piece of melting-
point capillary tubing bonded to a microscope slide. Prior to use in the assays,
the chambers, supported and enclosed in petri-dishes, were prewarmed by
incubation at 37°C for at least 30 min. The chambers were then filled with
0.4 ml of bacterial suspension in CM.
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Capillaries (0.25 mm internal diameter, 45 mm in length and sealed at one end
by flaming) (Phase Separations Ltd., Deeside, Clwyd) were filled with potential
chemoattractants dissolved in CM. Control capillaries containing CM alone
were used in all experiments as a measure of background motility. The open
end of a capillary was inserted into the centre of a chamber containing the
bacterial suspension. After incubation for 30 min (unless otherwise indicated)
the capillaries were removed, their sealed ends carefully broken with a diamond
scribe, and the contents emptied into 1 ml of sterile saline with the aid of a
micropipette bulb. The contents were serially diluted in saline and plate counts
on NA made.
The accumulation of bacteria in each of two capillaries containing potential
chemoattractant was measured as CFU per capillary and a mean value
determined. A similar measurement was made from capillaries in which no
chemoattractant was present. The ratio of these CFU values (the relative
response) was then determined ie the ratio of the accumulation in attractant
capillaries to that in control capillaries. The ratio normalizes for experimental
or day to day variations. A meaningful chemotactic response as described by
Moulton & Montie (1979) is a relative response value of >2.0.
Some of the mucin preparations were treated with protease (Sigma Type XXV
pronase) prior to use in chemotaxis assays. Pronase made up at 1 mg/ml in CM
was added to the mucin preparation to a final concentration of 100 pg/ml.
Samples were incubated at 37°C for 24 h in a water bath prior to use in
chemotaxis assays.
2.23 MOTILITY ASSAYS
a) Motility inhibition assay. Motility inhibition studies were conducted by the
chemotaxis capillary assay described above. The anti-P. aeruginosa flagellar
(type-b) Mab was added to the bacterial suspension to a final dilution of 1:40.
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The bacterial/Mab solution was incubated at 37°C for 30 min prior to use in
the chemotaxis assay. Motility of cells with and without addition of the anti-
flagellar Mab was checked by phase contrast microscopy. Duplicate assays
were performed and the relative chemotactic responses obtained from test and
control assays compared.
b) Motility assay in semi-solid agar. Motility medium was prepared as
described on page 76. Bacterial strains were cultured on PLA and five colonies
for each strain were stab inoculated into the centre of the motility medium. For
each assay triplicate plates per strain were incubated at 37°C and examined for
colony spreading. Colony diameter was measured after 24 h.
2.24 ADHERENCE STUDIES OF P. AERUGINOSA TO MUCIN
Two novel methods were developed during the course of this thesis to examine
adherence of P. aeruginosa to mucin.
Electron microscopy
Visualisation of the mucin-bacterium association by transmission electron
microscopy incorporated a modification of a surfactant monolayer technique
described by Sheehan et al 1986 for the study of mucin architecture.
A log phase culture of bacteria grown in 10 ml NYB was centrifuged at 4,600 g
^ for 15 min and washed twice in 1% w/v ammonium acetate (Sigma) in distilled
water. The pellet was then gently resuspended in 15 ml of mucin solution (0.5
pg/ml in 50 mM magnesium acetate) (BDH), and the mixture was transferred
to a plastic petri dish and incubated for 30 min at 37°C. To prepare mucin
monolayers a small amount of fine graphite powder (BDH) was sprinkled on
the surface. A mucin monolayer was obtained by touching the surface of the
mucin solution with the tip of a pipette containing 1 pi of 1% w/v
benzyldimethylalkyl-ammonium chloride (BAC) (Sigma) in distilled water.
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The surfactant nature of the BAC propels the carbon particles to the side of
the dish, leaving a fine surface monolayer of mucin in BAC. After 15 min,
carbon-coated formvar 400-mesh electron microscope grids were touched to
the surface of the monolayer, stained for 1-2 s in a solution of uranylacetate (1
mM in 95% v/v ethanol BDH) and washed for 1-2 s in ethanol. The grids were
then allowed to dry in a desiccator before being subjected to unidirectional
shadowing with platinum at a grazing angle of 7-12°. Transmission electron
microscopy was performed with a 12A Hitachi microscope at 75 KV. Grids
were examined for mucin-bacterial interactions.
Microtitre ELISA
Many of the materials, reagents and solutions used in the development of this
adherence assay were as described previously (see page 91).
Mucins were diluted in coating buffer and added to wells at 100 pi per well. In
preliminary experiments mucin concentrations, doubly diluted in coating buffer
from 1.6 pg/ml to 200 pg/ml were investigated. A coating concentration of
100 pg/ml was shown to give optimal sensitivity, yielding maximal difference in
OD between mucin coated wells and background controls. Wells were coated
overnight at room temperature and washed four times with wash buffer. Non¬
specific binding sites were blocked by post-coating wells overnight at room
temperature with post-coat buffer. (Wells coated only with post-coat were used
as background controls).
An overnight culture of bacteria was harvested by centrifugation (4,600 g for 15
min) and washed twice in PBS. Cells were then resuspended in PBS containing
1% v/v sterile BSA (Organon-Technika, Cambridge, Cambs.) and 0.05% v/v
Tween 20 (Sigma). In preliminary experiments bacterial concentrations 10^-
10^ cells/ml were investigated in the adherence assays. A bacterial
concentration of 10^ cells/ml showed maximal measureable binding to mucin
coated wells and minimal non-specific binding to background control wells.
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Each individual experiment was performed in duplicate with three wells per
determination. Bacterial cells were added to wells at 100 pi per well in
triplicate and incubated at 37°C for 60 min. Wells were then washed eight
times with wash buffer. A Mab, cross- reactive with all serotypes of
P. aeruginosa, diluted 1:500 in dilution buffer, was added at 100 pi per well.
The optimal dilution of Mab was predetermined in initial experiments. After
incubation at 37°C for 90 min, wells were washed four times with wash buffer.
Urease-conjugated anti-mouse Ig (Sera Lab) diluted 1:500 was added at 100 pi
per well. After incubation (90 min at 37°C) wells were washed four times and
rinsed with distilled water, before substrate (Sera Lab) at 100 pi per well was
added. Plates were incubated for 60 min at room temperature before OD of
wells was read at 590 nm on a microplate reader. Results for each adherence
determination were expressed as the mean OD from triplicate wells after
subtraction of the OD of negative background controls. The mean from
duplicate experiments was then calculated to give the final result.
2.25 EFFECT OF MUCIN SUGARS ON ADHERENCE
The effect of the mucin sugars L-fucose, D-galactose, GalNAc, GlcNAc and
NANA on P. aeruginosa adherence to mucins was also investigated by the
above assay. Bacterial suspensions (10^ cells/ml) were prepared in the PBS
suspension buffer as described above and were mixed with an equal amount of
> suspension buffer (controls) or 200 mM sugar solutions in the same buffer, ie
equal concentrations of bacteria in buffer or 100 mM sugar solutions were
prepared. Solutions of NANA prepared in the PBS buffer had a pH of
ca. pH2.5 which is lethal for the bacteria. Therefore, bacterial suspensions were
prepared in solutions of NANA dissolved in Tris-HCl buffer and buffered to
pH7.2. The bacterial-sugar suspensions were mixed, incubated at room
temperature for 60 min, and then added in triplicate at 100 pi per well. The
remainder of the assay was as above. The effect of sugars on adherence of
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DETECTION OF ANTIBODIES TO P. AERUGINOSA LPS
1.1 SERUM ANTI-LPS ANTIBODIES DETECTED BY ELISA
The aim of this study was to produce an ELISA system based on defined
antigenic preparations, suitable for the routine detection of an antibody
response against all serotypes of P. aeruginosa. In the ELISA system
developed, two different coating antigens were employed for detection of anti-
P. aeruginosa LPS antibodies: i) polyvalent Pseudomonas smooth LPS vaccine
(PEV-02) composed of cell wall LPS extracts of 16 international serotypes of
P. aeruginosa^ ii) LPS from the rough mutant P. aeruginosa PAC605, deficient
in the ability to produce O-antigenic LPS.
Preliminary experiments were performed to determine the optimal coating
concentration of PEV-02, and PAC605 LPS complexed with polymyxin. The
results of checkerboard type titrations indicated that PEV-02 at 1 pg/ml or
PAC605 LPS at 10 ng/ml and serum from a CF patient chronically colonised by
P. aeruginosa produced strong readable absorbance values (OD>1.0) within a
reasonable substrate reaction time (30 min). In all subsequent experiments a
serum sample was classed as positive for anti-F. aeruginosa LPS antibodies if
the OD value was >0.1 after subtraction of background control.
Serum IgG anti-P. aeruginosa LPS antibodies in CF patients variously
colonised by P. aeruginosa are shown in Figure 4. A range of elevated levels
(OD>0.1) of anti-pseudomonal IgG antibodies directed to both PEV-02 S-LPS
and PAC605 R-LPS were demonstrated in sera from twenty patients with CF
who were chronically colonised by P. aeruginosa. Anti-pseudomonal IgG
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Figure 4. Serum IgG anti-P. aeruginosa LPS antibodies in 47 CF patients and 10 non-CF
individuals measured by ELISA with either heterogenous polyvalent S-LPS vaccine (PEV-02) or
core R-LPS (PAC605) as coating antigens: a total of 20 CF patients chronically colonised with
P. aeruginosa, 7 intermittently colonised, 20 non-colonised CF patients and 10 healthy adults are
included.
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substantially reduced compared to the chronically colonised group although a
detectable (OD>0.1) response to PEV-02 or PAC605 LPS was observed in
some of these patients. Raised anti-pseudomonal IgG antibody levels were not
found in sera from twenty non-P.aeruginosa colonised CF patients or in ten
healthy, non-CF controls, with the exception of one CF patient (OD = 0.124)
and one non-CF patient (OD = 0.119).
Statistical analysis of the results by the Student t test revealed: i) the
difference in absorbance readings between chronically colonised CF patients,
and those intermittently or non-colonised, or healthy control individuals, was
very highly significant (P< 0.001); ii) the difference in absorbance readings
between intermittently colonised CF patients and both non-colonised patients
and healthy controls was very highly significant (P< 0.001) for PEV-02, and
highly significant (P<0.01) for PAC605 core LPS; iii) there was no significant
difference in absorbance readings between non-P. aeruginosa colonised CF
patients and healthy controls.
Reproducibility of the assay was checked with twelve serum samples, four from
each of the three groups of CF patients ie chronically colonised with
P. aeruginosa; intermittently colonised and non- colonised. The results of
duplicate assays performed on five different occasions gave an intraplate
variation of 4%, an interplate variation of 6.5% and a day to day variation of
12%.
1.2 LONGITUDINAL STUDIES OF SERUM IgG ANTI-LPS
ANTIBODIES
The ELISA system described above was used to follow the serum IgG anti-
P. aeruginosa LPS antibody response in three CF patients who were initially
intermittently or non-colonised by P. aeruginosa (Figure 5) Low, but
detectable (OD>0.1) levels of IgG antibodies directed to P. aeruginosa LPS
were found in the two patients initially intermittently colonised by the organism.
Ill
Antibody levels to both PEV-02 S-LPS and PAC605 core R-LPS increased at
the same time as P. aeruginosa was cultured consistently (three consecutive
occasions) from sputum specimens obtained from each patient. Antibody levels
to the two LPS antigens continued to increase and then plateau during the
ongoing infection.
1.3 SERUM ANTIBODY RESPONSE TO INDIVIDUAL LPS
SEROTYPES OF P. AERUGINOSA
The serum IgG antibody response to individual LPS serotypes of P. aeruginosa
was measured by ELISA with the S-LPS O-serotype vaccine components, PVA
0:1-0:16. Serum from four patients chronically colonised with P. aeruginosa
produced a positive reaction with most of the sixteen individual serotype
vaccine components (Figure 6). Given the heterogeneity of antibody response,
a pronounced antibody response to any one particular serotype was not evident.
Indeed, a pronounced response to the S-LPS of the three most commonly
isolated P. aeruginosa serotypes (0:1, 0:6, 0:11) found in the Edinburgh area
was not evident, with equally strong responses occuring with some of the less
common serotypes.
In contrast, sera from non-colonised or intermittently colonised CF patients
produced barely detectable or undetectable antibody responses to the individual
serotype components (Figure 7).
1.4 SPUTUM AND SALIVA ANTI-LPS ANTIBODIES DETECTED BY
ELISA
Anti-P. aeruginosa LPS IgA and IgG antibodies in sputum and saliva were also
measured by ELISA with PEV-02 S-LPS and PAC605 R-LPS as coating
antigens.
A range of levels of anti-pseudomonal IgA antibodies directed to both PEV-02
and PAC605 LPS were demonstrated in sputa from patients with CF (Figure
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Figure 5. Longitudinal study of serum IgG anti-P. aeruginosa LPS antibodies in 3 CF patients
measured by ELISA with either a) heterogenous polyvalent S-LPS vaccine (PEV-02) or b) core
R-LPS (PAC605) as coating antigens. The arrows indicate the time when P. aeruginosa started
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Figure 6. Serum IgG anti-E. aeruginosa LPS antibodies in 4 CF patients chronically colonised
with P. aeruginosa measured by ELISA with individual S-LPS O-serotype vaccine components
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7igure 7. Serum IgG anti-P. aeruginosa LPS antibodies in CF patients intermittently or non-
alonised with P. aeruginosa measured by ELISA with individual S-LPS O-serotype vaccine
jmponents (PVA-1 to PVA- 16), core R-LPS (PAC605) and polyvalent vaccine (PEV-02).
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8). Patients chronically colonised with P. aeruginosa tended to show a greater
anti-pseudomonal LPS IgA response than the intermittently, or non-colonised
patients, although detectable levels of anti-LPS IgA antibodies were observed in
some of both these groups of patients. In the patients chronically colonised by
P. aeruginosa there tended to be a greater IgA antibody response towards the
R-LPS of PAC605 compared to the S-LPS of PEV-02. Statistical analysis by the
Student t test revealed that this difference was highly significant (PcO.Ol).
Further statistical analysis of the ELISA results for sputum anti-LPS IgA
antibodies showed: i) the difference in OD values between patients chronically
colonised with P. aeruginosa and non-P. aeruginosa colonised patients was
significant (P<0.02) for PEV-02 S-LPS and very highly significant (P< 0.001)
for PAC605 R-LPS; ii) the difference between chronically colonised patients
and intermittently colonised patients was not significant for antibodies directed
to PEV-02 S-LPS, but was significant (P<0.02) for IgA antibodies directed to
PAC605 R-LPS; iii) there was no significant difference in IgA antibody levels
between intermittently and non-P. aeruginosa colonised CF patients.
In contrast to the anti-pseudomonal LPS IgA antibodies found in sputum, anti-
pseudomonal LPS IgG antibodies were not detected (data not shown).
Anti-pseudomonal LPS IgA antibodies were also detected in saliva samples
from patients with CF (Figure 9). Patients chronically colonised with
P. aeruginosa again showed a tendency towards a greater anti-pseudomonal
LPS IgA antibody response than the intermittently or non-colonised patients.
However, as with the ELISA studies with sputum, IgA antibodies were found in
some of both these latter groups of patients. Statistical analysis of the ELISA
results for saliva anti-LPS IgA antibodies showed: i) the difference in OD values
between patients chronically colonised with P. aeruginosa and non-
P. aeruginosa colonised patients was highly significant (PcO.Ol) for PEV-02 S-
LPS and very highly significant (PcO.OOl) for PAC605 R-LPS; ii) the
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Figure 8. Sputum IgA anti-P. aeruginosa LPS antibodies in 32 CF patients measured by ELISA
with either heterogeneous polyvalent S-LPS vaccine (PEV-02) or core R-LPS (PAC605) as
coating antigens: a total of 15 CF patients chronically colonised with P. aeruginosa, 5
intermittently colonised, and 12 non-colonised CF patients are included.
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difference between chronically colonised patients and intermittently colonised
patients was not significant for antibodies directed to PEV-02 S-LPS, but was
highly significant (PcO.Ol) for IgA antibodies directed to PAC605 R-LPS;
iii) there was no significant difference in IgA levels between intermittently and
non-P. aeruginosa colonised CF patients.
In contrast to sputum, anti-pseudomonal LPS IgG antibodies were detected in
saliva samples from patients with CF. A range of levels of anti-pseudomonal
IgG antibodies directed to both PEV-02 S-LPS and PAC605 R-LPS were
observed in saliva of patients with CF (Figure 10).
The highest levels of IgG anti-LPS antibodies in saliva were found in patients
chronically colonised by P. aeruginosa. The difference in IgG anti-LPS antibody
levels between chronically colonised patients and non-P. aeruginosa colonised
patients was highly significant (PcO.Ol) for PEV-02 S-LPS and very highly
significant (P< 0.001) for PAC605 R-LPS. Differences in the antibody levels
between chronically colonised and intermittently colonised patients, and
between intermittently and non-colonised patients were not significant by the
Student t test.
1.5 IMMUNOBLOT ANALYSIS OF SERUM AND SPUTUM AGAINST
LPS
The serum IgG and sputum IgA antibody responses to P. aeruginosa LPS were
further investigated by immunoblotting. LPS from proteinase K digests of P.
aeruginosa whole cells was separated by SDS-PAGE, and electrophorectically
transferred to NIC paper for subsequent probing with serum and sputum from
patients with CF. The following P. aeruginosa LPS preparations were used in
each gel for subsequent immunoblot analysis: i) the CF patients own non-
mucoid and/or mucoid P. aeruginosa strains which had previously been
serotyped by standard typing sera; ii) P. aeruginosa standard serotype strains



















































Figure 9. Saliva IgA anti-P. aeruginosa LPS antibodies in 42 CF patients measured by ELISA
with either heterogeneous polyvalent S-LPS vaccine (PEV-02) or core R-LPS (PAC605) as
coating antigens: a total of 17 CF patients chronically colonised with P. aeruginosa, 6





























































































Figure 10. Saliva IgG anti-P. aeruginosa LPS antibodies in 39 CF patients measured by ELISA
with either heterogeneous polyvalent S-LPS vaccine (PEV-02) or core R-LPS (PAC605) as
coating antigens: a total of 15 CF patients chronically colonised with P. aeruginosa, 5
intermittently colonised and 19 non-colonised CF patients are included.
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serotype strains used included the three most commonly isolated serotypes
(0:1, 0:6 and 0:11) found in Edinburgh as well as some of the less common
serotypes; iii) P. aeruginosa strains defective in O-antigen production,
expressing only core, R-LPS.
The silver stained LPS profiles of six P. aeruginosa strains are shown in Figure
11a and include a non-mucoid isolate (serotype 0:1) from a CF patient
intermittently colonised by the organism. The adjacent photograph (Figure
lib) is the immunoblot probed with serum obtained from the CF patient
during the intermittently colonised state. The LPS profile of JN62, the CF
patient's strain, exhibits a ladder-like pattern of high molecular weight LPS
corresponding to O-antigen substituted LPS. The immunoblot, analysed for
anti-P. aeruginosa LPS IgG antibodies, shows a positive reaction with bands of
high molecular weight, O-antigen LPS of JN62 (Track 1) and the equivalent
standard serotype 0:1 (Track 6). In addition, a fainter band corresponding to
the low molecular weight, common core LPS of these strains was also observed.
Serum taken four months later from the above CF patient, during consistent
(isolated on three successive occasions) colonisation by non-mucoid
P. aeruginosa,was again examined for LPS antibodies by immunoblotting. The
LPS profiles of eight P. aeruginosa strains are shown in (Figure 12a) together
with the subsequent immunoblot (Figure 12b). Serum IgG antibodies directed
towards the ladder-like bands of high molecular weight LPS of a number of the
S-LPS strains are revealed, including against JN62 - the P. aeruginosa isolate
from the CF patient (Track 6), and standard serotype strains 0:1, 0:3 and 0:6
(Tracks 1, 2 and 3 respectively). IgG antibodies reactive with the common core
LPS of a number of the strains were also observed and included antibodies
against core LPS of strains 0:1, 0:3, 0:6, 0:8, PAC605, PAC608 and JN62
(Tracks 1, 2, 3, 4, 6, 7 and 8 respectively).
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Figure 11. a) Silver stained LPS profiles of proteinase K whole cell digests of 6 P. aeruginosa
strains separated by SDS-PAGE (14% w/v acrylamide). b) Immunoblot of anti-P. aeruginosa
LPS IgG antibodies following transfer of LPS to NIC paper and incubation with serum (1:100)
from a CF patient intermittently colonised by non-mucoid P. aeruginosa. Track 1, JN62 (CF
patient's non-mucoid strain, serotype 0:1); Track 2, PAC608 (R-LPS); Track 3, PAC605 (R-
LPS); Track 4, serotype 0:11 (S-LPS); Track 5, serotype 0:6 (S-LPS) and Track 6, 0:1 (S-LPS).
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Figure 12. a) Silver stained LPS profiles of proteinase K whole cell digests of 8 P. aeruginosa
strains b) Immunoblot of anti-P. aeruginosa LPS IgG antibodies following transfer of LPS to
NIC paper and incubation with serum (1:100) from a CF patient colonised by non-mucoid
P. aeruginosa. Track 1, serotype 0:1 (S- LPS); Track 2, serotype 0:3 (S-LPS); Track 3, serotype
0:6 (S-LPS); Track 4, serotype 0:8 (S-LPS); Track 5, serotype 0:11; Track 6, PAC605 (R-LPS);
Track 7, PAC608 (R-LPS) and Track 8, JN62 (CF patient's non-mucoid strain).
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Serum taken from a young (1 year old) CF patient three months after the first
isolation of P. aeruginosa from respiratory secretions, was examined for anti-
P. aeruginosa IgG antibodies by immunoblotting. The LPS profiles of six
P. aeruginosa strains including the patient's non-mucoid isolate JN61 (serotype
0:6) and the immunoblot profiles with the patient's serum are shown in Figure
13a & b. Serum IgG antibodies directed towards the ladder-like bands of high
molecular weight O-antigen LPS of the patient's own strain (Track 1) were
observed. A reaction with the LPS of the standard serotype 0:6 strain was also
noted (Track 5) including a faint reactive band corresponding to core LPS.
Sputum and serum from a CF patient colonised with non-mucoid P. aeruginosa
were analysed by immunoblotting for anti-F. aeruginosa LPS IgA and IgG
antibodies respectively (Figure 14). Sputum IgA antibodies which reacted with
the high molecular weight O-antigen LPS of the patient's strain JN8 (serotype
0:6, Track 3) and of serotype 0:6 (Track 2) were observed. In addition, a
lighter staining region corresponding to IgA antibodies directed towards the
faster migrating core LPS of a number of the strains was observed. Serum IgG
antibodies reacted with the ladder-like O-antigen LPS of the patient's strain
and standard serotype strains 0:6 and 0:11, Tracks 3, 2 and 5 respectively.
A very faint reactive band corresponding to the common core LPS of three
strains in Tracks 3, 5 and 7 was also observed.
The serum IgG and sputum IgA antibody responses to P. aeruginosa LPS of
patients colonised with mucoid P. aeruginosa were also examined by
immunoblotting. The silver stained LPS profiles of eight P. aeruginosa strains
are shown in Figure 15 and include a mucoid, non-typable isolate from a CF
patient (25 years old). The photographs in Figure 16 show the corresponding
immunoblots of the LPS profiles, probed with serum and sputum from the
patient. IgG and IgA antibodies, in serum and sputum respectively, directed
towards the high molecular weight LPS of some of the strains were found. In
addition, strong IgG and IgA antibody responses to the faster migrating
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Figure 13. a) Silver stained LPS profiles of proteinase K whole cell digests of 6 P. aeruginosa
strains separated by SDS-PAGE (14% w/v acrylamide). b) Immunoblot of anti-P. aeruginosa
LPS IgG antibodies following transfer of LPS to NIC paper and incubation with serum (1:100)
from a CF patient intermittently colonised by non-mucoid P. aeruginosa. Track 1, JN61 (CF
patient's non-mucoid strain, serotype 0:6); Track 2, PAC608 (R-LPS); Track 3, PAC605 (R-
LPS); Track 4, serotype 0:11 (S-LPS); Track 5, serotype 0:6 (S-LPS) and Track 6, serotype 0:1
(S-LPS).
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Figure 14. Immunoblots of proteinase K whole cell digests of 7 P. aeruginosa strains separated
by SDS-PAGE (14% w/v acrylamide) followed by transfer to NIC paper and probed with
sputum (1:50) and serum (1:200) from a CF patient colonised with non-mucoid P. aeruginosa.
Blots were analysed for a) sputum IgA and b) serum IgG anti-LPS antibodies. Track 1, serotype
0:1 (S-LPS); Track 2, serotype 0:6 (S-LPS); Track 3, JN8 (CF patient's non-mucoid strain,
serotype 0:6); Track 4; serotype 0:8 (S-LPS); Track 5, serotype 0:11 (S-LPS); Track 6, PAC605
(R-LPS) and Track 7, PAC608 (R-LPS).
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Figure 15. Silver stained LPS profiles of proteinase K whole cell digests of 8 P. aeruginosa
strains separated by SDS-PAGE (14% w/v acrylamide). Track 1, JN36 (CF patient's mucoid
strain, NT); Track 2, serotype 0:1 (S-LPS); Track 3, serotype 0:3 (S-LPS); Track 4, serotype 0:6
(S-LPS); Track 5, serotype 0:8 (S-LPS); Track 6, serotype 0:11 (S-LPS); Track 7, PAC605 (R-
LPS) and Track 8, PAC608 (R-LPS).
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Figure 16. Immunoblots of proteinase K whole cell digests of 8 P. aeruginosa strains separated
by SDS-PAGE (14% w/v acrylamide) followed by transfer to NIC paper and probed with
sputum (1:100) and serum (1:200) from a CF patient colonised with mucoid P. aeruginosa. Blots
were analysed for a) sputum IgA and b) serum IgG anti-LPS antibodies. Track 1, serotype 0:1
(S-LPS); Track 2, serotype 0:3 (S- LPS); Track 3, serotype 0:6 (S-LPS); Track 4, serotype 0:8
(S-LPS); Track 5, serotype 0:11 (S-LPS); Track 6, PAC605 (R-LPS); Track 7, PAC608 (R-LPS)
and Track 8, JN36 (CF patient's mucoid strain NT).
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common core LPS of most of the strains were observed. A blot probed with
sputum and analysed for IgG antibodies showed an absence of any reactive
bands confirming previous results obtained by ELISA (data not shown).
Immunoassay of serum from another CF patient with chronic P. aeruginosa
infection is shown in Figure 17. The silver stained LPS profiles of proteinase K
digests of ten P. aeruginosa strains, including the patient's own non-mucoid
and mucoid strains (Figure 17a), and the immunoblot analysis with the
patient's serum (Figure 17b) are shown. The LPS extracts of the patient's
P. aeruginosa isolates (Tracks 1 and 2) clearly showed the absence of any of the
high molecular weight, ladder-patterned O-antigen LPS characteristic of
serotypable, smooth P. aeruginosa strains eg serotype 0:11 (Track 4), ie the
LPS profiles resembled that of PAC605 (Track 3) displaying only the common
core R-LPS. In the immunoblot, a band was obtained against the low
molecular weight common core LPS of all the P. aeruginosa strains analysed.
Light bands were also observed with a number of the higher molecular weight
O-antigen subunits of some of the S-LPS serotype P. aeruginosa strains. In
addition, an immunoblot analysed for sputum anti-P. aeruginosa LPS IgA
antibodies (Figure 18) also showed a reactive band against the common core
LPS.
1.6 ABSORPTION OF SERA WITH P. AERUGINOSA WHOLE CELLS
The presence of a substantial anti-core LPS antibody component in sera from
CF patients chronically colonised by P. aeruginosa, shown in the ELISA and
immunoblotting studies, was confirmed by absorption experiments (Figure 19).
Serum IgG anti-P. aeruginosa LPS antibodies in CF patients chronically
colonised with P. aeruginosa were measured by ELISA before and after a
series of absorptions with P. aeruginosa whole cells. The reduction in the
measurable serum IgG anti- P. aeruginosa LPS antibody response after
previously absorbing serum with PAC605 (short, incomplete core R-LPS) and
PAC608 (complete core R-LPS) indicated the substantial anti-core LPS
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Figure 17. a) Silver stained LPS profiles of proteinase K whole cell digests of 10 P. aeruginosa
strains separated by SDS-PAGE (14% w/v acrylamide). b) Immunoblot of anti-P. aeruginosa
LPS IgG antibodies following transfer of LPS to NIC paper and probed with serum (1:200) from
a CF patient chronically colonised with P. aeruginosa. Track 1, JN50 (CF patient's mucoid
strain, NT); Track 2, JN49 (CF patient's non-mucoid strain, NT); Track 3, PAC605 (R-LPS);
Track 4, serotype 0:11 (S-LPS); Track 5, serotype 0:10 (S-LPS); Track 6, serotype 0:9, (S-LPS);
Track 7, serotype 0:8 (S-LPS); Track 8, serotype 0:3 (S-LPS); Track 9, serotype 0:1 (S-LPS)
and Track 10, serotype 0:6 (S-LPS).
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Figure 18. Immunoblot of proteinase K whole cell digests of 7 P. aeruginosa strains separated by
SDS-PAGE (14% w/v acrylamide) followed by transfer to NIC paper and probed with sputum
from a CF patient chronically colonised with P. aeruginosa The blot was analysed for IgA anti-
LPS antibodies. Track 1, JN50 (CF patient's mucoid strain, NT); Track 2, JN49 (CF patient's
non-mucoid strain, NT); Track 3, PAC605 (R-LPS); Track 4, serotype 0:1 (S-LPS); Track 5,
serotype 0:4 (S-LPS); Track 6, serotype 0:6 (S-LPS) and Track 7, serotype 0:11 (S-LPS).
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antibody component in sera from CF patients chronically colonised by the
organism.
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Figure 19. Serum IgG anti-P. aeruginosa LPS antibodies in CF patients chronically colonised
with P. aeruginosa measured by ELISA with (a) R-LPS from PAC605 and (b) S-LPS mixture
(PEV-02) as coating antigens before and after a series of absorptions with different strains of P.
aeruginosa whole washed cells. Unabsorbed sera; type-1, sera absorbed with PAC605; type-2,
sera absorbed with PAC605, and then with PAC608; type-3, sera absorbed with PAC605,
PAC608, and then a pooled mixture of P. aeruginosa serotypes 0:1-0:16. OD readings
represent the average from 6 individual sera.
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CHAPTER 2
DETECTION OF ANTIBODIES TO P. AERUGINOSA FLAGELLA
2.1 CHARACTERISATION OF ISOLATED FLAGELLA
Flagellar antigens were prepared from three non-mucoid P. aeruginosa strains,
J1385, JN61 and JN62 isolated from individual patients with CF. In addition,
flagellar antigens were prepared from P. aeruginosa PAOl. The flagellar
filaments were visualised by electron microscopy after staining with the
negative stain phosphotungstic acid (Figure 20) and after shadowing with
platinum (Figure 21).
Flagella were characterised by molecular weight determination in SDS-PAGE
and by immunoblot analysis with anti-flagellar type-a and -b antisera. Flagella
isolated from PAOl, classified as flagella type-b (Allison et al, 1985) were used
as a standard. Molecular weights of flagella separated by SDS-PAGE (Figure
22) were estimated from a calibration curve of log molecular weight of protein
standards against Rf, where Rf is the distance moved by a standard protein
through the separating gel divided by the distance moved by bromophenol blue
marker. Flagella from strain J1385 (Track 2) appeared to have a similar
mobility in SDS-PAGE as flagella from PAOl (Track 1) and had a calculated
Mr of 53,000 characteristic of type-b flagella. The flagella from strains JN61
(Track 3) and JN62 (Track 4) migrated further than PAOl flagella, with
calculated Mrs of 45,000 and 47,000 respectively, and were preliminary
designated as type-a flagella. The presence of a band of low molecular weight
protein in the gel profile of flagella from JN61 (Track 3) was noted.
Immunoblot analysis of flagella with anti-flagellar type-a and -b antisera
(Figure 23a & b) confirmed the results of SDS-PAGE. The antiserum against
type-a flagella reacted strongly with flagella from JN61 (Track 3) and JN62
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Figure 20. Electron micrographs of flagellar antigen preparations from P. aeruginosa strains
JN61 (flagellar type-a), (Figure a) and PAOl (flagellar type-b), (Figure b) stained with 2% w/v
phosphotungstic acid. Magnification x 15,000 (Figure a) and x 10,000 (Figure b).
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Figure 21. Electron micrographs of flagellar antigen preparations from P. aeruginosa strains
JN62 (flagellar type-a), (Figure a) and J1385 (flagellar type-b), (Figure b) shadowed with
platinum Magnification x 15,000 (Figure a) and x 12,000 (Figure b).
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Figure 22. SDS-PAGE of flagella preparations from P. aeruginosa strains PAOl (Track 1),
J1385 (Track 2), JN61 (Track 3) and JN62 (Track 4). Flagella were separated using 12% w/v
acrylamide gels and visualised with Coomassie blue stain. Molecular weights of protein
standards are indicated.
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(Track 4) with barely any detectable reaction with flagella from PAOl (Track
1) and J1385 (Track 2). Flagellar type-b antisera produced strong bands with
flagella from PAOl (Track 1) and J1385 (Track 2) and weaker bands with
flagella from JN61 and JN62 (Tracks 3 and 4).
22 SERUM ANTI-FLAGELLAR ANTIBODIES DETECTED BY ELISA
Anti-flagellar IgG antibodies were detected by ELISA in sera from patients
with CF and in sera from healthy controls (Figure 24). Elevated levels of anti-
flagellar IgG antibodies above the control range were found in CF patients
intermittently or chronically colonised with P. aeruginosa. However, a number
of CF patients classified as non-P. aeruginosa colonised on the basis of sputum
bacteriology also showed increased levels of serum anti-flagellar IgG antibodies.
For many of the CF patients a similar IgG antibody response to both type-a and
-b flagella was observed. A pronounced antibody response to either type-a or -b
flagella was also observed for some CF patients.
Statistical analysis of the results by the Student t test revealed: i) the difference
in absorbance readings between chronically colonised patients and both non-
P. aeruginosa colonised CF patients and healthy controls was very highly
significant (P< 0.001) for type-a and -b flagella; ii) the difference in OD
readings between intermittently colonised CF patients and healthy controls was
very highly significant (P< 0.001) for type-a flagella and highly significant
(P<0.01) for type-b flagella; iii) the difference between intermittently and non-
P. aeruginosa colonised patients was highly significant (P<0.01) for type-a
flagella and significant for type-b flagella; iv) differences between intermittently
and chronically colonised patients, and between non-colonised CF patients and
controls were not significant.
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Figure 23. Immunoblots of flagellar antigens separated by SDS-PAGE followed by
electrophoretic transfer to NIC paper and probed with anti-flagellar type-a antisera (a) and anti-
flagellar type-b antisera (b): flagellar antigens from PAOl (Track 1); J1385 (Track 2), JN61
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Figure 24. Serum IgG anti-flagellar antibodies 48 CF patients and 10 non-CF individuals
measured by ELISA. A total of 23 CF patients chronically colonised with P. aeruginosa, 5
intermittently colonised, 20 non-colonised CF patients and 10 healthy adults are included.
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2.3 SPUTUM AND SALIVA ANTI-FLAGELLAR ANTIBODIES
DETECTED BY ELISA
Anti-flagellar IgA antibodies were also detected by ELISA in sputum (Figure
25) and saliva (Figure 26) from a number of patients with CF who were
chronically or intermittently colonised with P. aeruginosa. A range of anti-
flagellar IgA antibodies in these two groups of patients were detected; a net
absorbance value >0.1 was classed as positive for anti-flagellar antibody. In
some patients a similar IgA response to both flagellar types was noted whilst in
other patients a preponderence of IgA antibodies to either type-a or -b flagella
was observed. Significant anti-flagellar IgA antibodies were not observed in
saliva or sputum from CF patients with no previous history of P. aeruginosa
colonisation. However, there was one exception in the case of an individual
who demonstrated sputum IgA antibodies directed towards type-b flagella (OD
= 0.840).
Statistical analysis (Student t test) of the ELISA results for sputum and saliva
anti-flagella IgA antibodies showed: i) the difference between chronically
colonised patients and non-P. aeruginosa colonised patients for sputum anti-flagellar
IgA antibodies was very highly significant (P< 0.001) for type-a and -b flagellar
antigens; in the case of saliva the difference was significant (P<0.05); ii) the
difference between intermittently colonised and non-P. aeruginosa colonised
patients for sputum anti-flagellar type-a and -b IgA antibodies was highly
significant (P<0.01); the difference, for the saliva results was not
significant; iii) the difference between intermittently colonised and chronically
colonised patients for sputum and saliva anti-flagella IgA antibodies was not
significant.
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Figure 25. Sputum IgA anti-F. aeruginosa flagellar antibodies in 39 CF patients measured by
ELISA. A total of 18 CF patients chronically colonised with P. aeruginosa, 7 intermittently
colonised, and 14 non-colonised CF patients are included.
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Figure 26. Saliva IgA anti-F. aeruginosa flagellar antibodies in 27 CF patients measured by
ELISA. A total of 10 CF patients chronically colonised with P. aeruginosa, 5 intermittently
colonised and 12 non-colonised CF patients are included.
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2.4 IMMUNOBLOT ANALYSIS OF SERA, SALIVA AND SPUTUM
AGAINST FLAGELLAR ANTIGENS
Immunoblot analysis of sera, saliva and sputa from patients with CF against
P. aeruginosa flagellar antigen types-a and -b was performed (Figures 27 & 28).
The immunoblot studies reflected the results obtained in ELISA. Positive blots,
with a response to either one or both P. aeruginosa flagellar types, were
obtained with sera, saliva or sputa which had conspicuously elevated anti-
flagellar IgG/IgA antibodies in ELISA studies. Immunoblot profiles positive
for serum IgG anti-flagellar type-a and/or -b antibodies are shown in Figure
27. Positive blots from:- i) healthy control (Strip 1); ii) two non-P. aeruginosa
colonised patients (Strips 2 and 3); iii) five CF patients intermittently or
consistently colonised with non-mucoid P. aeruginosa (Strips 4-8) and iv) four
CF patients chronically colonised with P. aeruginosa (Strips 9-12) are
displayed.
Similarly immunoblot profiles positive for saliva or sputum IgA anti-flagellar
antibodies are shown in Figure 28. A weak, detectable anti-flagellar (type-b)
IgA antibody response in a non-P. aeruginosa colonised patient is shown in
Strip 1; the antibody response to flagellar antigens, in saliva or sputum from
patients intermittently or consistently colonised by non-mucoid P. aeruginosa
(Strips 2-5) and patients chronically colonised by mucoid P. aeruginosa (Strips
6-8) are also displayed.
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Figure 27. Strip immunoblots of isolated P. aeruginosa flagella (type-a and/or type-b) reacted
with serum from patients with CF and analysed for the presence of anti-flagellar IgG antibodies.
Strip 1, healthy control; Strip 2, CF non-col.; Strip 3, CF non-col.; Strip 4, CF col.; Strip 5, CF
col.; Strip 6, CF int. col.; Strip 7, CF int. col.; Strip 8, CF int. col.; Strip 9, chron. col.; Strip 10,
chron. col.; Strip 11, chron. col.; Strip 12, chron. col.
(CF non-col. = CF patient non-/5. aeruginosa colonised;
CF col. = CF patient colonised with non-mucoid P. aeruginosa^
CF int. col. = CF patient intermittently colonised with non-mucoid P. aeruginosa^
CF chron. col. = CF patient chronically colonised with mucoid P. aeruginosa).
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Figure 28. Strip immunoblots of isolated P. aeruginosa flagella (type-a and/or type-b) reacted
with saliva or sputum from patients with CF and analysed for the presence of anti-flagella IgA
antibodies. Strip 1, CF non-col. (Sputum); Strip 2, CF int. col. (Sputum); Strip 3, CF int. col.
(Saliva); Strip 4, CF int. col. (Sputum); Strip 5, CF int. col. (Sputum); Strip 6, chron. col.
(Sputum); Strip 7, chron. col. (Sputum); Strip 8, chron. col. (Saliva).
(CF non-col. = CF patient non- P. aeruginosa colonised;
CF int. col. = CF patient intermittently colonised with non-mucoid P. aeruginosa,
CF chron. col. = CF patient chronically colonised with mucoid P. aeruginosa).
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CHAPTER 3
PRODUCTION AND CHARACTERISATION OF
ANTI-P. AERUGINOSA LPS MONOCLONAL ANTIBODIES
The initial aim of this work was to produce Mabs against P.aeruginosa LPS
antigen, with the antibodies able to recognise all O-antigenic serotypes of
P. aeruginosa. The ultimate aim was to use the Mabs in a capture ELISA
system for the detection of P. aeruginosa LPS in CF respiratory secretions (eg
saliva or sputum) as a means of facilitating early identification of respiratory
colonisation by non-mucoid P. aeruginosa.
3.1 VACCINATION OF MICE AND SCREENING OF TAIL BLEEDS
Five female BALB/c mice were inoculated with heat-killed whole cell
preparations of P. aeruginosa strains PAC608 and PAC605. These LPS
defective mutants, unable to produce serologically distinct O-antigenic side
chains, express only core LPS (Figure 29) common to all P. aeruginosa
serotypes. Mice were vaccinated (as described in Materials and Methods), and
blood samples taken for subsequent screening of serum anti-LPS antibodies in
ELISA. The serum anti-P. aeruginosa LPS antibody response in one mouse
(codename Angel), 38 days after initial vaccination, is shown in Figure 30.
Serum was screened against: i) core R-LPS extracted from six LPS defective
P. aeruginosa mutants (see Figure 29 for LPS profiles). PAC605 represents the
shortest core expressed by the mutants whilst PAC557 represents the most
complete core, the other four PAC mutants having core structures of
intermediate size (Rowe & Meadow, 1983); ii) O-antigenic S-LPS from three
serotype strains of P. aeruginosa (0:1, 0:2 and 0:11). A positive antibody
response (ELISA OD>0.1) against all the P. aeruginosa LPS antigens used in
the screen was noted. Particularly strong antibody responses to the core R-LPS
of PAC611, PAC556 and PAC609 were observed. Elevated antibody levels
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Figure 29. Silver-stained SDS-polyacrylamide gel (14%) of LPS extracted from 6 LPS defective
mutants of P. aeruginosa, The profiles of PAC557, PAC608, PAC605, PAC611, PAC556 and
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Figure 30. Serum anti-P. aeruginosa LPS antibodies in a female BALB/c mouse immunised with
heat-killed cells of P. aeruginosa strains PAC608 and PAC605 which express only the core
component of LPS. Antibodies were measured by ELISA with extracted LPS from 6 LPS
defective mutants (PAC) and three LPS O-serotype P. aeruginosa strains.
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directed towards these intermediate core structures were also observed in the
ELISA screening of serum from the other four mice used in the study.
The mouse (Angel), for which data is shown, was used for the production of
Mabs since it produced the strongest, most cross- reactive antibody response to
the different P. aeruginosa LPS antigens.
3.2 PRIMARY AND SECONDARY SCREENING FOR ANTI-
P. AERUGINOSA LPS MONOCLONAL ANTIBODIES
Mabs produced by the hybrids, and their resultant clones, were screened by
ELISA. A primary screen consisting of three different LPS cocktails was used
to gain an initial assessment of the LPS reactivity of antibodies present in hybrid
and clone growth supernatants. Cocktail-A consisted of O-antigenic S-LPS
from three serotype strains of P. aeruginosa (0:1, 0:2 and 0:11); cocktail-B
consisted of core R-LPS from the six LPS defective mutants PAC605, PAC611,
PAC556, PAC609, PAC608 and PAC557; cocktail-C (negative control)
consisted of LPS from S. typhimurium 1542 and E. coli Rl. Clones producing a
strong antibody response (ELISA OD>1.0) directed to one or both of the
P. aeruginosa LPS cocktails were selected and the antibodies subsequently
tested in a secondary ELISA screen consisting of the individual LPS antigens
which made up the LPS cocktails of the primary screen. The nature and extent
of the reactivity of antibodies with the different LPS antigens was assessed.
Results of some of the secondary screens are included in Figures 36-40 (see
below).
3.3 SCREENING OF CROSS-REACTIVE ANTI-P. AERUGINOSA LPS
MONOCLONAL ANTIBODIES
Based on results from the secondary ELISA screens, antibodies which cross
reacted (ELISA OD>0.1) with all or at least seven out of the nine P. aeruginosa
LPS antigens were selected for further study. Five Mabs were selected: Mabs
304.1.4, 360.7. 61.3.2, 73.5 and 334.4. These antibodies were subsequently
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screened and characterised in ELISA against a comprehensive range of
antigens, the results of which are shown in Figures 31-45.
The ELISA antigens used in the screens included: i) P. aeruginosa LPS
antigens (incorporating those used in the secondary screens) including S-LPS
from standard serotype strains; R-LPS from the PAC mutants and LPS from
two non-mucoid P. aeruginosa strains isolated from patients with
CF; ii) P. aeruginosa whole cell antigens including standard serotype strains
0:1-0:16; core, LPS defective (PAC) mutants; and non-mucoid strains isolated
from patients with CF; iii) PVA 0:1-0:16; iv) whole cell antigens from other
Pseudomonas spp as well as whole cells from other Gram-negative bacteria
including H. influenzae, H. parainfluenzae, E. coli, K. aerogenes and Pr.
mirabilis.
a) P. aeruginosa whole cell antigen ELISA screens
The five Mabs produced a positive response against all the P. aeruginosa whole
cell antigens used in the screens (Figures 31-35). A strong reaction
(ELISA OD>1.0) against most of the whole cell antigens was particularly
evident for Mabs 304.1.4 and 360.7 (Figures 31 and 32). All five Mabs tended
to produce a lower response with whole cells from serotypes 0:1 and 0:4. This
may either reflect the nature of the antibody binding site, or the coating of
these whole cell antigens to the wells of the ELISA microtitre plate.
b) P. aeruginosa LPS and vaccine antigen ELISA screens
Confirmation of the cross-reactive nature of the five Mabs with all serotypes of
P. aeruginosa was provided by the positive response of each Mab to the cell
wall extracts of the vaccine antigens (PVA), serotypes 0:1-0:16 (Figures 36-
40). The strongest reactions were again observed for Mabs 304.1.4 and 360.7
(Figures 36 and 37).
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Figure 32. Reactivity in ELISA of Mab 360.7 against P. aeruginosa whole cell antigens.
153
WHOLE CELL ANTIGENS Mab 61-3-2
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Figure 33. Reactivity in ELISA of Mab 61.3.2 against P. aeruginosa whole cell antigens.
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WHOLE CELL ANTIGENS Mab 73-5
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Figure 35. Reactivity in ELISA of Mab 334.4 against P. aeruginosa whole cell antigens.
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The Mabs also reacted with each of the extracted P. aeruginosa LPS antigens:
Mabs 304.1.4 and 360.7 generally showed the strongest reactions for each of
the LPS antigens. Compared to the responses of the Mabs with whole cell and
vaccine antigens, the absorbance readings obtained for the different LPS
antigens tended to show greater variation. This was particularly apparent for
Mabs 61.3.2, 73.5 and 334.4 (Figures 38-40). The response of the five Mabs to
core R-LPS from the PAC mutants tended to be lower towards the shortest core
structure, PAC605, and the complete core structure, PAC557, ie for each
individual Mab, OD values were generally higher against the intermediate core
structures (PAC611, PAC556, and PAC609). Unlike the reduced Mab
responses to whole cells from P. aeruginosa serotype 0:1, the responses to
extracted LPS from serotype 0:1 were generally higher and comparable to the
reactions observed with the other LPS serotypes. The antibodies did not react
with the enterobacterial LPS antigens from E. coli R1 and S. typhimurium
1542. The latter were chosen since potential reaction of the Mabs with
enterobacterial LPS was most likely to be detected with these LPS antigens (Dr
G.R. Barclay pers. comm.).
3.4 PSEUDOMONAS SPECIES AND OTHER GRAM-NEGATIVE WHOLE
CELL ELISA SCREENS
The Mabs also showed reactions with whole cells from other Pseudomonas spp
(Figures 41-45). All five Mabs reacted with the whole cells of P. mendocina,
P. fluorescens, P. pseudoalkaligenes, P. putida and P. stutzeri; all the Mabs
except 61.3.2 produced a positive reaction with P. acidovorans whilst only Mab
73.5 produced a detectable reaction with P. testosteroni.
The Mabs were also screened against the whole cells of ten individual strains of
P. cepacia and seven strains of P. maltophilia; these two Pseudomonas species
are the most common pseudomonads, after P. aeruginosa, to be isolated from
the respiratory secretions of patients with CF. Mab 304.1.4 (Figure 41) failed to
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Figure 36. Reactivity in ELISA of Mab 304.1.4 against i) P. aeruginosa S-LPS O-serotype
vaccine components (PVA-1 - PVA-16); ii) extracted LPS antigens (LPS complexed with
polymyxin) including S-LPS (0:1-0:11) and R-LPS (PAC605-PAC557); iii) LPS from two
P. aeruginosa strains (JN61 and JN62) from patients with CF, and iv) LPS from two
Enterobacteriaceae (negative controls).
158












































Net OD (590 nm)
Figure 37. Reactivity in ELISA of Mab 360.7 against i) P. aeruginosa S-LPS O-serotype vaccine
components (PVA-l - PVA-16); ii) extracted LPS antigens (LPS complexed with polymyxin)
including S-LPS (0:1-0:11) and R-LPS (PAC605-PAC557); iii) LPS from two P. aeruginosa
strains (JN61 and JN62) from patients with CF, and iv) LPS from two Enterobacteriaceae
(negative controls).
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Figure 38. Reactivity in ELISA of Mab 61.3.2 against i) P. aeruginosa S-LPS O-serotype vaccine
components (PVA-1 - PVA-16); ii) extracted LPS antigens (LPS complexed with polymyxin)
including S-LPS (0:1-0:11) and R-LPS (PAC605-PAC557), iii) LPS from two P. aeruginosa
strains (JN61 and JN62) from patients with CF, and iv) LPS from two Enterobacteriaceae
(negative controls).
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Figure 39. Reactivity in ELISA of Mab 73.5 against i) P. aeruginosa S-LPS O-serotype vaccine
components (PVA-l - PVA-16), ii) extracted LPS antigens (LPS complexed with polymyxin)
including S-LPS (0:1-0:11) and R-LPS (PAC605-PAC557); iii) LPS from two P. aeruginosa
strains (JN61 and JN62) isolated from patients with CF, and iv) LPS from two
Enterobacteriaceae (negative controls).
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Figure 40. Reactivity in ELISA of Mab 334.4 against i) P. aeruginosa S-LPS O-serotype vaccine
components (PVA1 - PVA16); ii) extracted LPS antigens (LPS complexed with polymyxin)
including S-LPS (0:1-0:11) and R-LPS (PAC605-PAC557); iii) LPS from two P. aeruginosa
strains (JN61 and JN62) isolated from patients with CF, and iv) LPS from two
Enterobacteriaceae (negative controls).
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whilst Mabs 73.5 (Figure 44) and 334.4 (Figure 45) produced a weak reaction
with one of the P. maltophilia strains (different in each case). Mabs 360.7
(Figure 42) and 61.3.2 (Figure 43) also failed to produce a positive reaction
with any of the P. cepacia strains. However, these Mabs reacted weakly with
some of the P. maltophilia strains; Mab 360.7 produced weak (all ODs <0.25)
reactions with P. maltophilia strains J115, J118, J122 and J135, whilst Mab
61.3.2 reacted weakly (all ODs <0.30) with five out of the seven P. maltophilia
strains.
In most cases the five Mabs failed to react with whole cells of H. influenzae
and H. parainfluenzae (Figures 41-45). Only Mabs 360.7 and 61.3.2 produced
detectable reaction with any of these organisms; both reacted very weakly
(ELISA OD <0.08) with one of the H. influenzae strains and the
H. parainfluenzae strain. None of the Mabs reacted with the whole cells of
E. coli, K. aerogenes, and Pr. mirabilis.
3.5 IMMUNOBLOT ANALYSIS OF MONOCLONAL ANTIBODIES
AGAINST LPS
The ELISA studies showed that the Mabs were able to react with all the
serotypes of P. aeruginosa as well as with LPS deficient mutants expressing
only core R-LPS. Since the Mabs were originally produced from spleen cells
derived from a mouse vaccinated with heat killed cells from core R-LPS
mutants, these results would indicate that the Mabs recognise the common core
component of P. aeruginosa LPS. In order to confirm and further investigate
the LPS binding site of each of the Mabs, immunoblot assays against LPS from
proteinase K digests of P. aeruginosa cells were performed. The immunoblots
of the five Mabs against S-LPS of P. aeruginosa serotype strains, and core R-
LPS of P. aeruginosa LPS defective mutants, are shown in Figures 46-48.
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Figure 41. Reactivity in ELISA of Mab 304.1.4 against whole cell antigens.
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Figure 43. Reactivity in ELISA of Mab 61.3.2 against whole cell antigens.
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Figure 45. Reactivity in ELISA of Mab 334.4 against whole cell antigens.
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The immunoblots of Mabs 304.1.4 and 360.7 are shown in Figure 46. A positive
reactive band corresponding to the low molecular weight core LPS of each of
the P. aeruginosa LPS preparations analysed was observed. The weakest
responses were against the core LPS regions of serotypes 0:9 (Track 9) and
0:11 (Track 11) and with R-LPS core of PAC605 (Track 16). The apparent
absence of bands corresponding to high molecular weight LPS of serotype
strains indicated that the Mabs were unable to recognise core LPS substituted
with O-antigenic side chains. However, a very faint ladder pattern
corresponding to the high molecular weight O-antigenic LPS of serotype 0:6
(Track 6) was observed in both cases, especially in the case of Mab 360.7.
The immunoblots obtained with Mabs 61.3.2, 73.5 and 334.4 (Figures 47
and 48) were all very much weaker than the immunoblots obtained for Mabs
304.1.4 and 360.7 (Figure 46). Indeed, immunoblots with the former antibodies
were only obtained using the Mab concentrates prepared as described in the
Materials and Methods. The concentrates were twenty-fold concentrations of
Mab containing supernatants.
Mab 61.3.2 reacted weakly with most of the unsubstituted core regions of the
different LPS preparations (Figure 47). The strongest reactions were generally
those observed against the core regions of the R-LPS mutants PAC609,
PAC556, PAC557 and PAC608 (Tracks 17-20 respectively). However, a
reaction was not obtained against the two roughest PAC mutants, P. aeruginosa
strains PAC605 and PAC611 (Tracks 15 and 16). In the ELISA studies Mab
61.3.2 reacted with whole cell and LPS antigens of all the PAC mutants,
although only weakly with PAC605 LPS. Similarly, in the immunoblot obtained
with Mab 73.5 (Figure 47) a reaction with most of the core components of the
different LPS preparations was observed. However, as with Mab 61.3.2, a
reaction with PAC605 or PAC611 (Tracks 15 and 16) was not detected.
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Figure 46. Immunoblot of proteinase K whole cell digests of 20 P. aeruginosa strains separated
by SDS-PAGE (14% w/v acrylamide) followed by transfer to NIC paper and probed with Mabs
a) 304.1.4 and b) 360.7 (supernatant 1:5). The immunoblot profiles against P. aeruginosa
serotype strains 0:1, 0:2, 0:3, 0:4, 0:5, 0:6, 0:7, 0:8, 0:9, 0:10, 0:11, 0:12, 0:13, 0:15 and
P. aeruginosa LPS defective mutants PAC611, PAC605, PAC556, PAC609, PAC557 and PAC608
are shown in Tracks 1-20 respectively.
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Figure 47. Immunoblots of proteinase K whole cell digests of 20 P. aeruginosa strains separated
by SDS-PAGE (14% w/v acrylamide) followed by transfer to NIC paper and probed with Mabs
a) 61.3.2 and b) 73.5 (concentrate 1:5). The immunoblot profiles against P. aeruginosa
serotype strains 0:1, 0:2, 0:3, 0:4, 0:5, 0:6, 0:7, 0:8, 0:9, 0:10, 0:11, 0:12, 0.13, 0:15 and
P. aeruginosa LPS defective mutants PAC611, PAC605, PAC556, PAC609, PAC557, and
PAC608 are shown in Tracks 1-20 respectively.
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Figure 48. Immunoblot of proteinase K whole cell digests of 20 P. aeruginosa strains separated
by SDS-PAGE (14% w/v acrylamide) followed by transfer to NIC paper and probed with Mab
334.4 (concentrate 1:5). The immunoblot profiles against P. aeruginosa serotype strains 0:1,
0:2, 0:3, 0:4, 0:5, 0:6, 0:7, 0:8, 0:9, 0:10, 0:11, 0:12, 0:13, 0:15 and P. aeruginosa LPS
defective mutants PAC611, PAC605, PAC556, PAC609, PAC557 and PAC608 are shown in
Tracks 1-20 respectively.
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The immunoblot obtained for Mab 334.4 (Figure 48) showed weak reactions
with the unsubstituted core LPS of all serotype strains of P. aeruginosa (Tracks
1-14). However, reactions were observed with only three out of the six core R-
LPS mutants, not being detected against PAC605, PAC611 and PAC609
(Tracks 15, 16 and 18 respectively). Except for the weak reaction of Mab 334.4
with PAC605 LPS, these immunoblot profiles were not reflected by the
corresponding ELISA results.
Immunoblotting was also performed with Mabs 304.1.4 and 360.7 against LPS
(prepared by proteinase K digestion of whole cells) from non-mucoid and
mucoid P. aeruginosa strains isolated from patients with CF. The silver stained
LPS profiles of each strain are shown in Figure 49. The two Mabs gave a
strong positive band corresponding to the low molecular, unsubstituted core
region of each LPS preparation (Figure 50a & b). The reaction of Mab 360.7
was particularly strong. In addition Mab 360.7 reacted very weakly with the
high molecular weight LPS bands (ie core substituted with O-antigen LPS) of
non-mucoid strain JN61 (serotype 0:6) in Track 2 and mucoid strain JN10
(non-typable) in Track 8. These bands are not evident in the photograph.
3.6 TYPING AND ANALYSIS OF MONOCLONAL ANTIBODY
PREPARATIONS
The Mabs were typed and classified as:
Mab 304.1.4 = IgG2b
Mab 360.7 = IgG2b
Mab 61.3.2 = IgG3
Mab 73.5 = IgGl
Mab 334.4 = IgG3.
Mabs in bulk growth supernatants were concentrated twenty-fold and partially
purified using a tangential-flow filtration system. The presence of antibody in
the retentate and absence in the filtrate was checked by ELISA. The
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Figure 49. Silver-stained SDS-polyacrylamide gel of proteinase K- digested whole cell lysates
from P. aeruginosa isolates from CF lung infection. The profiles of P. aeruginosa strains JN62
(non-mucoid, serotype 0:1); JN61 (non-mucoid, serotype 0:6); JN8 (non-mucoid, serotype
0:6), JN28 (non-mucoid, NT); JN45 (non-mucoid, NT); JN9 (non-mucoid, NT); JN49 (non-





Figure 50. Immunoblots of proteinase K whole cell digests of 10 P. aeruginosa strains (isolated
from patients with CF) separated by SDS- PAGE (14% w/v acrylamide) followed by transfer to
NIC paper and probed with Mabs a) 304.1.4 and b) 360.7 (supernatants 1:5). The immunoblot
profiles against P. aeruginosa strains JN62 (non-mucoid, serotype 0:1); JN61 (non-mucoid,
serotype 0:6); JN8 (non-mucoid, serotype 0:6); JN28 (non-mucoid, NT); JN45 (non-mucoid,
NT) JN9 (non-mucoid, NT); JN49 (non-mucoid, NT); JN50 (mucoid, NT); JN10 (mucoid, NT)
and JN56 (mucoid, NT) are shown in Tracks 1-10 respectively.
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immunoglobulins in each concentrate were further purified by ammonium
sulphate precipitation. The final preparations were titred in ELISA in order to
check for the presence of antibody. The Mab preparations before and after
ammonium sulphate precipitation were analysed by agarose gel electrophoresis
and the Coomassie blue stained profiles are shown in Figure 51a. Ammonium
sulphate precipitation of the Mab preparations resulted in a substantial
reduction in a number of contaminating proteins including albumin, alpha-2-
macroglobulin and transferrin. The Mab bands found near the head of each
profile were weak and barely detectable in comparison to bands obtained for












Figure 51. a) Coomassie blue stained profiles of proteins, separated by agarose gel
electrophoresis found in concentrated supernatants containing Mab before and after ammonium
sulphate precipitation. Track 1, 334.4 (after); Track 2, 334.4 (before); Track 3, 73.5 (after);
Track 4, 73.5 (before); Track 5, 61.3.2 (after); Track 6, 61.3.2 (before); Track 7, 360.7 (after);
Track 8, 360.7 (before); Track 9, 304.1.4 (after); Track 10, 304.1.4 (before), b) Coomassie blue
stained profiles of proteins found in human serum.
CHAPTER 4
LABELLING AND APPLICATIONS OF THE MONOCLONAL ANTIBODIES
4.1 BIOTIN LABELLING OF MONOCLONAL ANTIBODIES
In order to determine the degree of biotinylation of the mouse Mabs which
would yield the highest reactivity, various molar ratios of biotin to Mab free
amino groups were reacted. These differentially biotinylated Mabs were tested
in ELISA against individual cocktails of P. aeruginosa R- and S-LPS. In
addition, two enzyme streptavidin conjugate systems were investigated:-
i) streptavidin-alkaline phosphatase and ii) streptavidin-urease. The results of
different biotin: Mab ratios and the two different enzyme conjugates for Mabs
304.1.4 and 360.7 are shown in Figures 52 and 53. All OD readings were
expressed after subtraction of the relevant background control.
Conjugation of Mabs 304.1.4 and 360.7 with 1:1, 2:1 or 4:1 biotin: Mab/amino
acid ratios appeared to produce usable reagents in each case. The 1:1 ratio
gave maximal OD readings for each dilution of Mab. As the dilution of each
biotinylated Mab increased, OD readings for wells coated with R-LPS were
usually higher than those obtained for wells coated with S-LPS. Since the Mabs
recognise unsubstituted core LPS, the increased sensitivity with R-LPS may
simply be due to the presence of more available core LPS compared with S-
LPS. Comparison of the two streptavidin conjugates showed, for a given
dilution of Mab, that OD readings were greater for streptavidin-alkaline
phosphatase (Figure 52) than for streptavidin-urease (Figure 53), ie the former
is more sensitive.
4.2 BIOTIN-STREPTAVIDIN AMPLIFICATION ELISA SYSTEMS
The sensitivity of different conjugate systems for bio-Mabs used against
P. aeruginosa S-LPS and R-LPS were compared. The conjugate systems
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Figure 52. Reactivity in ELISA of Mabs 304.1.4 (a and b) and 360.7 (c and d) coupled with
different ratios of biotin. Reactions against a cocktail of smooth (a and c) and rough (b and d)
P. aeruginosa LPS were measured. Streptavidin-alkaline phosphatase and the corresponding
substrate were used to measure the reaction (OD 405 nm).
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Figure 53. Reactivity in ELISA of Mabs 304.1.4 (a and b) and 360.7 (c and d) coupled with
different ratios of biotin. Reactions against a cocktail of smooth (a and c) and rough (b and d)
P. aeruginosa LPS were measured. Streptavidin-urease and the corresponding substrate were
used to measure the reactions (OD 590 nm).
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included: i) alkaline phosphatase labelled biotin-streptavidin complex (the
amplification system); ii) alkaline phosphatase labelled streptavidin; iii) urease
labelled streptavidin.
The results obtained for bio-Mabs (1:1) 304.1.4 and 360.7 with the different
conjugate systems are shown in Figure 54. The conjugate system employing
alkaline phosphatase labelled biotin- streptavidin complex produced the
highest OD values for each respective dilution of bio-Mab (304.1.4 or 360.7)
against either P. aeruginosa R- and S-LPS. Comparison of the less sensitive
non-amplified systems again showed that the alkaline phosphatase labelled
streptavidin conjugate was more sensitive than urease labelled streptavidin.
Greater sensitivity of the conjugates against P. aeruginosa R-LPS was also
observed. In addition, Mab 360.7 tended to give higher OD readings than Mab
304.1.4.
The sensitivity of the amplification system (alkaline-phosphatase labelled
biotin-streptavidin complex) for P. aeruginosa LPS bound to the solid phase of
polystyrene microtitre plate wells was investigated (Figure 55). Optimal
dilutions of the bio-Mabs (1:1 biotinylation) 304.1.4 and 360.7 were selected
from the titration of the Mabs against P. aeruginosa S- and R-LPS shown in
Figure 54. Bio-Mab 304.1.4 was diluted 1:200 and bio-Mab 360.7 was diluted
1:500. Although these dilutions did not give the maximum possible OD values,
they provided strong OD values (OD >1.0) against P. aeruginosa R- and S-LPS
and helped conserve the amount of bio-Mab used. The bio-Mabs were added
separately to wells coated with a doubling dilution series of R-LPS or S-LPS,
from 0.08-10.0 ng/ml. A reading was considered significant if the OD value
was 3SDs greater than the mean of the background control. The assay system
utilizing bio-Mab 304.1.4 and the alkaline phosphatase labelled biotin-
streptavidin complex was capable of detecting 0.16 ng/ml R-LPS and 0.08
ng/ml S-LPS. The amplification system incorporating bio-Mab 360.7 was able
to detect down to 0.08 ng/ml of R- and S-LPS. In the case of both Mabs, OD
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Figure 54. Comparison of the sensitivity of enzyme immunoassays with bio-Mabs 304.1.4 (a and
b) and 360.7 (c and d) against smooth (a and c) and rough (b and d) P. aeruginosa LPS. The
conjugate systems utilized were as follows:- i) alkaline phosphatase labelled biotin streptavidin
complex (BAPS); ii) alkaline phosphatase labelled streptavidin (SAP) and iii) urease labelled
streptavidin (SUR). The OD values obtained with alkaline phosphatase conjugates were





Figure 55. Sensitivity of ELISA for the measurement of P. aeruginosa R- and S-LPS bound to
the solid phase of microtitre wells. The ELISA system incorporated bio-Mabs a) 304.1.4
(1:200) and b) 360.7 (1:500) and a conjugate system consisting of alkaline phosphatase-labelled
biotin-streptavidin complex.
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readings were greater for the higher concentrations of R-LPS compared to the
same concentrations of S-LPS; however, at the lower concentrations the
situation was reversed.
4.3 MONOCLONAL ANTIBODY COMPETITION ASSAYS
The antigen binding sites of the five core LPS specific Mabs were compared by
adding various combinations of Mabs (one labelled with biotin and one
unlabelled) to wells of microtitre plates coated with core R-LPS. If the labelled
antibody and unlabelled antibody bind to separate and discrete sites on the
core antigen, the labelled antibody will bind at the same level whether or not
the competing antibody is present. However, if the sites of interaction are
identical or overlapping, the unlabelled antibody will compete and the amount
of labelled antibody bound to the antigen will be lowered.
In order to assess the ability of one Mab to compete with another Mab, a
standard curve was established by titrating one Mab against itself, ie the same
antibody was used as both the label and the inhibitor (self-inhibition). The
capacity of the unlabelled inhibitor to inhibit the binding of other bio-Mabs
was also titrated. Doubling dilutions of bio-Mabs were titrated against
doubling dilutions of unlabelled inhibitor: the results for bio-Mabs 304.1.4 and
360.7 diluted 1:80, bio-Mabs 61.3.2 and 73.5 diluted 1:10, and bio-Mab 334.4
diluted 1:40 are shown. The results were plotted as shown in Figures 56-58 and
the concentration of inhibitor required for 50% inhibition of binding of
r>©t
labelled Mabs was compared. A labelled Mab was consideredAto compete with
an unlabelled inhibitor if the dilution of inhibitor, at the 50% inhibition level
was at least one dilution less (ie inhibitor more concentrated) than required for
self-inhibition. Based on this rationale, Mabs 304.1.4, 360.7 and 73.5 appeared
not
unable to compete one against the other ie Mabs 360.7 and 73.5 could ^compete
not
against 304.1.4 (Figure 56); Mabs 304.1.4 and 73.5 couldAcompete against 360.7
(Figure 57) etc. Mab 61.3.2 appeared to follow the binding pattern of Mab
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Figure 56. Mab competition assay measured by ELISA (OD 405 nm) with R-LPS from
P. aeruginosa PAC557 as coating antigen. Doubling dilutions of Mab 304.1.4 (a) and Mab 360.7
(b) inhibitors were run against biotin labelled competing Mabs. The OD values obtained in the
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Figure 57. Mab competition assay measured by ELISA (OD 405 nm) with R-LPS from
P. aeruginosa PAC557 as coating antigen. Doubling dilutions of Mab 61.3.2 (a) and Mab 73.5
(b) inhibitors were run against biotin labelled competing Mabs. The OD values obtained in the
presence of inhibitor were calculated as a percentage of OD values obtained without inhibitor, ie
percentage inhibition.
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Figure 58. Mab competition assay measured by ELISA (OD 405 nm) with R-LPS from
P. aeruginosa PAC557 as coating antigen. Doubling dilutions of Mab 334.4 inhibitor were run
against the following biotin labelled competing Mabs. The OD values obtained in the presence
of inhibitor were calculated as a percentage of OD values obtained without inhibitor, ie
percentage inhibition.
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able to compete with any of the other unlabelled Mabs, indicating that it
may have a similar or overlapping binding site to these Mabs. However, when
the other Mabs were biotinylated they appearedAto compete effectively with
unlabelled 334.4 inhibitor (Figure 58). This may indicate that Mab 334.4 has a
lower affinity for the antigen binding site than the other Mabs.
4.4 CAPTURE ELISA FOR THE DETECTION OF P. AERUGINOSA LPS
A capture ELISA was developed for the detection of P. aeruginosa LPS in
solution. The system developed incorporated the two most cross-reactive,
highest affinity Mabs characterised above: 304.1.4 and 360.7 which were also
not
foundAto compete against each other. Mab 360.7 was used as the
coating/capture antibody since it had the greatest affinity for P. aeruginosa
LPS. Mab 304.1.4 was used as the conjugated antibody (1:1 biotinylation). The
amounts of coating and conjugate antibodies were determined by
checkerboard titrations: conjugate antibody was used at 1:200 and coating
antibody at 1:25. The capture ELISA incorporated the biotin-streptavidin
amplification system investigated earlier. Ten-fold dilutions of P. aeruginosa
LPS, whole cells and heat-killed cells were tested (Figures 59-61).
Various incubation times (1 h, 2 h, 4 h, overnight) with the added antigens were
investigated; an incubation of 2 h gave comparable sensitivity to longer
incubations and was used in subsequent experiments. A sample was considered
positive for antigen if it yielded an OD value which was 3 SDs greater than the
mean of background controls. The sensitivity of the assay was between 0.1- 1.0
ng/ml P. aeruginosa LPS eg 0.1 ng/ml for JN61 (S-LPS) and PAC608 (R-LPS)
and 1.0 ng/ml for serotypes 0:2 and 0:11 (S-LPS) (Figure 59). The assay
limits of detection with P. aeruginosa whole cells was 10^ - 10^ cells/ml eg
PAC608 (core R-LPS) 10^ cells/ml, and serotype 0:6, 10^ cells/ml (Figure 60).
Similarly, LPS antigen in heat-killed whole cell preparations was detected;
sensitivity was 10^ -10^ cells equivalent /ml (Figure 61).
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Figure 59. Sensitivity of capture ELISA incorporating a biotin-streptavidin amplification system
for the detection of P. aeruginosa LPS. The P. aeruginosa LPS antigens included: O-antigenic S-
LPS from JN61 (non-mucoid, serotype 0:6, isolated from patient with CF) and serotype strains
0:2, 0:6 and 0:11, and core R-LPS from PAC608. Concentrations indicated by an asterisk






Figure 60. Sensitivity of capture ELISA incorporating a biotin-streptavidin amplification system
for the detection of P. aeruginosa LPS in solutions containing P. aeruginosa whole cells. The P.
aeruginosa whole cell strains include: JN61 (non-mucoid, serotype 0:6 isolated from patient with
CF); serotypes 0:6 and 0:11, and PAC608 (R-LPS strain). Concentrations indicated by an
asterisk denote the first value significantly greater than the negative control values (>3 SDs of
control mean).
190
Figure 61. Sensitivity of capture ELISA incorporating a biotin-streptavidin amplification system
for the detection of P. aeruginosa LPS in solutions containing heat-killed P. aeruginosa whole
cells. The P. aeruginosa heat-killed cell preparations included: O-antigenic S-LPS strains
serotypes 0:1 and 0:11, and core R-LPS strains PAC608 and PAC609. Concentrations indicated
by an asterisk indicate the first value significantly greater than negative control values ( > 3 SDs of
control mean).
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The capture ELISA system was also applied for the detection of P. aeruginosa
LPS in saliva and sputum specimens obtained from patients with CF.
Specimens were categorised according to the sputum bacteriology of the
patient at that particular time: i) colonised with P. aeruginosa; ii) Non-
P. aeruginosa colonised. Boiling of samples prior to use in the assay was found
to increase sensitivity of the assay, caused by the deproteinization and
subsequent liberation of LPS antigen in samples containing antigen-antibody
complexes, and also reduced non-specific background reactions. P. aeruginosa
LPS was detected in saliva and sputum specimens from both P. aeruginosa
colonised and non-colonised CF patients (Figure 62). However, false negative
values were observed for two sputums and one saliva from CF patients known
to be colonised by P. aeruginosa. The CF patient classified as non-
P. aeruginosa colonised (on the basis of sputum bacteriology) but who had the
highest sputum OD value (ELISA OD = 1.35) for P. aeruginosa LPS in the
non-colonised group, subsequently became intermittently colonised by P.
aeruginosa, as detected by bacteriological culture. Saliva samples from six





































Figure 62. Capture ELISA incorporating a biotin-streptavidin amplification system for the
detection of P. aeruginosa LPS in sputum and saliva from patients with CF: i) P. aeruginosa
colonised and ii) non-F. aeruginosa colonised. A sample was considered positive for




CHEMOTAXIS, MOTILITY AND ADHERENCE OF P. AERUGINOSA
The purpose of this work was to investigate the chemotactic and adherence
properties of non-mucoid P. aeruginosa strains isolated from patients with CF,
and to analyse the possible role these factors may play in the initial stages of
pulmonary colonisation by the organism.
5.1 P. AERUGINOSA STRAINS USED IN CHEMOTAXIS EXPERIMENTS
The chemotactic response of ten individual strains of P. aeruginosa, towards
various mucin preparations and the major amino acid and sugar components
of mucin were investigated. The strains used in the studies included:
a) The standard genetic strain P. aeruginosa PAOl.
b) P. aeruginosa strains J1385 and J1375, which were isolated during an
investigation into the primary respiratory colonisation in two CF patients
who had bathed in a hydrotherapy pool contaminated with multiple strains
of P. aeruginosa. J1385 is the colonising strain which was isolated from
both the CF patients and from the pool water. J1375 represents one of the
four other environmental isolates taken from the water. The clonal
relation of these isolates was determined by pyocin typing and confirmed
by DNA probe analysis by Dr M.L. Vasil and Dr J.W. Ogle (Health
Sciences Center, Denver, Colo. USA).
c) P. aeruginosa strains JN8, JN47, JN61 and JN62 were isolated from the sputa
of four CF patients with no previous history of pulmonary colonisation by
P. aeruginosa
d) P. aeruginosa strains WR-5, a non-chemotactic mutant; M2Fla", a non-
flagellate mutant and M2Rev, the motile revertant of M2Fla".
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In all chemotaxis experiments a meaningful chemotactic response was defined
as a relative response > 2.0.
5.2 CHEMOTACTIC RESPONSES OF P. AERUGINOSA TO PORCINE
MUCIN
In the initial studies the chemotactic response of P. aeruginosa towards a
commercial preparation of porcine gastric mucin was investigated (Table 4).
All strains except non-motile M2Fla" and non-chemotactic WR-5 exhibited a
meaningful chemotactic response towards porcine gastric mucin at some point
over the 60 minute assay period. The three highest relative responses were
obtained by P. aeruginosa strains J1385 (12.7), PAOl (10.6) and JN47 (10).
5.3 CHEMOTACTIC RESPONSES OF P. AERUGINOSA TO PURIFIED
CF MUCINS
Chemotaxis of P. aeruginosa to purified mucins derived from the
tracheobronchial secretions of a patient with CF were investigated (Tables 5-9).
The chemotactic responses of P. aeruginosa strains towards purified CF (gel
fraction) mucin are shown in Table 5. All strains except negative controls
demonstrated a meaningful chemotactic response towards CF mucin. The three
highest peak responses were obtained by P. aeruginosa strains J1385 (17.2),
PAOl and J1375 (6.7).
In subsequent experiments the chemotactic response of P. aeruginosa towards
individual fractions of CF gel mucin was investigated to determine if any of the
fractions were particularly chemoattractive for P. aeruginosa (Tables 6-9). A
meaningful response towards each of CF mucin fractions (A-D) was obtained
for most of the P. aeruginosa strains, excluding negative controls. All strains
showed a meaningful response towards gel fraction B of CF mucin (Table 7),
which appeared to be the most effective chemoattractant of the four fractions
studied. Certain strains showed a meaningful response to only some of the
mucin fractions, eg JN47 showed meaningful responses to fractions B and D
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Table 4. Chemotactic responses of P. aeruginosa strains
towards porcine-gastric mucin (100 pg/ml) over a period of
60 min.
STRAIN TIME (Min)
15 30 45 60
PAOl 10.6 4 . 5 1 . 5 3.2
J1385 2.4 12 . 7 4.9 1.8
J1375 6 . 1 3 . 7 0.9 1 . 1
JN8 4.0 3 . 0 4.6 1.9
JN4 7 ooo ooH 0 . 6 0.2
JN61 3 . 7 2.6 1 . 7 0 . 5
JN62 1.6 3.0 2 . 6 5.8
M2Rev 1.8 4.6 0 . 3 1.2
M2Fla~ 0.9 0.3 1.0 0 . 2
WR-5 0 . 2 1.5 0.6 0 . 9
a. The chemotactic response is the ratio of accumulation
of bacteria (viable count) in capillaries containing mucin
to control capillaries containing no chemoattractant. The
mean from duplicate experiments is shown. A response value
>2.0 is considered meaningful (Moulton & Montie, 1979).
b. M2Fla~ = non-flagellate control.
c. WR-5 = non-chemotactic control.
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Table 5. Chemotactic responses of P. aeruginosa strains
towards CF tracheobronchial gel mucin (100 pg/ml) over an
assay period of 60 min.
STRAIN TIME (Min)
15 30 45 60
PAOl 2 . 7 11.6 1 . 1 00o
J1385 17 . 2 0.4 OJ 00 2.3
J1375 0.8 1.8 6 . 7 2.9
JN8 5 . 1 1 . 7 0.9 0.8
JN4 7 3 . 5 0.7 0 . 5 1.0
JN61 0.4 4.3 3.4 1.5
JN6 2 0 . 5 3.3 1.3 1 . 1
M2Rev 1 . 3 2 . 8 1 . 5 0.9
M2Fla~ 0 . 5 1.8 00o 0 . 7
WR-5 0.8 1.3 1.0 0.8
a. The chemotactic response is the ratio of accumulation
of bacteria (viable count) in capillaries containing mucin
to accumulation of bacteria in a control capillary
containing no chemoattractant. The mean from duplicate
experiments is shown. A response value >2.0 is considered
meaningful (Moulton & Montie, 1979) .
b. M2Fla" = non-flagellate control.
c. WR-5 = non-chemotactic control.
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Table 6. Cheraotactic responses of P. aeruginosa strains
towards CF tracheobronchial mucin gel fraction A (100
pg/ml) over an assay period of 60 min.
STRAIN TIME (Min)
15 30 45 60
PAOl 1.8 1.2 4 . 0 1.9
J1385 3 . 4 0.6 0 . 5 0.9
J1875 4 . 8 1 . 2 2 . 5 2 . 1
JN8 0 . 5 2 . 0 0 . 9 0.8
JN47 0 . 9 0.3 0.4 0.8
JN61 1 . 2 1.8 2.2 2 . 0
JN62 4 . 0 0.3 2.9 2 . 0
M2Rev 1 . 1 2 . 5 2 . 2 0.9
M2Fla~ 1 . 5 1.0 0.7 0.8
WR-5 1.7 1 . 1 1.5 0.9
a. The chemotactic response is the ratio of accumulation
of bacteria (viable count) in capillaries containing mucin
to accumulation of bacteria in a control capillary
containing no chemoattractant. The mean from duplicate
experiments is shown. A response value >2.0 is considered
meaningful (Moulton & Montie, 1979).
b. M2Fla" = non-flagellate control.
c. WR-5 = non-chemotactic control.
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Table 7. Chemotactic responses of P. aeruginosa strains
towards CF tracheobronchial mucin gel fraction B (100
pg/ml) over an assay period of 60 min.
STRAIN TIME (Min)
15 30 45 60
PAOl 4.0 2 . 1 1 . 1 1 . 0
J1385 12 . 5 1 . 3 1.4 1 . 2
J1375 1.2 4.8 3.0 1. 9
JN8 10.9 6.2 5 . 6 3.3
JN4 7 1.6 5 . 6 1 . 1 1.3
JN61 1 . 8 3.4 4 . 2 2 . 2
JN6 2 5.0 1 . 4 0 . 5 0.9
M2Rev 4 . 4 1 . 1 1.3 1.5
M2Fla~ 1.5 0.2 1.3 1.4
WR-5 1.2 1 . 3 1.0 1 . 1
a. The chemotactic response is the ratio of accumulation
of bacteria (viable count) in capillaries containing mucin
to accumulation of bacteria in a control capillary
containing no chemoattractant. The mean from duplicate
experiments is shown. A response value >2.0 is considered
meaningful (Moulton & Montie, 1979).
b. M2Fla~ = non-flagellate control.
c. WR-5 = non-chemotactic control.
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Table 8. Chemotactic responses of P. aeruginosa strains
towards CF tracheobronchial mucin gel fraction C (100







PAOl 5.6 1.3 2 . 2 2.1
J1385 0.3 1.4 1.3 1.6
J1375 5.0 1.0 3.2 1.4
JN8 6 . 0 2 . 3 1 . 1 1.4
JN4 7 ooo 0 . 7 0.3 0.9
JN61 0.5 0 . 8 1.5 1 . 1
JN6 2 1 . 1 0.3 4.7 2.6
M2Rev 1 . 5 3 . 1 2 . 2 1.7
M2Fla~ 1. 4 1.5 1 . 2 1.0
WR-5 1.8 1 . 9 1.4 1.6
a. The chemotactic response is the ratio of accumulation
of bacteria (viable count) in capillaries containing mucin
to accumulation of bacteria in a control capillary
containing no chemoattractant. The mean from duplicate
experiments is shown. A response value >2.0 is considered
meaningful (Moulton & Montie, 1979).
b. M2Fla~ = non-flagellate control.
c. WR-5 = non-chemotactic control.
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Table 9. Chemotactic responses of P. aeruginosa strains
towards CF tracheobronchial mucin gel fraction D (100
pg/ml) over an assay period of 60 min.
STRAIN TIME (Min)
15 30 45 60
PA01 6 . 5 3 . 2 4.6 3 . 0
J1385 0.6 7 . 6 4.0 2 . 1
J1375 1.6 1 . 5 4 . 1 2.9
JN8 1.3 3.5 1.6 1 . 7
JN47 3 . 2 0 . 6 0 . 6 0 . 9
JN61 0 . 2 0 . 6 0 . 6 0 . 7
JN6 2 1. 1 1.0 1 . 7 1 . 5
M2Rev 1 . 4 4.0 2 . 5 2 . 1
M2Fla" 1.2 1.4 1.3 0.7
WR-5 2 . 1 2.0 2.2 1.2
a. The chemctactic response is the ratio of accumulation
of bacteria (viable count) in capillaries containing mucin
to accumulation of bacteria in a control capillary
containing no chemoattractant. The mean from duplicate
experiments is shown. A response value >2.0 is considered
meaningful (Moulton & Montie, 1979).
b. M2Fla~ = non-flagellate control.
c. WR-5 = non-chemotactic control.
201
whilst JN61 showed responses only to fractions A and C. The strains which
obtained the highest response for each CF mucin fraction were: fraction A -
J1375 (4.8); fractions B and D - J1385 (12.5 and 7.6) and fraction C - JN8 (6.0).
5.4 CHEMOTACTIC RESPONSES OF P. AERUGINOSA TO PURIFIED
HUMAN, NON-CF MUCINS
Chemotaxis of P. aeruginosa to other human mucins, derived from non- CF
sources were also investigated (Tables 10 & 11). A meaningful, strain
dependent chemotactic response towards chronic bronchitic mucin was
observed (Table 10). The three highest responses were obtained by JN8 (8.2),
J1385 (5.6) and JN61 (4.0). Similarly, meaningful chemotactic responses were
obtained for all strains, except negative controls, towards salivary mucins
obtained from a normal healthy individual (Table 11). The three highest
responses were obtained by J1375 (7.6), PAOl (7.4) and JN62 (6.0).
5.5 CHEMOTACTIC RESPONSES OF P. AERUGINOSA TO MUCIN
FRAGMENTS
The chemotactic response of individual strains of P. aeruginosa to CF mucin
glycopeptides (gel) was investigated to establish the presence, or otherwise, of
an enhanced response to low molecular weight mucins compared to those of
high molecular weight. (The CF gel glycopeptides have a Mr of between 300-
500,000, compared to 10-12 x 10^ for CF gel mucins). In addition, salivary
mucins and CF gel mucin (fraction B) were pretreated with pronase for 24 h
prior to use in chemotaxis assays in order to determine whether or not the
smaller fragments enhanced the chemotactic response of P. aeruginosa. (The
naked peptide regions of human tracheobronchial mucins are extensively
degraded by pronase (Vishwanath & Ramphal, 1985)).
Meaningful chemotaxis towards CF gel glycopeptides was observed for all
strains examined except non-motile and non-chemotactic controls (Table 12).
The three peak responses were obtained with J1385 (7.4), PAOl (6.5) and
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Table 10. Chemotactic responses of P. aeruginosa strains






PAOl 2.4 0.9 1.8 1 . 0
J1385 5.6 1. 1 0.4 0 . 8
J1375 2 . 1 0.5 0.9 0.9
JN8 8.2 7 . 1 0.5 1 . 1
JN4 7 2.8 1.2 0.4 0.9
JN61 0.8 2 . 6 4 . 0 1 . 8
JN6 2 2.3 3.0 0.6 1.2
M2Rev 2.2 2.4 1.8 1. 1
M2Fla~ 1.4 1.5 0.7 0.8
WR-5 1.0 1.3 1.8 1 . 3
a. The chemotactic response is the ratio of accumulation
of bacteria (viable count) in capillaries containing mucin
to accumulation of bacteria in a control capillary
containing no chemoattractant. The mean from duplicate
experiments is shown. A response value >2.0 is considered
meaningful (Moulton & Montie, 1979).
b. M2Fla~ = non-flagellate control.












15 30 45 60
PAOl 7 . 4 4.8 4 . 8 3.0
J1385 0.6 5.5 2.9 2.5
J1375 7.6 1.0 1.9 1 . 5
JN8 4 . 3 4 . 9 1.6 1.2
JN4 7 6.3 1.0 0.6 1 . 1
JN61 1 . 2 3.0 0.3 0.7
JN6 2 6.0 3 . 3 1.3 1.2
M2Rev 2.9 2.5 1.0 0.9
M2Fla" 2 . 2 0.7 0 . 8 0 . 6
WR-5 0.9 1.2 1.2 1 . 1
a. The chemotactic response is the ratio of accumulation
of bacteria (viable count) in capillaries containing mucin
to accumulation of bacteria in a control capillary
containing no chemoattractant. The mean from duplicate
experiments is shown. A response value >2.0 is considered
meaningful (Moulton & Montie, 1979).
b. M2Fla~ = non-flagellate control.
c. WR-5 = non-chemotactic control.
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J1375/JN8 (5.0) which mirror the responses with CF gel mucin. An enhanced
chemotactic response with glycopeptides compared to CF mucin (gel) was not
observed.
Similarly, treatment of salivary or CF (gel fraction B) mucins with pronase,
prior to use in chemotaxis assays, did not appear to significantly affect the
chemotactic response of the P. aeruginosa strains compared to the untreated
mucin, ie responses before and after pronase treatment of mucins were similar,
indicating that degradation of mucins into smaller fragments did not enhance
or decrease the chemotactic response (Tables 13 and 14).
5.6 SUMMARY OF THE CHEMOTACTIC RESPONSES OF
P. AERUGINOSA TO MUCINS
Table 15 shows the peak chemotactic response for each of the strains against
each of the mucins studied. All P. aeruginosa strains including standard
strains PAOl and M2Rev, and the non-mucoid, colonising strains isolated from
patients with CF demonstrated chemotactic tendencies towards mucin.
Chemotaxis was not specifically towards CF mucin or human mucins in
general, since strains also demonstrated meaningful chemotaxis towards
porcine-gastric mucin. P. aeruginosa J1385, the colonising strain, showed a
greater chemotactic response compared to J1375 (environmental strain) to six
out of the nine mucin preparations.
5.7 CHEMOTAXIS TO MUCIN-ASSOCIATED AMINO ACIDS AND
SUGARS
The ability of the major amino acid and sugar components of mucin to act as
chemoattractants was investigated. The chemotactic responses of P. aeruginosa
towards the eight major amino acids present in mucin, namely alanine, aspartic
acid, cysteine, glutamic acid, glycine, proline, serine and threonine, at
concentrations 10"! - 10"-* M were measured. For most of the amino acids













15 30 45 60
PAOl 0.9 6 . 5 4 . 1 2. 2
J1385 1.0 7.4 0.3 0.9
J1875 5 . 6 1. 5 2 . 6 1.8
JN8 5.6 0.8 1.0 1.3
JN47 3 . 7 0.9 1 . 0 1. 1
JN61 2 . 9 1.0 1.6 1.0
JN62 4.3 5.0 2 . 2 2.0
M2Rev 4 . 1 1 . 1 0 . 4 0 . 7
M2Fla~ 1.0 0.6 o 00 0.9
WR-5 0.9 0.8 0.7 00o
a. The chemotactic response is the ratio of accumulation
of bacteria (viable count) in capillaries containing mucin
to accumulation of bacteria in a control capillary
containing no chemoattractant. The mean from duplicate
experiments is shown. A response value >2.0 is considered
meaningful (Moulton & Montie, 1979).
b. M2Fla~ = non-flagellate control.
c. WR-5 = non-chemotactic control.
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Table 13. Chemotactic responses of P. aeruginosa strains
towards salivary mucins (large) (100 pg/ml) pretreated with








PAOl 6.7 (7.4) 4.4 (4.8) 4.1 (4.8) 2.5 (3.0)
J1385 0.4 (0.6) 3.7 (5.5) 00•o (2.9) 2.1 (2.5)
J1375 5.0 (7.6) 0.7 (1.0) to • (1.9) 1.9 (1.5)
JN8 3.4 (4.3) 5.1 (4.9) 1.6 (1.6) 1.5 (1.2)
JN4 7 3.5 (6.3) 0.3 (1.0) 0.2 (0.6) 0.9 (1.1)
JN61 1.6 (1.2) 3.2 (3.0) 0.7 (0.3) 0.9 (0.7)
JN6 2 o•CO (6.0) 4.0 (3.3) 0.9 (1.3) 1.0 (1.2)
a. The chemotactic response is the ratio of accumulation
of bacteria (viable count) in capillaries containing mucin
to accumulation of bacteria in a control capillary
containing no chemoattractant. The mean from duplicate
experiments is shown. A response value >2.0 is considered
meaningful (Moulton & Montie, 1979).
b. Figure in bold represents the chemotactic response
obtained after treatment of mucin with pronase.
c. Figure in brackets represents the chemotactic response
obtained in the absence of pronase treatment.
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Table 14. Chemotactic responses of P. aeruginosa strains
towards CF tracheobronchial mucin gel fraction B (100
yg/ml) pre-treated with pronase (100 yg/ml for 24 h at
37°C) over an assay period of 60 min.
STRAIN TIME (Min)
15 30 45 60
PAOl 3.9 (4.0) 1.4 2.1) 2.0 1.1) 1.2 1.0)
J1385 8.6 (12.5) 1.4 1.3) 2.7 1.4) 1.2 1.2)
J1375 2.0 (1.2) 3.5 4.8) 2.4 3.0) 1.6 1.9)
JN8 10.4 (10.9) 3.7 6.2) 3.5 5.6) 2.5 3.3)
JN47 1.0 (1.6) 5.2 5.6) 0.9 1.1) 1.7 1.3)
JN61 1.5 (1.8) 2.5 3.4) 5.0 4.2) 2.7 2.2)
JN62 5.5 (5.0) 3.8 1.4) 1.4 0.5) 1.6 0.9)
M2Rev 10.9 (4.4) 4.3 1.1) 1.2 1.3) 1.8 1.5)
M2Fla" 1.8 (1.5) 1.4 0.2) 1.5 1.3) 1.0 1.4)
WR-5 0.8 (1.2) 1.1 1.3) 1.6 1.0) 1.5 1.1)
a. The chemotactic response is the ratio of accumulation
of bacteria (viable count) in capillaries containing mucin
to accumulation of bacteria in a control capillary
containing no chemoattractant. The mean from duplicate
experiments is shown. A response value >2.0 is considered
meaningful (Moulton & Montie, 1979).
b. Figure in bold represents the chemotactic response
obtained after treatment of mucin with pronase.
c. Figure in brackets represents the chemotactic response
obtained in the absence of pronase treatment.
d. M2Fla" = non-flagellate control.
e. WR-5 = non-chemotactic control.
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each of the strains examined were observed (Tables 16a & b). Chemoattraction
to serine, alanine, glycine, proline and threonine was particularly evident; with
most of the amino acids the peak chemotactic response occurred at a
concentration of 10"J M.
Chemotaxis assays were also performed to assess the potential of the major
sugars of mucin, namely L-fucose, D-galactose, GalNAc, GlcNAc and NANA
to act as chemoattractants for P. aeruginosa. The relative chemotactic
responses for the strains (Table 17) reflected the results of other chemotaxis
assays, emphasizing a strain-dependent response to L-fucose, D-galactose,
GalNAc and GlcNAc. No strain showed a chemotactic response to NANA
(data not shown). Comparison of the chemotactic responses measured for
mucin associated sugars and amino acids, indicated that the former were less
effective chemoattractants than the latter.
5.8 COMPARISON OF THE CHEMOTAXIS OF NON-MUCOID AND
MUCOID P. AERUGINOSA STRAINS
The chemotactic responses of non-mucoid and mucoid P. aeruginosa isolates,
JN9 and JN10 respectively, were compared to assess the possible effect of
mucoidy on chemotaxis. JN9 and JN1Q were isolated from the same CF patient
and their clonal relationship confirmed by pyocin typing. The chemotactic
responses towards mucin associated amino acids and sugars were measured
(Figure 63). Both strains demonstrated comparably meaningful (>2.0)
responses towards proline and threonine. However, only non-mucoid strain
JN9 demonstrated a meaningful response towards serine and the sugars fucose
and GlcNAc. The response of JN9 towards serine was approximately five-fold
greater than that obtained for mucoid strain JN10.
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Table 16a. Chemotactic responses of P. aeruginosa strains
towards mupin-associated amino acids at concentrations of
10"1 - 10~5 M
STRAIN Alanine Aspartate
io-5 10"4 10"3 10~2 10"1 10"5 10~4 ID'3 o 1 ro 10'
PA01 NC 2.4 2.6 2.3 NC NC NC NC NC NC
J1385 2.4 3.9 7.2 5.3 2.7 NC 4.1 5.0 2.7 NC
J T 375 NC 3.2 4.3 4.0 3.5 NC 2.4 2.5 2.3 NC
JN8 4.0 3.1 5.7 12.4 NC NC NC NC NC NC
JN47 2.4 4.8 5.0 2.7 2.1 NC NC NC 2.0 NC
JN61 7.7 7.6 8.2 5.5 3.0 2.4 2.7 3.1 NC NC
JN62 2.5 2.1 3.3 5.5 3.1 NC NC NC 2.1 NC
M2Rev 2.1 2.5 3.3 3.0 2.7 NC NC NC NC NC
M2F1a" NC NC NC NC NC NC NC NC NC NC
WR-5 NC NC NC NC NC NC NC NC NC NC
STRAIN Cysteine Glutamate
10"5 10"4 10~3 10~2 10"1 10"5 10~4 10-3 10~2 10~1
PA01 NC NC NC NC NC NC NC 2.3 2.2 2.2
J1385 NC NC 2.2 NC NC NC 4.0 6.5 2.9 2.5
J1375 NC NC NC NC NC 2.7 4.5 4.9 3.4 NC
JN8 NC NC 3.3 2.1 NC NC NC NC 2.6 NC
JN47 NC NC NC NC NC NC NC NC NC NC
JN61 NC NC NC NC NC NC 3.5 4.0 NC NC
JN62 NC NC NC NC NC NC NC NC 2.7 NC
M2-Rev NC NC NC NC NC NC NC NC NC NC
M2-F1a" NC NC NC NC NC NC NC NC NC NC
WR-5 NC NC NC NC NC NC NC NC NC NC
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Table 16b. Chemotactic responses of P. aeruginosa strains
towards mucin-associated amino acids at concentrations of
10"1 - 10"5 M
STRAIN Glycine Proline
10"5 10~4 10"3 io"2 10"1 10"5 Sf1O io"3 10~2 10"
PA01 NC 2.4 2.5 2.4 2.2 3.0 3.5 3.7 2.9 2.1
J1385 3.8 4.0 4.7 2.7 2.8 NC 5.1 5.2 4.3 NC
J1375 NC 3.8 4.2 4.0 3.3 2.4 3.9 4.8 2.9 3.4
JN8 NC 4.5 14.3 14.4 4.3 NC 8.7 10.0 4.5 NC
JN47 2.2 2.9 3.7 2.3 NC 2.6 NC 2.4 NC NC
JN61 4.9 4.9 5.9 5.1 3.1 NC 2.4 7.1 3.7 3.4
JN62 4.5 NC 3.5 NC 8.1 2.1 2.7 2.9 3.7 2.5
M2Rev NC 2.7 3.6 3.0 2.9 NC 3.1 3.8 2.5 2.2
M2Fla~ NC NC NC NC NC NC NC NC NC NC
WR-5 NC NC NC NC NC NC NC NC NC NC
STRAIN Serine Threonine
10
"5 10''4 10''3 io-'2 10"1 10' 5 10" 4 10"'3 10''2 10
PA01 NC 2.7 6.1 5.2 2.2 NC NC NC NC NC
J1385 3.3 3.9 4.7 3.5 NC NC NC 2.9 2.5 2.7
J1375 NC 3.7 4.0 3.4 3.3 2.9 2.2 3.1 3.0 NC
JN8 NC 8.1 19.2 15.7 10.9 NC 4.7 6.6 NC 4.3
JN47 5.5 NC 6.1 4.2 NC 3.2 5.5 NC 72. 2.7
JN61 2.0 3.9 3.8 2.7 NC NC 2.1 4.4 NC 3.0
JN62 1.9 2.9 2.2 NC NC NC 2.8 3.7 NC NC
M2Rev NC 2.8 3.0 2.7 NC NC NC 2.3 NC NC
M2Fla" NC NC NC NC NC NC NC NC NC NC
WR-5 NC NC NC NC NC NC NC NC NC NC
a. The chemotactic response is the ratio of accumulation
of bacteria (viable count) in capillaries containing an
amino acid to accumulation of bacteria in a control
capillary containing no chemoattractant. A response value
>2.0 is considered meaningful (Moulton & Montie, 1979).
b. NC = no chemotaxis (ie <2.0).
c. M2Fla~ = non-flagellate control.
d. WR-5 = non-chemotactic control.
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Table 17. Chemotactic responses of P. aeruginosa strains





1 10"3 10~2 10"1 o 1 CXI io"4 10"3 10~2 10"1
PA01 NC NC NC 2.1 2.5 2.4 3.7 5.7 6.9 15.1
J1385 3.0 5.8 2.2 2.4 2.6 NC NC 3.8 2.2 3.5
J1375 NC NC NC 2.8 NC NC NC NC NC NC
JN8 NC NC NC 3.6 5.4 NC 2.3 3.3 NC NC
JN47 NC 2.1 2.8 NC NC NC 2.4 3.0 NC NC
JN61 NC NC NC NC NC 5.6 NC NC NC NC
M2Rev NC 3.1 2.8 2.9 NC NC NC NC NC NC
M2F1a" NC NC NC NC NC NC NC NC NC NC
WR-5 NC NC NC NC NC NC NC NC NC NC
STRAIN GalNAc GlcNAc
10"5 10"4 ID"3 10~2 10"1 10"5 10~4 10'3 10~2 10'1
PA01 NC NC NC NC NC NC 2.3 NC NC NC
J1385 NC 3.4 NC NC NC 3.5 4.5 3.2 3.0 2.7
J1375 NC NC NC NC NC 3.0 2.7 NC NC NC
JN8 NC 2.1 2.3 2.3 4.2 NC NC 3.5 4.3 3.5
JN47 NC 2.8 2.1 NC NC NC NC 2.4 2.8 NC
JN61 NC NC NC NC 2.3 NC NC NC NC NC
JN62 NC NC NC NC NC NC NC NC NC NC
M2Rev NC 4.7 NC NC NC 2.1 2.1 NC 2.4 2.2
M2F1a" NC NC NC NC NC NC NC NC NC NC
WR-5 NC NC NC NC NC NC NC NC NC NC
a. The chemotactic response is the ratio of accumulation
of bacteria (viable count) in capillaries containing a
sugar to accumulation of bacteria in a control capillary
containing no chemoattractant. A response value >2.0 is
considered meaningful (Moulton & Montie, 1979).
b. NC = no chemotaxis (ie <2.0).
c. M2Fla" = non-flagellate control.
d. WR-5 = non-chemotactic control.
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5.9 MOTILITY STUDIES
a) Effect of anti-flagellar Mab on chemotaxis/motility
Experiments were carried out to assess the effect of an anti- flagellar Mab
(type-b) on chemotaxis of P. aeruginosa strains, PAOl and J1385 (both flagellar
type-b), towards porcine gastric mucin (Figure 64). In the absence of antibody
both strains showed a peak chemotactic response to mucin after 15 min (PAOl)
and 30 min (J1385). However, in the presence of antibody no meaningful
chemotactic response was observed, indicating inhibition of motility and
consequently chemotaxis of the two organisms.
b) Motility assay
Migration of non-mucoid and mucoid P. aeruginosa strains in semi- solid
motility agar was investigated (Table 18). Considerable variation in motility,
indicated by the diameter of the spreading colony, was noted. The five non-
mucoid, colonising strains of P. aeruginosa, isolated from CF patients with no
previous history of CF, showed good motility in the semi-solid agar. The
difference between motility of these colonising strains and all other clinical
strains of P. aeruginosa was significant (Student t test, P < 0.05). However, the
motility difference between all the non-mucoid and mucoid clinical strains was
not significant.
Motility of non-mucoid P. aeruginosa strains in semi-solid minimal media
containing various concentrations of porcine gastric mucin as the
carbon/nitrogen source was also observed (Table 19), and indicated that mucin
was able to support growth and advancement of the spreading colonies of
P. aeruginosa.
5.10 GROWTH OF P. AERUGINOSA ON MUCINS
In a more comprehensive study involving both non-mucoid and mucoid strains
of P. aeruginosa, mucin was shown to support the growth of P. aeruginosa,




Pro Ser Thr Fuc GalNAc GlcNAc
_3
Chemoattractant (10 M)
Figure 63. Chemotactic responses of isogenic non-mucoid (JN9) and mucoid (JN10)
P. aeruginosa strains toward amino acid and sugars. The relative response is the ratio of the
mean accumulation of bacterial CFU in duplicate capillaries containing a potential
chemoattractant to the accumulation of bacterial CFU in control capillaries containing CM





Figure 64. Relative chemotactic responses of two P. aeruginosa strains - PAOl (a) and J1385 (b)
towards porcine gastric mucin (100 pg/ml) in the absence (•—•) and presence (O—O) of anti-
P. aeruginosa flagellar type-b Mab (1:40 in the bacterial suspension).
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Table 18. Motility of clinical (from patients with CF) and
non-clinical P. aeruginosa strains in semi-solid agar as
determined by diameter (mm) of the spreading colony, after
24 h.
a) Muc = mucoid strain.
b) * = early colonising, non-mucoid strains from patients
with CF.
c) M2Fla" = non-flagellate control.
d) M2Rev = motile revertant of M2Fla".







































































Table 19. Motility of P. aeruginosa strains from patients
with CF, and non-clinical strains in semi-solid minimal
media (MM) supplemented with mucin as the carbon/nitrogen
source.
MM + mucin MM + mucin MM + mucin MM only
STRAIN 1% w/v 0.5% w/v 0.1% w/v
PAOl 15 21 17
J1385 16 18 14
J1375 14 10 9
JN8 13 15 10
JN4 7 12 9 5
JN61 15 9 5
JN6 2 15 14 11
a. PAOl = classic genetic
isolate. All other strains
b. Motility determined by
colony.
strain; J1375 = environmental
isolated from patients with CF.
diameter (mm) of the spreading
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Table 20. Growth of P. aeruginosa strains on minimal media
containing mucin (1% w/v) as a nitrogen, carbon, and
nitrogen/carbon source.
Mucin as Mucin as Mucin as
nitrogen carbon nitrogen/carbon Nutrient
STRAIN source source source agar
PA01 + + + + + + + + + +
J1385 + + + + + + + + + + +
J1375 + + + + + + + + + + +
JN8 + + + + + + + + + + +
JN9 + + + + + + + + +
JN10 (Muc ^ + + + + + + + +
JN2 0 (Muc) + + + + + + + + + + +
JN36 (Muc) + + + + + + + + +
JN4 7 + + + + + + + +
JN61 + + + + + + + + + +
a. Growth measured relative to growth on nutrient agar:
++++ (maximal); +++ (good); ++ (Moderate); + (slight),
b. Muc = mucoid strain.
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production of the mucoid phenotype (Table 20).
Growth studies with the individual sugars of mucin (L-fucose, D-galactose,
GalNAc, GlcNAc and NANA) as carbon sources, revealed that only GlcNAc
was able to support growth of P. aeruginosa. (Glucose as the positive control
was also included in the study.
5.11 ADHERENCE OF P. AERUGINOSA TO MUCINS
Two novel methods were developed to examine adherence of P. aeruginosa to
mucin. The P. aeruginosa strains included in these studies corresponded to
those used for the chemotaxis experiments plus two non-mucoid colonising
strains, JN83 and JN89, isolated from patients with CF.
a) Adherence to mucin monolayers
Adherence of P. aeruginosa to both porcine and CF mucin monolayers was
observed with each of the P. aeruginosa strains examined. Initial experiments,
performed with porcine gastric mucin, showed P. aeruginosa cells to be
associated with, and often entangled in, a highly aggregated mucin matrix,
(Figures 65a-c & 66). When these experiments were repeated with mucin (gel
fraction) purified from the tracheobronchial secretions of a CF patient,
P. aeruginosa adhesion was again observed. CF mucin appeared in an
aggregated form attached to the bacterial cell surface (Figure 67a-d).
Attachment of mucin fragments to flagella was also observed (Figure 67c). Many
of the bacterial cells observed in the monolayers possessed flagella, and phase-
contrast microscopy confirmed that all the bacteria, except strain M2Fla", were
initially motile when incubated in the presence of mucin. As a control for
random association or simple entanglement between mucin and bacterial cells,
cultures of E. coli K12, Pr. mirabilis and K. aerogenes were added to mucin,
and monolayers prepared. In contrast to P. aeruginosa only an occasional
bacterial cell was observed in these monolayers, and those observed were not
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Figure 65a-c). Electron micrographs of P. aeruginosa strains JN8, J1385, and JN61 in association
with purified porcine gastric mucin (0.05 Jig/ml) spread in BAC monolayer stained with uranyl
acetate and subjected to unidirectional shadowing with platinum. Bar, 1 pim.
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Figure 66. Electron micrograph of P. aeruginosa strain JN62 in association with purified porcine
gastric mucin (0.05 pig/ml) spread in BAC monolayer stained with uranyl acetate and subjected
to unidirectional shadowing with platinum. Bar, 1 Jim.
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Figure 67a-d). Electron micrographs of P. aeruginosa strains WR-5, J1385, J1375, and JN62 in
association with purified tracheobronchial mucin from a CF patient showing adhesion of mucin
aggregates to bacterial surfaces. Monolayers were stained with uranyl acetate and subject to
unidirectional shadowing with platinum. Bars, 1 pm.
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attached to mucin (Figure 68a & b). In these control monolayers with non¬
adherent bacteria, the mucin appeared as lightly stained linear filaments
similar in appearance to mucin in the absence of bacteria.
b) Microtitre ELISA for measurement of P. aeruginosa adhesion to mucin
Interaction and association of P. aeruginosa cells with mucin were clearly
demonstrated in the electronmicrographs. Transmission electron microscopy
of bacteria in mucin monolayers was, however, not suitable for screening many
P. aeruginosa strains with a number of different mucins. As an alternative, a
microtitre ELISA technique incorporating one of the anti-F. aeruginosa Mabs
described earlier (see Chapter 3) was used to measure the adherence of twelve
P. aeruginosa strains to mucins bound to the wells of polystyrene microtitre
plates.
In preliminary experiments commercially available porcine gastric mucin was
used to coat wells of microtitre plates. The concentration of mucin required to
optimally coat wells, and the optimal concentration of bacteria added to wells
were determined. A mucin coating concentration of 100 pg/ml was shown to
give optimal sensitivity, yielding a maximal difference in OD between mucin
coated wells and background controls. A bacterial concentration of 10'
cells/ml showed maximal measurable binding to mucin coated wells and
minimal non-specific binding to background control wells. At bacterial
concentrations greater than 10^ cells/ml, significant binding to uncoated wells
was evident. The effect of increasing mucin concentration on adherence of six
strains of P. aeruginosa is shown in Figure 69. In general, measurable
adherence of P. aeruginosa cells increased with increasing concentration of
mucin, optimal binding occurring at between 100-200 pg/ml of mucin.
Adherence of twelve P. aeruginosa strains to porcine mucin was observed
(Figure 70).
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Figure 68. Electron micrographs of one of the few bacterial cells observed when E. coli K-12 (a)
and K. aerogenes (b) were investigated in mucin monolayers. No direct mucin-bacterium
associate is evident, and the mucin appears as lightly stained linear filaments. Monolayers were
stained with uranyl acetate and subjected to unidirectional shadowing with platinum. Bars 1 pm.
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Concentration of mucin vig/ml
Figure 69. Effect of increasing mucin (porcine-gastric) concentration on the adherence of 6
P. aeruginosa strains. Adherence measured by ELISA (OD 590 nm) incorporating Mab (1:500).
OD values represent the mean from duplicate experiments in which the mean OD from triplicate
wells is expressed after subtraction of negative background controls.
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Figure 70. Adherence of 12 P. aeruginosa strains to porcine gastric mucin (100 pig/ml).
Adherence measured by ELISA (OD 590 nm) incorporating anti-P. aeruginosa LPS Mab (360.7).
OD values represent the mean from duplicate experiments in which the mean OD from triplicate
wells is expressed after subtraction of negative background controls.
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In subsequent experiments adhesion of P. aeruginosa strains to a number of
human derived mucins was investigated (Table 21). Strain dependent
adhesion to most of the mucin preparations was observed, particularly to the
small salivary mucins and CF gel glycopeptide fragments. Measurable adhesion
of all the P. aeruginosa strains to fraction D of the fractioned CF gel mucin was
observed. On the basis of the results obtained, there appeared to be no
significant correlation between adhesion and chemotaxis to particular mucins,
eg examination of results for the fractioned CF gel mucin indicated that fraction
B was the most effective chemoattractant whilst adhesion of P. aeruginosa to
fracion D was most evident.
5.12 EFFECT OF SUGARS ON ADHERENCE
The effect of the mucin sugars L-fucose, D-galactose, GalNAc, GlcNAc and
NANA, on P. aeruginosa adherence to mucins was investigated. The effect of
the different mucin sugars on adhesion of six P. aeruginosa strains to CF mucin
gel glycopeptides was strain dependent (Table 22). Overall inhibition of
bacterial adhesion to mucin was most evident with GlcNAc and NANA,
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DISCUSSION
CHAPTER 1
MUCINOPHILIC PROPERTIES OF P. AERUGINOSA
In contrast to the considerable accumulation of information on the adaptation
and pathogenesis of mucoid P. aeruginosa, little attention has been directed to
the bacterial and host factors which may contribute to the initial stages of
asymptomatic colonisation with non-mucoid P. aeruginosa which, arguably,
forms the microbial reservoir for the subsequent emergence of mucoid variants.
For example, why do some CF patients become colonised by P. aeruginosa
whilst other patients of the same age and attending the same centre remain
free from colonisation for long periods? Exposure to P. aeruginosa strains
more able to colonise the CF lung than others, may increase the risk of
colonisation, whilst some CF patients may be more susceptible to microbial
colonisation because of certain genetic or environmental factors (Govan &
Glass, 1990).
One of the aims of this thesis was to examine the mucinophilic properties of
non-mucoid P. aeruginosa and the role such characteristics may contribute to
the initial stages of pulmonary colonisation in patients with CF. The affinity of
P. aeruginosa for mucin was investigated since mucus glycoproteins (mucins)
are the major macromolecular components of the mucosal layer lining the
respiratory tract (Rose, 1988) and are produced in excessive amounts in the
respiratory secretions of patients with CF (Chace et al, 1985).
1.1 CHEMOTAXIS OF P. AERUGINOSA TOWARDS MUCIN
Many motile bacteria have the capacity to move towards nutrients
(chemotaxis), thus enter.ng a more favourable environment and perhaps en¬
hancing their association with a host surface ^Finlay & Falkow, 1989). Allweiss
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et al (1977) reported that chemotactic mechanisms promoted the association of
E. coli, vibrios and salmonellae with rabbit mucosal tissue. In a series of
subsequent and related investigations Freter and colleagues (Freter et al, 1979;
Freter et al, 1981a & b; Freter & O'Brien, 1981a & b) also observed
chemotaxis of Vibrio cholerae towards mucosal slices and a pepsin digest of
rabbit mucosal scrapings. Uhlman & Jones (1982) demonstrated that a
diffusible attractant released from HeLa cells greatly enhanced the collision
frequency between S. typhimurium and the epithelial cells. A more recent
study of the factors required by Salmonella typhi for invasion of HeLa cells
suggested that flagella, motility and chemotaxis were all necessary (Liu et al,
1988).
In addition to the chemotaxis studies of V. cholerae and its subsequent associa¬
tion with mucosal surfaces, a number of other studies also support the hypothe¬
sis that chemotaxis towards mucin or secretions of mucosal surfaces is a poten¬
tially important bacterial virulence mechanism. Chemotaxis of
Treponema hyodysenteria (Kennedy et al, 1988) and Campylobacter jejuni
(Hugdahl et al, 1988) towards porcine gastric mucin have been demonstrated,
whilst Hazell et al, 1986) speculated that the association of Helicobacter pylori
(Campylobacter pyloridis) with the gastric mucosa may be aided by chemotac¬
tic movement of the organism into the gastric pits and toward the intracellular
junctions from which potential nutrients diffuse.
In this thesis the chemotactic response of P. aeruginosa towards a number of
different mucin preparations was examined (Tables 4-11). Chemotaxis towards
both CF and non-CF mucins was observed and represents the first documented
report of the chemotaxis of P. aeruginosa towards mucin. The fact that chemo¬
taxis towards a number of different mucin preparations was demonstrated
suggests that the intrinsic composition and structure of CF mucin is not exclu¬
sively chemoattractive for P. aeruginosa. Comparisons of the carbohydrate
compositions cannot demonstrate structural differences between CF and non-
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CF mucins as the analyses reflect an averaging of hundreds of oligosaccharide
chains which may differ in size, core type and structure (Rose, 1988). However,
Houdret et al, 1989 reported that the increased acidity and the decreased
proportion of neutral glycopeptides in the respiratory secretions of both CF
and non-CF individuals was related to infection with P. aeruginosa. The high
lipid content of respiratory mucins in CF patients is also a result of infection
with P. aeruginosa and not directly related to infection (Houdret et al, 1986).
The CF mucin used in the chemotaxis and adherence experiments was
isolated from the tracheobronchial secretions of a female CF patient already
colonised by P. aeruginosa. Chemotaxis of P. aeruginosa to the fractions of CF
gel mucin as well as the CF gel glycopeptides also indicates that the chemotaxis
is not specific for a particular composition or structural domain of mucin. The
amount of sialic acid in the individual fractions of CF mucin decreases from
fraction A to fraction D, with a concomitant decrease in acidity (Dr D.J.
Thornton, pers. comm.).
Chemotaxis of P. aeruginosa towards the major amino acids and sugars of
mucin was demonstrated (Tables 16a & b and 17). The degree of chemotaxis
towards the different components appeared to be strain dependent. Previous
studies have indicated that P. aeruginosa is responsive to a wide range of at-
tractants including glucose, organic acids and many of the twenty commonly
occurring amino acids (Moulton & Montie, 1979; Craven & Montie, 1985). In
this thesis, the results obtained with the mucin-associated amino acids and
sugars showed that the chemotactic responses towards the amino acids were
generally greater than those obtained for sugars. These observations corre¬
spond to those made by other investigators who also demonstrated that
P. aeruginosa was highly responsive towards amino acids and less strongly
responsive towards glucose and organic acids (Moench & Konetzka, 1978;
Moulton & Montie, 1979). In the study of Moulton & Montie (1979) the au¬
thors observed a lack of response to glucose when P. aeruginosa was grown in
succinate, malate or citrate containing media and concluded that the results
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were consistent with the induction, by glucose, of a glucose binding protein
reported by Stinson et al (1976), which also functions as a chemoreceptor
(Stinson et al (1977). These findings may account for the generally low chemo-
tactic responses observed for the mucin sugars. Prior to use in the chemotaxis
assays P. aeruginosa was grown in minimal media, containing citrate as the
carbon source. Optimum chemotaxis towards some or all of the mucin sugars
may be dependent on inducible chemoreceptors.
No effect of the carbon source on P. aeruginosa chemotaxis towards amino
acids was observed by Moulton & Montie (1979). However, Craven & Montie
(1985) showed that chemotaxis towards several amino acids is subjected to
control by nitrogen availability and that this regulation is probably expressed at
the level of chemoreceptors or transducers. The authors concluded that chemo¬
taxis towards amino acids may be a mechanism of nitrogen acquisition by
P. aeruginosa. In an earlier study, Kay & Gronlund (1969) reported that
twenty common amino acids can be utilized by P. aeruginosa as sole nitrogen
sources and that transport of most of the amino acids is maintained or
increased under conditions of nitrogen starvation. The ability of P. aeruginosa
to respond to the amino acids of mucin, as demonstrated in this thesis, may
play a role in the scavenging of nitrogen within the environment of the CF lung.
In addition, mucin was shown to support the carbon and nitrogen source
requirements of P. aeruginosa.
The mechanism by which P. aeruginosa exhibits chemotaxis to mucins, which
are high molecular weight glycoproteins (Rose, 1988) is uncertain. The
bacterial chemoreceptors cited in the literature appear to be located in the
periplasmic space or cytoplasmic membrane (Brass, 1986), although chemotaxis
may be mediated by a mechanism involving binding of mucin to a
transmembrane outer-membrane receptor protein. Alternatively, chemotaxis
to mucin may involve initial degradation of mucin into glycopeptide fragments
or individual amino acid and sugar components. Hancock & Nikaido (1978)
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reported that protein F formed a large diffusion pore allowing the diffusion of
polysaccharides with a Mr of up to 9,000. The authors hypothesized that such
large pores would permit entry of large peptides into the periplasmic space,
rendering them susceptible to peptidases, whereas any extracellular proteases
may be involved in the initial processing of proteins in the environment.
Mucins have a general structure consisting of a protein core surrounded by a
sheath of carbohydrate side chains, as well as non-glycosylated regions (naked
regions) which are susceptible to proteolytic digestion (Clamp et al, 1978; Bara
et al, 1988). Pronase digestion of mucin results in the formation of mucin
glycopeptides (Scawen & Allen, 1977; Rose et al, 1984). In this thesis, proteo¬
lytic digestion of CF mucin and normal salivary mucin into glycopeptide frag¬
ments prior to their use in chemotaxis assays did not significantly affect the
chemotactic responses of P. aeruginosa compared to the non-pronase treated
mucins (Tables 13 & 14). Fragmentation of the mucins facilitating transport
uptake and provision of individual chemoattractants, may have been expected
to enhance the chemotactic response of P. aeruginosa. The degraded mucins
are likely to consist of glycosylated, proteolytic resistant glycopeptide fragments
as well as a mixture of peptides and amino acids. Similarly, the response to
CF mucin gel glycopeptides (from which the degraded proteins have been
removed) did not significantly alter the chemotactic response of P. aeruginosa
(Table 12).
In the CF lung, proteolysis of mucin by proteases from P. aeruginosa and neu¬
trophils (Poncz et al, 1988) could explain how mucin fragments and
components would be readily available in vivo to act as chemoattractants and
nutritional sources for P. aeruginosa. Indeed, Rose et al (1987) suggested that
the smaller size of CF mucins compared to normal and asthmatic mucins was
caused by bacterial or inflammatory cell proteases present in CF sputum. They
and others (Houdret et al, 1989) have postulated that bacterial glycosidases
may also be responsible for degradation of mucins in patients with CF. An
235
extracellular neuraminidase from a P. aeruginosa strain isolated from CF has
been reported and shown to hydrolyze CF mucin (Leprat & Michel-Briand,
1980). The mucin degrading exoglycosidases produced by oral streptococci
(van der Hoeven et al 1990) may also provide a ready source of
chemoattractants in vivo for chemotaxis of P. aeruginosa. In the case of V.
cholerae a mucinase complex has been reported, and may facilitate
penetration of the mucus barrier by the organism (Stewart-Tull et al, 1986).
The exposure and release of individual amino acids by proteolytic degradation
of mucin may influence the degree of chemotactic responses of individual
strains. The presence of proteolytic resistant regions within the mucin may
reduce the release of serine, proline, threonine, alanine and glycine which are
predominant in, but not exclusive to these regions (Scawen & Allen, 1977;
Clamp et al, 1978; Rose, 1988). However, the naked regions of mucin, un¬
sheathed by oligosaccharides are easily accessible for proteolytic attack. In
addition, in vivo, amino acids may also be made available because of
proteolysis of other proteins and glycoproteins such as the 65-kilodalton
protein reported by Ringler et al, 1988, or immunoglobulins and lacto-
transferrin, with which respiratory mucin is also associated in vivo (Houdret
et al, 1989).
Since human tracheobronchial mucins typically contain 80-87% w/v carbohy¬
drate (Rose, 1988) the sugar components are likely to play an important role in
the chemotaxis of P. aeruginosa towards mucin. Indeed, the sugars fucose and
NANA are invariably in a terminal position (Clamp et al, 1978) and would
therefore be likely candidates for chemoattractants. In this study, a strain
dependent response towards fucose was observed. In a study of the chemotaxis
of C. jejuni only fucose of the different mucin sugars tested was identified as a
chemoattractant (Hugdahl et al, 1988). In this thesis, NANA, which has been
reported to be an adhesin for P. aeruginosa (Vishwanath & Ramphal, 1985),
did not act as a chemoattractant for any of the P. aeruginosa strains tested.
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NANA is a relatively strong acid in biological systems; however, the failure of
NANA to act as a chemoattractant cannot be explained by a low pH value.
Although the buffered preparations of NANA at 10'^M did have a low pH,
the other preparations examined (10"^ - 10'^M) had neutral pHs.
On a technical note, accumulation of bacteria in the capillary tubes containing
mucin, amino acid, or sugar attractants cannot be explained by bacteria being
carried in passively by convection, brownian movement or random motility
since no accumulation of non-motile or non-chemotactic mutants was observed.
The different peak values obtained with individual strains showing a response
to a given chemoattractant could result from variation in the number of
chemoreceptors present, or in the affinities of those receptors. Chemotaxis
tends to operate over a limited range of concentrations, the 'response range'
(Adler, 1973). At the low extreme is the threshold concentration, the lowest
concentration of attractant in the capillary that gives a detectable response. At
the high extreme is the saturation concentration, the attractant concentration in
the bacterial suspension above which the bacteria cannot detect a still higher
concentration in the capillary (Adler, 1973). The operating range is different
for individual attractants eg in the case of strain JN8 for fucose, the range was
between 10"^ and lO'^M , and for galactose it was between 10"^ and 10'^M
(threshold and saturation respectively). The lag period before chemotaxis is
observed is considered to be the time taken to reduce the concentration of
attractant at the mouth of the capillary to just below the saturating concentra¬
tion. This reduction is brought about by utilization of attractant by the
bacteria, in the case of metabolizable attractants, and diffusion of the
attractant, eg in the case of strain J1375 and its chemotaxis towards CF mucin
(Table 5), the lag period was between 30-45 mins before a meaningful
chemotactic response was detected. A reduced response at high concentrations
of attractant simply reflects the longer lag periods found for high
concentrations: it does not usually represent an inhibition of chemotaxis
(Adler, 1973).
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The chemotaxis assays showed that P. aeruginosa strains isolated from patients
with CF as well as standard (eg PAOl and M2Rev) or environmental (J1375)
strains are able to respond to mucin as a chemoattractant. However, it could
be speculated that in a given environment (eg the whirlpool source of J1385
and J1375) enhanced chemotaxis would confer an advantage on a potential
colonising strain eg J1385. In support of this hypothesis J1385 showed greater
chemotaxis than J1375 towards most of the mucin preparations, including the
CF gel mucin, and towards the majority of mucin constituents.
Motility of Treponema (Kennedy et al, 1988) C. jejuni (Ferrero & Lee, 1988)
and H. pylori (Hazell et al, 1986) in viscous mucosal preparations have been
demonstrated. In this study, motility of non-mucoid P. aeruginosa strains in a
semi-solid medium containing various concentrations of mucin was observed
(Table 19). Motility of a number of P. aeruginosa strains was also compared
(Table 18): enhanced motility of the initial colonising strains, compared to the
other non-mucoid and mucoid strains isolated from patients with CF, was
demonstrated. These motility experiments confirm the earlier observations
of Luzar & Montie (1985) and Luzar et al (1985) who showed that several
physiological characteristics associated with invasiveness including chemotaxis
and motility, appeared to be selected against after initial colonisation of the
lungs by the organism: reduced motility and chemotaxis was particularly
associated with R-LPS strains isolated from patients in poor clinical condition
(Luzar et al, 1985). Since the genetic loci for motility and chemotaxis are in
close proximity (Tsuda & lino, 1983) a mutational event in that region of the
chromosome might alter both gene products. Alternatively, altered synthesis of
LPS could create envelope instability which could interfere with the secure
anchoring of the flagellum (Luzar et al, 1985). Some authors have attempted to
correlate mucoidy with non-flagellation (Boyce & Miller, 1982b). However,
motility of some of the mucoid strains was observed in the semi-solid agar
motility experiments and no such correlation was demonstrated in the results of
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the study by Luzar et al (1985). In this thesis, an experiment was performed to
compare chemotaxis of isogenic non-mucoid and mucoid P. aeruginosa isolates
(Figure 63). A similar response to some of the attractants was observed,
although an elevated response to other attractants by the non-mucoid strain
was evident, indicating that the mucoid phenotype may inhibit the motility
and/or chemotaxis of P. aeruginosa.
There have been relatively few reports describing the chemotactic properties
and motility of P. aeruginosa in vivo. However, some investigations have
demonstrated that motility or chemotactic ability, or both, are associated with
the virulence of P. aeruginosa. Strains which were highly chemotactic or
motile, or both, had lower 50%-lethal doses when tested in a burned mouse
model (Craven & Montie, 1981), and motility-deficient mutants were found to
be less virulent than their wild type parents in a burned rat model (McManus
et al, 1980). Further experiments with the burned mouse model have also
demonstrated that decreased virulence is associated with non-flagellated or
non-motile mutants of P. aeruginosa (Montie et al, 1982b; Drake & Montie,
1988). The results presented in this investigation indicate that the ability of
motile, chemotactically directed bacteria to quickly penetrate the mucus
blanket, across and against the cephalad movement of the mucociliary escalator
(albeit reduced in CF) may play an important role in respiratory colonisation of
P. aeruginosa in patients with CF.
1.2 ADHERENCE OF P. AERUGINOSA TO MUCIN
The ability of P. aeruginosa to bind to a number of respiratory cell surfaces as
well as tracheobronchial mucins was reviewed extensively in the Introduction.
In this thesis, the ability of colonising, non-mucoid strains of P. aeruginosa, to
bind to mucin was further investigated, the development of two methods
providing further evidence of the mucinophilic properties of P. aeruginosa.
Novel application of transmission electron microscopy and BAC monolayers
demonstrated P. aeruginosa entanglement and adherence to porcine gastric
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mucin and purified CF mucin. The observation that individual strains of
E. coll, Pr. mirabilis and K. aerogenes did not adhere to mucin agrees with the
observations of Vishwanath & Ramphal (1984), who also observed only the
occasional binding of non-pseudomonal cells, and concluded that the
association between mucin and P. aeruginosa is relatively specific.
The commercial preparation of porcine gastric mucin was included in the
initial adherence studies conducted in this thesis because of its availability and
the fact that it is reported to resemble human tracheobronchial mucin in its
carbohydrate, amino acid and sulphate ester composition (Boat et al, 1977;
Scawen & Allen, 1977). In addition to its mucin content the commercial
preparation is likely to be contaminated with cell membranes, proteins, DNA
etc (Dr J.K. Sheehan, pers. comm.). However, the in vitro studies performed
with this preparation are probably more reflective of the pulmonary
environment colonised by P. aeruginosa, where mucin will be associated with
the natural contaminants of the mucosal blanket. Confirmation of an
association between P. aeruginosa and mucin was provided by the studies with
the purified CF mucin preparation.
The observation that both non-motile and non-chemotactic mutants of P.
aeruginosa showed attachment to mucin indicates that adhesion, in this in vitro
assay, is not dependent on motility or chemotaxis. The presence of mucin
aggregates attached to individual cells of P. aeruginosa suggests that the bacte-
rium-mucin interaction is strong enough to overcome the sheer forces as the
mucin monolayer is formed. In the presence of P. aeruginosa, porcine and CF
mucin appeared in a highly aggregated form, or as small fragments decorating
the bacterial surface. This is in contrast to the flexible, linear, lightly stained
threads observed in the case of mucin alone (also reported by Rose et al (1984)
and Sheehan et al (1986)) and in the presence of non-adherent bacteria, eg
E. coll This observation suggests that mucin molecules are degraded or under¬
go a substantial conformational change in the presence of P. aeruginosa
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It has been proposed that adhesion of P. aeruginosa to mucin (and other sur¬
faces) is mediated by pili in the case of non-mucoid organisms and alginate in
the case of mucoid strains (Ramphal et al, 1987). However, examination of the
micrographs (Figures 65-67) showing fragments of aggregated mucin attached
to various surface points of non-mucoid P. aeruginosa did not suggest solely
pilus mediated adhesion. It has been reported however, that apparently non-
mucoid P. aeruginosa strains are able to express alginate antigens on their
surface (Pier et al, 1986; Anastassiou et al, 1987) and may account for some of
the adhesion to mucin observed. Alternatively, Marcus & Baker (1985) and
Plotkowski et al (1989) have suggested that lectins may play a crucial role in
forming a bridge between bacterial and host surface polysaccharides, resulting
in a firm bond between the two. Plotkowski et al (1989) observed that P.
aeruginosa strains exhibiting high internal lectin titres adhered significantly
better to elastase treated mucosa. P. aeruginosa has been reported to produce
two distinct lectins, PA-I and PA-II, which differ in their carbohydrate-binding
specificities (Gilboa-Garber, 1972). Most of the P. aeruginosa lectin activity is
distributed inside the cell but is released after bacterial disruption, prompting
the suggestion that P. aeruginosa lectins, released in vivo during bacterial dis¬
ruption by local host defence mechanisms, may enhance binding of
P. aeruginosa to host mucosa (Plotkowski et al, 1989). Further support for this
theory of lectin mediated binding of P. aeruginosa in the lung is provided by the
fact that the production of P. aeruginosa lectins in vitro is greatly stimulated by
the addition of choline to the culture medium (Gilboa-Garber, 1972):
phosphatidyl-choline, the major lung surfactant, can be degraded by
elaboration of P. aeruginosa phospholipase C and phosphatase, yielding free
choline (Plotkowski et al, 1989).
Adherence of P. aeruginosa to CF and non-CF mucins was confirmed in the
microtitre assay employing Mab to measure the binding (Table 21). Although a
propensity for adherence to CF mucin was not demonstrated, these results
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confirm those of other investigators (Kubesch et al, 1988; Herrmann et aL, 1989
and Ramphal et al, 1989), who also reported adhesion of P. aeruginosa to
tracheobronchial mucins obtained from CF patients. Kubesch et al (1988)
noted that a strain showed no preference for the mucin of its CF host and that
there was no selection to specific oligosaccharide sequences of mucin: porcine
submaxillary mucin was the best binding target for all P. aeruginosa strains
tested. In this thesis, substantial binding of P. aeruginosa strains to porcine
gastric mucin was observed in the microtitre assays and the the electron micro¬
scopic studies. In the study of Ramphal et al (1989) differences in adhesion of
P. aeruginosa to mucin glycopeptides from sputa of patients with CF and chron¬
ic bronchitis was observed, the authors suggesting that CF mucins may be al¬
tered after infection is established, resulting in less binding to some fragments.
The above study also revealed that the most mucin-like glycopeptides from
P. aeruginosa-infected CF sputa showed less bacterial adhesion than did the
corresponding bronchitic or uninfected CF samples, and the most adhesive
activity in CF samples came from a fraction containing O and N glycopeptides,
which may be a degradation product of P. aeruginosa infection (Ramphal et aL,
1989).
In the present study, adherence of P. aeruginosa to CF sol and gel mucins, frac¬
tions of CF gel mucin as well as sol and gel glycopeptide fragments was ob¬
served. Binding to the CF gel glycopeptides was particularly apparent indicat¬
ing that the bacteria may have a special affinity for these glycopeptides. This
may be due to more available binding sites (weight for weight) on the glycopep¬
tides devoid of naked protein regions, or perhaps a result of better attachment
of these fragments to the microtitre plate wells. Fraction D, the least acidic
(less sialic acid) of the CF mucin fractions, showed greatest P. aeruginosa
adhesion. Ramphal et al (1989) noted the absence of adhesion to
glycopeptides containing a high level of sialic acid.
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Adhesion to normal salivary mucins, especially the small salivary mucins (Mr
250,000) was observed, lending support to the hypothesis that the oral cavity
may provide the site of initial colonisation. Komiyama et al (1987b) reported
the sialic acid-induced aggregation of P. aeruginosa and speculated that such
aggregation or adherence to sialic acid containing mucins in the oral cavities of
CF patients may precede and facilitate colonisation of the lower respiratory
tract. The study of Reddy et al (1985) revealed that there were no apparent
qualitative differences in the neutral and sialic acid containing units in the
oligosaccharide structures of low-molecular weight salivary mucins from a
normal individual and one with CF. This would perhaps indicate that there is
nothing in terms of the composition or structure of CF salivary mucins which
confers increased susceptibility to P. aeruginosa infection. A carbohydrate
analysis of purified mucins from sputa of CF and asthmatic patients showed no
significant differences in the sugar components (Rose 1988).
In this study both CF and non-CF P. aeruginosa strains showed adherence to
mucin, as demonstrated by both the microtitre assay and electron microscopy.
In contrast, Herrmann et al (1989) reported that only P. aeruginosa strains
isolated from patients with CF, displayed substantial affinity to mucin.
Given that the carbohydrate side chains on mucins are exposed and make up to
80% w/w of mucin (Rose, 1988), it would seem reasonable to speculate that
sugar epitopes are the primary receptor for P. aeruginosa adhesion to mucin.
Kubesch et al (1988) noted that the removal of oligosaccharide side chains
abolished binding of bacteria to mucin, whilst Vishwanath & Ramphal (1985)
showed that treatment of mucin with periodate (oxidises hydroxyl groups on
carbohydrates), neuraminidase and heat inactivated influenza virus (binds to
sialic acid) reduced P. aeruginosa adherence; pronase treatment had no effect.
The study of Vishwanath & Ramphal (1985) concluded that NANA and
GlcNAc may form the binding site for P. aeruginosa on human tracheobronchi¬
al mucin; similar observations were also made by Herrmann et al (1989), al-
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though a broad heterogeneity of CF P. aeruginosa strains for their mucin car¬
bohydrate receptor was reported. Sugar inhibition studies with the microtitre
ELISA (Table 22) also reflected the possible participation of NANA and
GlcNAc in the binding of P. aeruginosa to mucin. Sialic acid is also thought to
be important in the cellular receptor for P. aeruginosa including buccal cells
(McEachran & Irvin, 1985; Doig et aL, 1989, Baker et al, 1990) and epithelial
cells (Ramphal & Pyle, 1983b).
Interactions between bacteria and host mucins are thought to be important in
bacterial colonisation of mucosal surfaces, eg binding of pathogenic E. coli to
intestinal mucin may be protective for the host or may enhance colonisation
and allow toxins to be delivered at high concentration to the underlying mucosa
(Sajjan & Forstner, 1990); some oral bacteria bind to mucin molecules on teeth
(Liljemark & Gibbons, 1972) and some E. coli strains bind to urinary tract
mucus (Chick et aL, 1981). In healthy individuals, tracheobronchial mucins
serve to protect respiratory cells from bacterial colonisation by binding
bacteria, the adherent or entangled bacteria being removed by mucociliary
clearance (Reynolds, 1983; Reynolds, 1989). However, in the lungs of CF
patients, mucociliary clearance is impaired (Fick, 1989) and binding of bacteria
to the stagnant mucus would not be beneficial to the host. The particular
affinity of P. aeruginosa for respiratory mucins, including specific adherence,
could explain the propensity of the organism to colonise and persist in the static
mucosal secretions of CF patients. Adherence of non-mucoid P. aeruginosa to
mucin may act as a focus for infection, and subsequent development and
establishment of alginate enclosed microcolonies, enmeshed in a mucin matrix.
If the organisms colonise the mucosal blanket, adherent to mucins, then
secretory immunity may be less effective since IgA itself may be mucinophilic
(Ramphal, 1990). Binding of P. aeruginosa to mucin has also been shown to
protect the organism from opsonophagocytic killing, but not poorly adhering
strains including E. coli, Staph, aureus or group B S-freptococci (Vishwanath
et al, 1988). Thus P. aeruginosa could reside in the mucus and evade the
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immunological response enabling it to coexist for long periods within the host.
Although H. influenzae. Staph, aureus and S. pneumoniae also show some
adhesion to mucus (Ramphal, 1990) the subsequent manifestation of the
mucoid phenotype by P. aeruginosa is probably a key factor for its persistence
and selection as the predominant coloniser in CF.
The structure of the terminal sugar chains of some mucin glycoproteins is the
same as that determining the specificity of blood groups (Clamp et al 1978).
The inability to secrete blood group substances may be an important factor in
the development of chronic obstructive lung disease, blood group substances
perhaps having a role in the interaction of microbes with mucosal surfaces
(Haponik et al, 1985). However, a correlation between secretor status in CF
patients and rate of correlation with P. aeruginosa has not been demonstrated
(Haponik et al, 1985).
245
CHAPTER 2
ANTI-P. AERUGINOSA ANTIBODIES IN PATIENTS WITH CYSTIC
FIBROSIS
2.1 ANTI-P. AERUGINOSA FLAGELLAR ANTIBODIES
In this study, analysis of flagella isolated from four non-mucoid P. aeruginosa
strains confirmed the correlation between antigenic type and molecular weight
(relative mobility) as described by Allison et al (1985). The appearance of the
low molecular weight protein band in the gel profile of flagella isolated from
JN61 (flagella type-a) appears to correspond to the observations made by Alli¬
son et al (1985). These authors noted a protein band of Ah 15,000-20,000 and
reasoned that these small polypeptides were dissociated or protease nicked
flagella, since increasing amounts of these bands and a decrease in native fla-
gellin correlated with length of time in storage.
Bacterial flagella are known to be potent immunogens evoking both humoral
and cellular immune responses (Newton et al, 1989). In this thesis anti-
flagellar antibodies in serum, saliva and sputum from patients with CF were
detected (Figures 24-26). The observation of similar levels of anti-flagellar
type-a and type-b antibodies observed in many of the CF patients, especially
those chronically colonised by P. aeruginosa, could result from infection with
two different P. aeruginosa strains. The study of anti-flagellar antibodies in
serum from CF patients reported by Anderson et al (1989) also indicated that
colonisation with organisms of different flagellum type could have occurred at
some point. Epidemiological evidence, however, suggests that CF patients
remain colonised with a single strain of P. aeruginosa (Ogle et al, 1987) whilst
other studies have reported that although a given serotype tends to persist in
each patient, there is the occasional appearance of others (Diaz et al, 1970,
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Horrevorts et aL, 1990). Alternatively, the presence of the b or aQ epitope in all
seventeen flagellar serotypes (Ansorg, 1978) as well as a common N-terminal
amino acid sequence in the flagellin protein (Rotering & Dorner, 1989) may
account for some of the dual responses observed in the ELISA and
immunoblot studies. Rotering & Dorner (1989) also observed that antibodies
directed against type-a flagella can weakly bind to b-type flagellins and vice
versa. Such cross-reactions were also observed in the immunoblot
characterisations of the flagella preparations (Figure 23). Another possible
explanation for the response to both flagellar types is diphasic variation in the
flagellar antigens (Pitt, 1980) although no such variations were reported by
Montie & Anderson (1988). In contrast, a pronounced antibody response to
either type-a or -b flagella indicates either infection by P. aeruginosa of one
flagellum type or perhaps by one single strain.
Shand et al (1988a) reported that many CF patients infected with P. aeruginosa
show serum antibodies against flagellar preparations soon after the onset of
colonisation; immunoblotting and ELISA studies showed an early response to
flagellar antigen, which preceded the antibody response to other outer mem¬
brane components. In this thesis, the elevated anti-flagellar antibody levels,
above the control range, observed in sera from some CF patients intermittently
or non-colonised by P. aeruginosa adds support to the report of Shand et al
(1988a). An early antibody response to flagella is likely to occur, since motility
and expression of flagella are probably less important after initial colonisation,
and establishment of chronic infection (Luzar et aL, 1985).
Anti-flagellar IgA antibodies in saliva and sputum from patients with CF were
also observed and may represent the local immune response to P. aeruginosa
colonisation or infection. The raised anti-flagellar IgA antibodies in saliva or
sputum from patients intermittently or even non-colonised by P. aeruginosa
may indicate an early antibody response to recent colonisation by the organism.
Although patients may be classified as non-colonised on the basis of sputum
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bacteriology, colonisation by P. aeruginosa could be present, since sputum
bacteriology does not necessarily reflect the current status of all lung regions
(Przyklenk & Bauernfeind, 1988). Raised anti-flagellar IgA antibodies were
particularly evident in patients chronically colonised by P. aeruginosa, although
absence or reduced levels of antibodies in some of these patients may be
caused by involvement in immune complex formation (Brown et al, 1989;
Kronborg et al, 1989) or degradation by P. aeruginosa elastase (Heck et al,
1990).
ELISA screening of anti-P. aeruginosa flagellar IgA and IgG antibodies in
patients with CF may provide a useful indication of the early onset of pulmo¬
nary colonisation by P. aeruginosa and provide a suitable parameter for instiga¬
tion of anti-pseudomonal antibiotic therapy. Longitudinal monitoring of anti-
flagellar antibodies in serum, sputum or saliva in patients classified as non-
P. aeruginosa colonised may give a particularly early indication of
P. aeruginosa colonisation.
The ability of anti-flagellar antibodies to inhibit motility, and indirectly chemo-
taxis, was shown by the inhibition of chemotaxis of two P. aeruginosa strains
towards porcine mucin by the anti-flagellar type-b Mab (Figure 64). These
studies reflect those of Montie et al (1982a) who demonstrated that antisera
raised against flagellar preparations inhibited motility. Experiments with the
burned mouse model involving vaccination with P. aeruginosa flagellar antigens
(Holder et al 1982; Montie et al 1982a; Montie et al 1987) or passive immuni¬
sation with anti-flagellar sera (Drake & Montie, 1987; Drake & Montie, 1988)
have shown the protective efficacy of anti-flagellar antibodies in the inhibition
of the lethal spread from a localised infection. Anti-flagellar antibodies may
act by simple inhibition of the motility of P. aeruginosa (Montie et al 1982a;
Rotering & Dorner 1989) or by opsonophagocytosis of the organism (Anderson
& Montie, 1989; Rotering & Dorner, 1989). Since chemotactically directed
motility of P. aeruginosa may be important in initial lung colonisation of patients
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with CF, vaccination with a bivalent vaccine consisting of type-a and -b flagellar
antigens would appear a rational, but as yet unproven strategy for prevention of
colonisation. The role of mucosal immunity and the protective capacity offered
by secretory IgA antibodies, present predominantly in the upper and large
airways, is not well understood. The main role of IgA antibodies appears to be
inhibition of bacterial adherence to epithelial surfaces (Bienenstock, 1984)
whilst IgG antibodies are required for optimal clearance of P. aeruginosa from
the distal airway (Fick & Hata, 1989).
22 ANTI-P. AERUGINOSA LPS ANTIBODIES
a) Anti-LPS antibodies in CF sera
A number of studies have reported the presence of antibodies to P. aeruginosa
LPS in CF patients (Moss & Lewiston, 1980; Pitt et al, 1985; Moss et al, 1986a;
Jacobson et al, 1987; Cochrane et al, 1988b; Schaad et al, 1990) . ELISA based
methods for determining antibodies to P. aeruginosa have previously proved
useful in monitoring both course and treatment of infection in CF (Brett et al,
1986a & b, Brett et al, 1987; Brett et al, 1990; Pedersen et al, 1987). The system
developed by Brett et al (1986b) was based on whole cells representing com¬
monly isolated O-serotypes whilst the ELISA method of Pedersen et al (1987)
used a pooled sonicated extract of seventeen individual P. aeruginosa O-
serotypes. In the present study, the ELISA system, based on PEV-02 (S-LPS)
or core LPS from P. aeruginosa PAC605, was an attempt to refine existing
techniques with a more defined antigenic preparation and monitor
P. aeruginosa anti-LPS antibodies in CF patients. An ELISA system based on
PEV-02, which consists of cell wall extracts of sixteen international O-serotypes
of P. aeruginosa (IATS 0:1-0:16) (Miler et al, 1977) or the common core
component of LPS were considered appropriate coating antigens given that
there are at least seventeen O-serotypes of P. aeruginosa. (Serotype 0:17 is an
extremely rare serotype and its omission from PEV-02 is not likely to have
affected the results).
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The ELISA data obtained (Figure 4) clearly shows an elevated anti-pseudo-
monal LPS antibody response in serum from CF patients chronically colonised
by P. aeruginosa with low or undetectable levels of antibodies in intermittently
and non-P. aeruginosa colonised patients. Elevated anti-pseudomonal anti¬
bodies in colonised patients and generally low levels of antibodies in intermit¬
tently colonised patients were reported by Brett et al (1986a & b), Pedersen
et al (1987) and Brett et al (1990). In addition Fomsgaard et al (1988b) and
Fomsgaard et al (1989) have reported that anti-LPS antibodies increased signif¬
icantly at the onset of chronic infection and continued to increase to very high
levels in the later stages of infection, whilst Moss et al (1986a) observed a
thirty-fold elevation of P. aeruginosa LPS antibodies in twenty-one patients
colonised with the organism compared to ten non-colonised CF patients and
eleven healthy controls. In a more recent study Schaad et al (1990) also
reported that antibody titres in chronically colonised patients were significantly
higher than in patients with intermittent P. aeruginosa colonisation; CF
patients without P. aeruginosa colonisation showed no detectable antibody
titres to LPS. This latter finding corresponds to the results obtained in the
present study ie absence of antibodies directed to S-LPS or core R-LPS in
serum from non-P. aeruginosa colonised patients.
A response to core R-LPS is perhaps indicative of chronic colonisation by
P. aeruginosa deficient in O-polysaccharide leaving the unsheathed common
core LPS as the predominant LPS antigen. Such strains are typically polyagglu-
tinable with O-typing sera (Hancock et al, 1983; Pitt et al, 1986) reflecting the
presence of common antigenic structures in the core-lipid A region of the
molecule (Fomsgaard et al, 1988a). The isolation of polyagglutinable and non-
typable P. aeruginosa strains lacking high molecular O-antigen LPS, (as visua¬
lised by silver staining of polyacrylamide gels) from the patients chronically
colonised by the organism reflects observations made by others. However, a
strict relationship between non-typability and lack of O-antigen was not
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observed, since some strains, including mucoid variants (eg JN10 in Figure 49),
were non-typable yet shown to express LPS O-antigen. These observations
were consistent with the findings of Cochrane et al (1988b).
The increased levels of IgG anti-LPS antibodies measured in patients
previously non-colonised or intermittently colonised by P. aeruginosa indicate
the presence and/or increasing persistence of P. aeruginosa in the respiratory
tract (Figure 5). Brett et al (1986a) and Pedersen et al (1987) commented that
the rate of increase in antibody titres to P. aeruginosa was fast or slow in
different patients: some patients may show an increase in P. aeruginosa specific
antibodies very shortly after P. aeruginosa organisms have been cultured for
the first time, whilst in others colonisation with P. aeruginosa may persist for 1-
2 years without eliciting a systemic immune response (Pedersen et al, 1987).
The urease ELISA, with either PEV-02 vaccine or core R-LPS, was found to be
rapid, reproducible, suitable for routine use, and clearly distinguished between
CF patients chronically colonised with P. aeruginosa and those non-colonised
by the organism. The positive colour change of the urease ELISA substrate
(yellow to purple) obtained with serum from patients chronically colonised with
P. aeruginosa could easily be read visually, and could obviate the need for an
automated plate reader. The ability to identify chronic P. aeruginosa colonisa¬
tion of patients is useful, since implementation of anti-pseudomonal therapy as
soon as chronic infection is diagnosed is known to improve patient prognosis
(Szaff et al, 1983; Pedersen et al, 1987). Indeed, Fomsgaard et al (1989)
recommend the quantitation of specific IgG and IgA antibodies to
P. aeruginosa LPS by ELISA as a diagnostic tool for CF in order to distinguish
between superficial colonisation and early or persistent infection caused by P.
aeruginosa.
The absence of a systemic immune IgG response in the CF patients non-colo¬
nised by P. aeruginosa (Figure 4) may indeed indicate that these patients have
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never been colonised by the organism. Alternatively, the absence of a systemic
humoral response may be due to the presence of P. aeruginosa in sputum that
was transient or non-pathogenic and failed to invade tissue and establish infec¬
tion, or perhaps because there was an adequate local immune response
utilizing secretory IgA antibodies. In the studies of Brett et al (1986b), Brett
et al (1987) and Brett et al (1988) serum IgG antibody titres to P. aeruginosa
surface antigens in patients with no known P. aeruginosa infection were
monitored and often found to exceed the normal control range; in some cases
the titre of IgG antibodies was greater than control values at or up to 24
months before the first isolation of P. aeruginosa (Brett et al, 1988). In a more
recent study, Brett et al 1990 evaluated serum IgA antibodies in CF patients
and reported that an increased serum IgA titre can give an even earlier
indication than measurement of serum IgG titre, of the presence of
P. aeruginosa in the respiratory tract of a proportion of patients. However, as
the authors indicated, these results represent detection only of early
P. aeruginosa tissue infection, although the organism may have been present for
some time. This scenario is likely, given the fact that bacteriological
examination of many of their patients was based on throat swabs, and
bacteriological culture of sputum was only capable of detecting greater than
104 organisms/ml of sputum. Indeed, Przyklenk & Bauernfeind (1988) also
found that 63% of their non-colonised CF group showed elevated antibody
titres against some of the O-antigens, and conceded that the presence of
P. aeruginosa may well have gone undetected in sputum, and furthermore, that
sputum does not always reflect the current status of all lung regions. The
bacteriology of sputum specimens in our laboratory is based on a quantitative
culture procedure which allows detection of P. aeruginosa at concentrations as
low as 10^ CFU/ml sputum (Dr J.R.W. Govan, pers. comm.). In addition,
although the difference between harmless colonisation and early infection is
open to debate (Brett et al, 1988), isolation of P. aeruginosa even in low num¬
bers should be regarded with caution since they ultimately form the reservoir
from which mucoid variants arise: once established, eradication of the organism
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even with aggressive treatment is extremely rare (Pier, 1985). From accumu¬
lated evidence it seems reasonable to suggest that detection of raised serum
anti-P. aeruginosa antibodies, whether in the presence or absence of detectable
organisms in sputum, should encourage instigation of anti-pseudomonal
therapy in an attempt to improve patient prognosis.
In this study, P. aeruginosa LPS antibodies were not detectable in the sera
obtained from ten blood donor controls (Figure 4). The absence of antibodies
in these healthy individuals may be a reflection of the small sample size since
anti-P. aeruginosa LPS antibodies in some normal individuals have been
detected in certain studies (Fomsgaard et al, 1989; Grzybowski et al, 1989).
Although P. aeruginosa is not usually found in the normal human microflora, it
is ubiquitously distributed, and sometimes found in the intestinal tract and on
normal skin. Thus multiple contacts of healthy subjects with P. aeruginosa
may occur, trivial epidermal infections, or sporadically occurring colonisation
of the gastrointestinal or genitourinary tracts, being possible sources of
infection, and stimulation of anti-pseudomonal antibodies (Grzybowski et al,
1989). The low levels of anti-flagellar antibodies detected in some of the
normal sera (Figure 24) may be indicative of such infections and illustrate the
potent immunogenic nature of flagellar antigens.
The monovalent cell-wall extract components of the polyvalent P. aeruginosa
vaccine PEV-02 are predominantly LPS (Miler et al, 1977). Serum anti-
pseudomonal antibodies measured using PEV-02 as antigen, may represent (i)
antibodies to any of the sixteen O-serotype antigens, (ii) antibodies directed
against the common core region of the LPS or (iii) antibodies to the common
A-band LPS of P. aeruginosa (Rivera & McGroarty, 1989) which is particularly
expressed by non-typable clinical isolates commonly found in patients with CF
(Lam et al, 1989). Other common LPS antigens have also been identified by
Sawada et al (1985) and Kocharova et al (1988). In this study, serum from
patients chronically colonised with P. aeruginosa produced a positive reaction
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with most of the sixteen individual serotype vaccine components (Figure 6),
again indicating the presence of antibodies directed to a common antigenic
component of LPS and/or a number of serotype specific antibodies.
Examination of the immunoblots of serum from patients chronically colonised
by P. aeruginosa revealed a response to the high molecular weight O-antigenic
LPS of a number of the serotypes, as well as a strong response to the core-lipid
A region of the molecule (Figures 16b & 17b). The response to different O-
serotypes may indicate infection of the patient with a number of individual
serotype strains or reflect a serologically cross-reactive component associated
with high molecular weight LPS. As mentioned previously, patients tend to be
colonised by a single strain with occasional, transient colonisation by others.
The study of Diaz et al (1970) reported that seven out of seventeen patients
showed a serum antibody response against two or more serogroups of
P. aeruginosa, whilst immunoblot analysis of serum from a CF patient in the
report of Schaad et al (1990) displayed bands in the O-side chain region of S-
type LPS of three P. aeruginosa strains. Broadly reactive anti-F\ aeruginosa
antibodies in CF patients were also reported by Przyklenk & Bauernfeind
(1988) who suggested a course of infections with several O-antigens or a more
pronounced cross-reactivity among CF P. aeruginosa isolates than in non-CF
isolates.
In contrast to the immunoblots obtained with serum from chronically colonised
patients, sera from CF patients intermittently colonised with non-mucoid
P. aeruginosa tended to show an antibody response primarily directed towards
O-antigenic LPS of the typable, colonising strain as well as that of the corre¬
sponding standard serotype strain (Figures lib, 12b, 13b & 14b). The immuno¬
blots of sera from intermittently and chronically colonised patients suggests
that antibodies directed to a number of serotype strains as well as core R-LPS,
develop as infection progresses. Increased exposure of core antigen or other
common LPS antigens, commensurate with loss of O-specific side chains,
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coupled with persistent infection may account for these antibodies. The re¬
sponse to the core regions of a number of different serotype strains also indi¬
cates the presence of a common antigenic structure in the core-lipid A region
of the molecule. Conversely a response to core LPS of some strains but not
others, may indicate a certain degree of core heterogeneity.
The significant anti-core response found in sera from CF patients chronically
colonised with P. aeruginosa is consistent with Hancock et aFs (1984) study in
which 74% of CF sera reacted with the core portion of outer membrane prepa¬
rations (presumed to represent core LPS). Furthermore Jacobson et al (1987)
showed an elevated IgG antibody response to PAC605 LPS in P. aeruginosa
colonised patients, where Western blotting demonstrated that sera from most
of these patients displayed bands in the core R-LPS region.
The presence of a faint, anti-S-LPS response to PAC605 LPS blotted with some
sera or sputa (eg Figure 16a) was unexpected since it is reported to lack high
molecular weight smooth carbohydrate molecules (Rowe & Meadow, 1983;
Meadow et aL, 1984; Engels et aL, 1985) and appeared to lack such molecules in
silver stained SDS-polyacrylamide gels. However, the Western blot analysis of
Meadow et al (1984) and Jacobson et al (1987) also demonstrated comparable
faint, high molecular weight ladder bands. The disparity between the
immunoblotting and silver staining may be caused by the relative insensitivity
of the latter to detect small amounts of O-antigen LPS. The presence of small
amounts of S-LPS could be a result of partial reversion to the parent strain or
the presence of small amounts of S-LPS in native PAC605 cell walls.
b) Anti-LPS antibodies in CF sputum and saliva
The presence of anti-P. aeruginosa LPS antibodies in saliva and sputum from
CF patients was also investigated in this thesis (Figures 8-10). The elevated
levels of sputum IgA anti-LPS antibodies, particularly observed in chronically
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colonised patients, is in accordance with the studies of Schiotz et al (1979) and
Przyklenk & Bauernfeind (1988) who also reported significantly higher IgG
antibodies in sputum from patients colonised with the organism. The immuno-
fluorescent studies of Hann & Holsclaw (1976) also showed that P. aeruginosa
cells isolated from CF sputum were coated with substantial amounts of IgA
antibodies. The high levels of anti-core IgA antibodies in sputum from chroni¬
cally colonised patients is indicative of persistent infection by P. aeruginosa
expressing exposed core antigens caused by loss of smooth O-serotype antigen;
the response to core LPS was confirmed by immunoblotting. As discussed for
the serum antibody response to vaccine, the sputum IgA antibodies may be
directed to any of the sixteen O-serotype antigens or directed to a common LPS
component. The formation of immune complexes or degradation by P. aerugi¬
nosa elastase (Heck et al, 1990) may be responsible for an underestimation of
IgA antibodies in sputum.
Detectable levels of anti-P. aeruginosa LPS antibodies (IgA) were also found in
sputum from intermittently colonised patients as well as those classified as non-
P. aeruginosa colonised. These antibodies may represent an early response to
colonisation by P. aeruginosa or reflect previous transient colonisation by the
organism. The demonstration of anti-LPS antibodies in sputum from the non-
colonised patients is in contrast to the absence of detectable anti-LPS IgG in
serum. The IgA response may represent antibodies produced locally by the
bronchus associated lymphoid tissue, indicating the presence of the organism,
at some point. The antibodies may prevent tissue invasion, and account for the
absence of a systemic immune response.
In contrast to IgA, anti-LPS IgG antibodies were not detected in sputum from
any of the CF patients. This observation concurs with the data of Cochrane
et al (1988b) who noted only a very low IgG response in sputum from a
P. aeruginosa colonised patient. Failure to detect LPS-specific IgG antibodies
in sputum is consistent with the hypothesis that these antibodies combine with
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LPS in the CF patients' lungs to form immune complexes (H0iby & Axelsen,
1973; H0iby et al, 1986; Moss et al, 1986a). In addition some of the IgG anti¬
bodies may have been degraded by P. aeruginosa elastase (Fick et aL, 1985) or
elastase from polymorphonuclear leucocytes (Doring et aL, 1985). The inability
to detect IgG antibodies may also be a reflection of its importance as an opso¬
nizing antibody for clearance of antigen from the distal human airway (Fick &
Hata, 1989; Reynolds, 1989).
Salivary anti-P. aeruginosa LPS IgA antibodies were also demonstrated in a
number of CF patients including non-P. aeruginosa colonised patients (Figure
9). In immunologically sufficient individuals, secretory IgA is the major
immunoglobulin species detected in salivary secretions and is considered to be
the principal mediator of salivary immunity (Reynolds, 1983; Bienenstock,
1984; Kilian et aL, 1988; Smith et aL, 1989). The antibodies detected reflect a
response to both S-LPS and core R-LPS antigens. As discussed for sputum,
these antibodies in non-P. aeruginosa colonised patients may reflect an early
response to the organism, which is not detectable by sputum bacteriology.
Alternatively, they may indicate a number of previous transient encounters with
the organism. In contrast to the immunological analysis of sputum, IgG anti-
LPS antibodies were detected in salivary secretions from many of the CF
patients included in the study (Figure 10). Although IgG is not the principal
antibody of the upper respiratory tract it is known to be produced in significant
amounts in saliva from minor salivary glands (Smith et al, 1989), and may be
particularly evident during respiratory infection when transudation from serum
may account for a large portion of the IgG seen. Some of the IgG detected in
saliva may be from contaminating peripheral pulmonary secretions.
Longitudinal studies of anti-P. aeruginosa LPS antibodies in saliva and sputum
from individual CF patients may prove useful in the assessment of patient
prognosis. Przyklenk & Bauernfeind (1988) concluded that secretory IgA
antibodies in sputum correlated well with the current clinical status of patients,
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titres increasing during acute exacerbations and decreasing to normal values in
more stable periods, adding that detection of serum anti-LPS antibodies was
reflective of infections of a more chronic nature.
In summary, the presence of anti-P. aeruginosa antibodies in various
anatomical sites in patients with CF is indicated by the data presented in this
thesis. Although these antibodies, directed to O-antigenic and core LPS
antigens as well as to flagella, may help protect CF patients from bacteremia
and endotoxemia, it appears that they are unable to mediate elimination of the
organism from the CF respiratory tract. The existence of antibodies at the
stage of initial colonisation by non-mucoid P. aeruginosa does not appear to be
beneficial: Brett et al (1990) reported serum IgA antibodies in a majority of
their CF patients prior to isolation of the organism from the respiratory tract,
but added that these were unable to prevent pseudomonal infection becoming
established. Indeed, there is clear support for the hypothesis that a pronounced
antibody response to P. aeruginosa antigens, once colonisation is established,
has deleterious effects because of immune complex induced destruction of lung
tissue (see Introduction). Vaccination of patients already harbouring
Pseudomonas is contra-indicated because of the resultant immune complex
mediated tissue damage (Langford & Hiller, 1984).
Given the poor pulmonary clearance characteristic of CF and the ability of
P. aeruginosa to colonise the copious, static mucosal secretions, the protective
value of antibodies induced prior to any pulmonary colonisation is uncertain.
However, mucosal immunity has received relatively little attention (Pedersen
et al, 1989b) and induction of a protective IgA response may well be the way to
prevent colonisation. Strategies to improve pulmonary clearance via the muco¬
ciliary escalator, coupled with the presence of pre-existing mucosal antibodies
induced by suitable immunisation, may, combined, present a more formidable
barrier to initial colonisation. The nature of a successful, probably composite
vaccine must consider the relevance and importance of the multitude of
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MONOCLONAL ANTIBODIES AGAINST P. AERUGINOSA CORE LPS
3.1 CHARACTERISATION OF THE MONOCLONAL ANTIBODIES
Mabs recognising P. aeruginosa core LPS, unsubstituted by O-serotype
antigens, were isolated and characterised. The Mabs were shown to be cross-
reactive with all or most core LPS antigens belonging to a variety of standard
and clinical P. aeruginosa strains. The pan-reactive, core specific response may
support the idea of the presence of a common antigenic structure in the core
region of P. aeruginosa LPS. The inner core region of P. aeruginosa LPS is
believed to be homogeneous in P. aeruginosa and also common to most Gram-
negative bacteria, whilst the outer core region is considered to be
heterogeneous and different from that of other Gram-negative genera (Rowe
& Meadow, 1983; Wilkinson, 1983; Kropinski et aL, 1985). The concept of LPS
core heterogeneity in P. aeruginosa is supported by the observations of
Hancock et al (1983) and Yokota et al (1989). The former observed that core
R-LPS specific Mabs interacted with only six of the seventeen serotypes and
only two of sixteen CF isolates, whilst the latter, utilizing outer core specific
Mabs, reported heterogeneity of the L-rhamnose residue on the outer core of
P. aeruginosa LPS. The Mabs of Yokota et al (1989) bound to some, but not
all of the Homma serotypes, binding beyond the O-serotype antigen, and
binding particularly strongly to R-LPS strains.
In this study, immunoblot analysis of the Mabs showed that high molecular-
weight polysaccharide prevented the Mabs from gaining access to the core
epitope. However, the fact that the Mabs showed strong reactions with
P. aeruginosa strains expressing S-LPS antigen, indicates that the covering of
long O-polymer is unable to prevent access to unsheathed core antigen. This
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may be a reflection of the low level of LPS on P. aeruginosa which contains a
long O-polymer: Hancock et al (1983); Wilkinson (1983) and Rivera et al
(1988) estimated the mole percentage of S-form LPS to be between 0.2 and
14%. In contrast, however, this low level of covering with O-polymer was able
to inhibit the binding of the rough-core specific Mabs characterised by Sadoff
et al (1985). The Mabs studied in this thesis were shown to react with various
forms of P. aeruginosa LPS including extracted LPS preparations, cell wall
extracts (PVA) and whole bacterial cells. In the case of some of the extracted
LPS antigens with some of the Mabs, the ELISA OD readings tended to be
weaker with extracted LPS compared to the other LPS forms: perhaps the core
epitopes recognized by the Mabs are not optimally orientated in extracted LPS.
The detailed chemical structure of the LPS core region of the different mutant
strains is shown in Figure 71. The gel profiles of the LPS defective core
mutants (Figure 29) showing a leading band of core LPS followed by a higher
molecular weight band (24-kilodaltons), correspond to LPS fractions containing
a mixture of unsubstituted core, and core oligosaccharide with a single copy of
side chain oligosaccharide attached (Wilkinson, 1983), and correspond to the
core LPS profiles of other investigators (Meadow et al, 1984; Engels et al
1985; Jacobson et al, 1987). In a structural analysis of the core mutants, Rowe
& Meadow (1983) found that PAC608 and PAC609 were able to produce high
molecular weight fractions, whilst PAC611 was leaky and also produces some
O-antigenic material. In the other defective mutants which lacked both O-
antigenic side chains and different amounts of core material, there was an
absence of core components containing a single copy of side chain
oligosaccharide. The bands observed for these mutants (ie PAC605, PAC556
and PAC557) in this and the other studies may indicate the presence of leaky
variants.
In order to give an indication of the residue(s) in the core region of













Figure 71. Detailed core LPS structure of P. aeruginosa PAC1R and its defective mutants (from
Rowe & Meadow, 1983). ALA = alanine; GALN = galactosamine; GLC = glucose; HEP =
heptose; KDO = keto-deoxy octanoic acid, O-AG = O-antigen; RHA = rhamnose.
defective mutants was studied. Analysis of the reactivities of the Mabs in
ELISA (against whole cells and extracted LPS) and immunoblotting
experiments gives a tentative indication of the Mab binding sites. Mabs 304.1.4
and 360.7 appear to show similar binding patterns: a reaction with all core
mutants was observed although weak reactions against PAC605 LPS in ELISA
and immunoblotting were noted. The binding sequence indicates that
galactosamine and, to a lesser extent, its neighbouring glucose residue may
form the epitope for Mabs 304.1.4 and 360.7. Discernment of the epitopic
binding sites of the less avid Mabs 61.3.2, 73.5 and 334.4 is hindered by certain
disparities in the ELISA and immunoblotting data. However, analysis of the
ELISA whole cell results indicates that these Mabs also recognise an inner to
mid core region, common to all the core mutants. The competition assays
revealed that the binding sites of Mabs 304.1.4, 360.7 and 73.5 were probably
slightly different, with Mab 61.3.2 having a similar binding site to Mab 304.1.4.
A competitive ELISA involving the various core components may provide a
more definitive answer for the determination of the epitopic site recognised by
each of the Mabs.
Cross-reactivity of the Mabs with whole cells representing a number of other
Pseudomonas spp implies that these species contain core LPS similar in
composition and structure to P. aeruginosa. Alternatively their LPS may be
structurally dissimilar but serologically cross-reactive with that of P. aeruginosa.
The absence of a significant response to P. maltophilia confirms the observa¬
tions of Neal & Wilkinson (1982) who reported similarities between the LPS
of P. maltophilia and that of some Xanthomonas species. This analysis
confirms their close taxonomic relationship based on rRNA/DNA
hybridization (Palleroni, 1984), which is distinct from the other pseudomonads.
The lack of a significant response to P. cepacia may also reflect some of the
reported differences in the structure of P. cepacia LPS (Palleroni, 1984): the
core polysaccharide is known to contain glucose, rhamnose and heptoses but no
phosphorus.
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Significant cross-reactions with H. influenzae were also absent. The LPS of
H. influenzae is rough, the core oligosaccharide containing glucose, galactose,
heptose and ketodeoxyoctonic acid with the variable presence of minimal
amounts of glucosamine (Zamze & Moxon, 1987) and would appear to be dif¬
ferent to that of P. aeruginosa. Although the inner core region of LPS from
P. aeruginosa is believed to be similar to that of the enterobacteria (Wilkinson,
1983; Kropinski et al, 1985) no cross reactions of the Mabs with LPS and/or
whole cells of Salmonella, E. coli, Proteus, or Klebsiella were observed. This
would support the idea that the Mabs recognise epitopes in the outer core of
P. aeruginosa LPS and which are absent from the core LPS of enterobacteria.
3.2 DEVELOPMENT OF A MONOCLONAL ANTIBODY ENZYME
IMMUNOASSAY FOR THE DETECTION OF P. AERUGINOSA LPS
Pulmonary colonisation of patients with CF by P. aeruginosa can be diagnosed
by bacteriological culture or, as described in this and many other studies, by the
detection of Pseudomonas specific antibodies. However, in the early stages of
asymptomatic colonisation such techniques may be limited by the absence of
the organism in bacterial culture and the absence of anti-pseudomonal
antibodies. The development of a Mab based enzyme immunoassay for the
detection of the early emergence of P. aeruginosa antigens in saliva and
sputum, facilitating early identification of respiratory colonisation, was
considered a useful alternative to existing techniques.
The Mabs considered for the assay are core-LPS specific, pan-reactive with all
P. aeruginosa strains regardless of serotype and therefore suitable for the
detection of any of the twenty distinct serotypes (Liu & Wang, 1990) which may
colonise individual CF patients. P. aeruginosa produces a number of intra-and
extracellular antigens. Amongst these, LPS is specific, highly immunogenic and
easily released into the surrounding medium (Cadieux et al, 1983; Kusama,
1983) and therefore considered an appropriate antigen for the detection of
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P. aeruginosa in respiratory secretions from CF patients.
There has been increasing interest in the development of assays capable of
detecting infectious agents directly in clinical specimens and which can be
adapted to the rapid screening of a large number of specimens (Yolken, 1982,
Yolken et al, 1983). Enzyme immunoassays have been developed for the
detection of antigens of a variety of microorganisms eg S. pneumoniae and
H. influenzae (Yolken et al 1983); meningococci (Sugasawara et al, 1984);
Bordetella pertussis (Gustaffson & Askelof, 1988); 5. typhi (Sadallah et al, 1989)
as well as P. aeruginosa (Kusama, 1983). In the latter study, double antibody
ELISA systems for the detection of the corresponding homologous LPS in
solution were developed (Kusama, 1983).
Mab based systems have advantages over polyclonal antibody immunoassays:
Mabs can be supplied in almost unlimited amounts once the hybridoma cell
line is established; problems arising from batch variations are avoided when
Mabs are used; Mabs generally show higher specificity since each molecule of
antibody is directed at the antigen in question, and high concentrations of spe¬
cific antibody can be obtained (Yolken, 1982; Harlow & Lane, 1988).
There are a number of ways in which enzyme immunoassay systems can be
formulated to provide for the direct measuremant of infectious agents in body
fluids (Yolken, 1982). In this particular study a Mab based double antibody
sandwich ELISA was developed for the detection of P. aeruginosa LPS in solu¬
tion, and in saliva and sputum specimens from patients with CF. Bio-Mabs
were used in the assays developed. Biotin labelling of antibodies is a simple,
mild reaction giving high labelling efficiency and enables the antibodies to
retain full biological activity. The stable monomeric conjugates generated have
a number of advantages for use in enzyme immunoassays including the
extraordinarily high affinity between biotin and avidin which provides stable
complexes and has the potential for magnification at the level of cofactor-
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enzyme interaction (Guesdon et al, 1979). Biotin-streptavidin reagents are also
non-sticky in nature and therefore produce only low background reactions
(Kendall et al 1983).
A biotin/Mab ratio of 1:1, 2:1 or 4:1 yielded usable reagents and corresponds
to the results reported by others (Kendall et al, 1983; Yolken et al, 1983). Since
one molecule of streptavidin can efficiently bind four molecules of biotin,
multiple avidin-biotin interactions can be achieved, offering the possibility of
increased sensitivity (Yolken, 1982). There are a number of ways of utilizing
biotinylated antibodies. In this study the most efficient immunoassay system
was one employing a complex of unlabelled avidin and alkaline-phosphatase
labelled biotin to bind to the bio-Mab. Thus the ELISA system utilizing strep-
tavidin-biotin-alkaline phosphatase complexes is more sensitive than the one
utilizing bio-Mab reacted with streptavidin-directly labelled with enzyme, since
in the case of the former each 'bridging' streptavidin molecule can bind three
biotinylated alkaline phosphatase molecules to every biotinylated antibody.
The double Mab sandwich ELISA was shown to detect P. aeruginosa LPS in
solution, with a detection limit of 0.1 ng/ml P. aeruginosa LPS or a minimum
of between 10** - 10^ cells /ml. A single Mab competitive inhibition ELISA
was also attempted, but although the sensitivity was comparable to that of the
sandwich ELISA, preliminary results were inconsistent with poor reproducibili¬
ty. The principle of the competitive inhibition ELISA is that antigen (eg
P. aeruginosa LPS in this case) is bound to the solid phase and a sample of test
solution containing putative antigen is added together with labelled antibody
(bio-MAb) specific for the antigen. Any antigen in the test solution will com¬
pete with the immobilised antigen for binding with the labelled Mab. The
assay is quantified by the amount of labelled antibody bound to the solid phase.
The advantages of this system are that it requires fewer incubation steps and
requires only a single, labelled antibody compared to the sandwich ELISA
technique (Harlow & Lane, 1988). However, problems may arise caused by
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preferential binding of the labelled antibody to the solid phase compared to the
antigen in solution. Antibody in clinical specimens may also interfere with the
reaction by binding to the solid phase, or by preventing binding of labelled
antibody to the antigen.
Sensitivity of a double antibody sandwich ELISA is dependent on a number of
factors: i) ability of the capture antibody to bind to the plate, including the
amount of immunoglobulin which can be tightly bound to a microtitre well
(Yolken, 1982); ii) avidity of the capture antibody for antigen; iii) avidity and
specific activity of the labelled antibody. This assay also requires two Mabs
which have non-overlapping epitopes on the antigen showing non-competitive
activity. In the sandwich ELISA system developed Mabs 304.1.4 and 360.7
were used. These Mabs showed strong cross-reactivity with P. aeruginosa LPS
and appeared to be non-competitive. Mab 360.7 was used as the capture
antibody since it showed the maximum avidity for P. aeruginosa LPS.
Sensitivity of the assay may possibly be increased by further purification of the
capture Mab (eg by ion exchange chromatography) since the preparations used
still contained contaminating proteins as visualised by agarose gel
electrophoresis.
The sandwich ELISA was able to detect various forms of LPS including
extracted LPS, heat-killed whole cells and viable whole cells, and was therefore
suitable for the detection of P. aeruginosa LPS in CF respiratory secretions,
where it may exist in a variety of forms. Subsequent application of the system
with saliva and sputum from CF patients indicated its ability to detect
P. aeruginosa in respiratory secretions. Comparison of the results with the
documented bacteriology for each of the patients showed a positive reaction for
most of the patients known to be colonised by P. aeruginosa, although two false
negatives were encountered: these may be caused by the precise nature of the
LPS or by levels of LPS below the detection limit of the assay. Positive results
were also noted for some patients considered to be non-P. aeruginosa colonised.
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Longitudinal screening of such patients is required to confirm the significance
of these results. However, it was of interest that the patient with the elevated
positive absorbance reading for sputum, and previously considered to be non-
P. aeruginosa colonised, has since had intermittent colonisation with non-
mucoid P. aeruginosa. False positives caused by detection of H. influenzae,
P. maltophilia and P. cepacia are unlikely given the fact that the Mabs failed to
react significantly with whole cells from these organisms. Background
reactions as well as false negative results were reduced considerably by boiling
of the samples prior to use in the assay: heating liberates bacterial
polysaccharides from antibody complexes (Doskeland & Berdal, 1980).
Further examination of this sandwich ELISA will indicate whether it is suffi¬
ciently sensitive and specific to provide useful information for the diagnosis and
management of patients with CF: namely early identification of respiratory
colonisation by P. aeruginosa, a basis for the determination of a patient's
prognosis and design of rational therapeutic strategies, as well as a better
understanding of the bacterial and host factors involved in early colonisation of
the CF lung. Longitudinal studies including monitoring of P. aeruginosa LPS in
CF respiratory secretions, coupled with measurement of P. aeruginosa specific
antibodies and standard bacteriological examinations will be of value.
Given that ELISA systems tend to require more assay time than other immu¬
noassay systems, eg immunofluorescence and latex agglutination (Yolken,
1982), the development of alternative immunoassays may be of benefit. Pfaller
et al (1989) reported a direct fluorescent Mab test for the detection of P.
aeruginosa in blood cultures, and Sofianou & Doumboyas (1989) used a
coagglutination assay for the detection of soluble P. aeruginosa antigens in
bronchial secretions. The feasibility of a latex agglutination test or a dot blot
assay may also be considered. Commercial Mab based assay kits are currently
available for detection of meningococci, pneumococci and H. influenzae in
clinical specimens.
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The immunoprotective potential of the Mabs and their possible use in passive
immunotherapy (Holder, 1988) also remain to be evaluated. Use of the Mabs
in patients with CF would probably be contraindicated because of the
possibility of immune complex formation.
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